https://trial.medpath.com/news/425bc55546b30aee/man-with-incurable-cancer-among-first-to-undergo-ground-breaking-new-treatment-stv-news 2024-09-10T12:23:13+00:00 weekly 0.7 https://trial.medpath.com/news/ac901d174ee4273f/could-a-pill-help-ease-sleep-apnea 2024-09-10T12:15:36+00:00 weekly 0.7 https://trial.medpath.com/news/7d7986bfb5616540/halia-therapeutics-to-present-an-update-on-phase-ii-clinical-trial-data-of-ht-6184-pr-newswire 2024-09-10T12:15:06+00:00 weekly 0.7 https://trial.medpath.com/news/64a8f12397b7fd39/reveal-genomics-r-announces-positive-top-line-results-for-her2dx-r-in-cleopatra 2024-09-10T12:14:31+00:00 weekly 0.7 https://trial.medpath.com/news/8d5fc19d5bf56753/belite-bio-announces-first-patient-dosed-in-phase-2-3-dragon-ii-trial-of-tinlarebant-for 2024-09-10T12:07:25+00:00 weekly 0.7 https://trial.medpath.com/news/c1966a4d60320fb0/academic-community-collaboration-improves-multiple-myeloma-treatment-outcomes-experts-report 2024-09-10T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f537ece10c2c1863/quralis-doses-first-participant-cohort-in-phase-1-multiple-ascending-dose-mad-clinical 2024-09-10T11:45:39+00:00 weekly 0.7 https://trial.medpath.com/news/7966895a9aeb6952/regeneron-s-libtayo-shows-durable-survival-benefits-in-phase-3-lung-cancer-study 2024-09-10T11:45:39+00:00 weekly 0.7 https://trial.medpath.com/news/0f5e529205068955/europe-sidelines-alzheimer-s-drug-lessons-must-be-learnt-nature 2024-09-10T11:45:31+00:00 weekly 0.7 https://trial.medpath.com/news/01dbafe93a007ec4/cardiol-therapeutics-announces-completion-of-the-maveric-phase-ii-study-in-recurrent 2024-09-10T11:40:18+00:00 weekly 0.7 https://trial.medpath.com/news/ab8952ec0e14558e/delta-fly-pharma-inc-phase-i-ii-combo-study-of-dfp-10917-with-venetoclax-in-patients 2024-09-10T11:33:16+00:00 weekly 0.7 https://trial.medpath.com/news/d46a973c460dfbe8/zydus-lifesciences-completes-phase-iia-trial-of-usnoflast-in-als-patients-cnbc-tv18 2024-09-10T11:27:02+00:00 weekly 0.7 https://trial.medpath.com/news/b67a056ee0df1a3f/silo-pharma-announces-completion-of-fda-pre-ind-meeting-to-advance-development-of 2024-09-10T11:07:11+00:00 weekly 0.7 https://trial.medpath.com/news/f444546aabb7400c/kalvista-pharmaceuticals-to-participate-in-the-2024-cantor-global-healthcare-conference 2024-09-10T11:06:30+00:00 weekly 0.7 https://trial.medpath.com/news/1ecf0156d09daa64/media-update-ers-dupixent-data-reinforce-clinically-meaningful-benefit-from-pooled 2024-09-10T10:40:54+00:00 weekly 0.7 https://trial.medpath.com/news/4ba045c89862e419/phase-2-predict-ild-imaging-study-commences-in-interstitial-lung-disease-pharmatimes 2024-09-10T10:34:12+00:00 weekly 0.7 https://trial.medpath.com/news/e04a92be4e063f7c/astrazeneca-shares-fall-5-on-disappointing-lung-cancer-drug-trial-results-cnbc 2024-09-10T10:15:18+00:00 weekly 0.7 https://trial.medpath.com/news/ea4e7a4f36f85a23/tc-biopharm-announces-plans-for-monkey-pox-treatment-studies 2024-09-10T10:09:21+00:00 weekly 0.7 https://trial.medpath.com/news/55686c0ad9bcb84b/updated-data-from-phase-ii-clinical-trial-of-iruplinalkib-tablets-qixinke-r-presented-at 2024-09-10T10:06:03+00:00 weekly 0.7 https://trial.medpath.com/news/8ec8726e66fdca7d/maia-biotechnology-announces-positive-survival-updates-in-phase-2-study-of-thio-in-non 2024-09-10T10:04:12+00:00 weekly 0.7 https://trial.medpath.com/news/6db2e23e6159b0af/global-exosome-market-size-forecast-trials-and-trends-globenewswire 2024-09-10T09:43:59+00:00 weekly 0.7 https://trial.medpath.com/news/63238e643bd3b709/libido-can-drop-after-menopause-but-this-therapy-can-help 2024-09-10T09:09:33+00:00 weekly 0.7 https://trial.medpath.com/news/0494ac1df56ea4ef/us-fda-advisors-want-iterum-s-antibiotic-indication-narrowed-pink-sheet-citeline 2024-09-10T09:07:17+00:00 weekly 0.7 https://trial.medpath.com/news/d5e859d0e5d9c9af/expert-challenges-benign-classification-of-gleason-6-prostate-cancer-emphasizes-need-for-comprehensive-assessment 2024-09-10T08:56:53+00:00 weekly 0.7 https://trial.medpath.com/news/5ad965a5fe911789/astrazeneca-says-lung-cancer-drug-trial-shows-no-significant-improvement-in-overall-survival 2024-09-10T08:32:37+00:00 weekly 0.7 https://trial.medpath.com/news/63148204cb8a764e/study-links-testosterone-to-heightened-covid-19-severity-in-men-through-immune-response-modulation 2024-09-10T06:58:09+00:00 weekly 0.7 https://trial.medpath.com/news/d2fad241397c1d33/the-airpods-pro-2-will-soon-double-as-hearing-aids-the-verge 2024-09-10T06:36:29+00:00 weekly 0.7 https://trial.medpath.com/news/fabf6fc2674baa47/first-patient-enters-dmx-200-open-label-extension-study-after-successfully-completing 2024-09-10T06:20:14+00:00 weekly 0.7 https://trial.medpath.com/news/d01f2384137caff0/ose-immunotherapeutics-announces-global-launch-of-artemia-phase-3-registration-study 2024-09-10T06:12:10+00:00 weekly 0.7 https://trial.medpath.com/news/2ccd06c4c8ecb311/fda-approval-for-sickle-cell-disease-gene-therapy-medical-news-bulletin 2024-09-10T06:01:26+00:00 weekly 0.7 https://trial.medpath.com/news/b7da05fb607ed110/non-small-cell-lung-cancer-nsclc-clinical-trials-2024-ema-openpr-com 2024-09-10T05:50:56+00:00 weekly 0.7 https://trial.medpath.com/news/522c28b6e84e514c/hs-20093-generates-responses-in-pretreated-es-sclc-onclive 2024-09-10T05:17:20+00:00 weekly 0.7 https://trial.medpath.com/news/79bea42a924bfe71/novel-proteomics-test-prophet-shows-promise-in-guiding-lung-cancer-immunotherapy-decisions 2024-09-10T05:00:35+00:00 weekly 0.7 https://trial.medpath.com/news/72847f64d6de5ea2/closing-the-gender-diagnostic-gap-with-a-sample-collecting-tampon 2024-09-10T05:00:06+00:00 weekly 0.7 https://trial.medpath.com/news/b7d104ee3cc1805f/biotron-updates-on-bit225-012-phase-2-covid-19-clinical-trial-biotech-dispatch 2024-09-10T02:38:27+00:00 weekly 0.7 https://trial.medpath.com/news/ac133c6de9d0d976/zongertinib-yields-meaningful-responses-in-pretreated-her2-mutated-nsclc 2024-09-10T02:22:11+00:00 weekly 0.7 https://trial.medpath.com/news/1c0380c4d2c86221/type-1-diabetes-uab-startup-gains-fda-clearance-to-test-novel-oral-drug-the-alabama 2024-09-10T02:02:32+00:00 weekly 0.7 https://trial.medpath.com/news/1355a60c0d4358ad/innovent-delivers-oral-presentation-of-updated-results-from-a-pivotal-phase-2-pr-newswire 2024-09-10T01:23:45+00:00 weekly 0.7 https://trial.medpath.com/news/16d20dfd811def90/sacituzumab-govitecan-generates-responses-with-manageable-safety-profile-in-es-sclc 2024-09-10T01:01:55+00:00 weekly 0.7 https://trial.medpath.com/news/59aa9368b5e8c1c5/how-daratumumab-sc-is-being-perceived-versus-the-iv-form-ppa-dove-medical-press 2024-09-10T00:58:41+00:00 weekly 0.7 https://trial.medpath.com/news/294e6dd49eb2c4b8/oxford-scientists-develop-first-cancer-prevention-vaccine-for-lynch-syndrome-patients 2024-09-10T00:01:46+00:00 weekly 0.7 https://trial.medpath.com/news/06c6b8a36686037e/bevacizumab-addition-to-first-line-chemotherapy-shows-real-world-benefit-in-high-risk-ovarian-cancer 2024-09-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a871fde4b8860c66/breakthrough-in-parkinson-s-treatment-personalized-deep-brain-stimulation 2024-09-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/3f31316db1fbdbaf/real-world-evidence-shows-apixaban-reduces-major-bleeding-risk-compared-to-rivaroxaban-in-atrial-fibrillation-patients 2024-09-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/01e3120a0a4ef72d/eu-chmp-opinions-and-maa-updates-citeline-news-insights 2024-09-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/1d01ddbc51412033/phanes-therapeutics-announces-first-patient-dosed-in-clinical-study-of-pt886-in 2024-09-09T23:52:51+00:00 weekly 0.7 https://trial.medpath.com/news/9df35a3fd359fa93/who-still-benefits-from-paxlovid-idsa 2024-09-09T23:38:25+00:00 weekly 0.7 https://trial.medpath.com/news/18402029cbb9f7a1/medicinova-announces-abstract-regarding-mn-166-ibudilast-in-combat-als-clinical 2024-09-09T23:22:07+00:00 weekly 0.7 https://trial.medpath.com/news/6cc4f3081dde0d7f/withings-sleep-rx-receives-fda-clearance-for-home-sleep-apnea-testing 2024-09-09T23:03:49+00:00 weekly 0.7 https://trial.medpath.com/news/befe5c3a924ee5db/sleep-apnea-detection-will-be-on-apple-watches-soon-here-s-how-it-will-work-cnet 2024-09-09T22:54:45+00:00 weekly 0.7 https://trial.medpath.com/news/cf7b1b7c57086dc8/analysis-further-shows-perioperative-pembrolizumab-efficacy-in-early-stage-nsclc 2024-09-09T22:01:16+00:00 weekly 0.7 https://trial.medpath.com/news/5ee6334fcca514a5/fda-clears-deepwell-digital-therapeutics-software-development-kit-massdevice 2024-09-09T21:32:54+00:00 weekly 0.7 https://trial.medpath.com/news/865ffde98d3d310f/study-compares-dose-escalation-with-biologics-in-psoriasis-dermatology-times 2024-09-09T21:12:19+00:00 weekly 0.7 https://trial.medpath.com/news/66f73e61b9a744db/aumolertinib-improves-pfs-in-unresectable-stage-iii-egfr-nsclc-after-chemoradiotherapy 2024-09-09T20:52:49+00:00 weekly 0.7 https://trial.medpath.com/news/aee6c215a5684a7a/eyen-shares-are-trading-higher-today-what-you-need-to-know-benzinga 2024-09-09T20:20:52+00:00 weekly 0.7 https://trial.medpath.com/news/2563cfad0ac1e7f4/solid-biosciences-tracking-long-term-effects-of-duchenne-muscular-dystrophy-gene 2024-09-09T20:15:16+00:00 weekly 0.7 https://trial.medpath.com/news/1077d35ff443ab0a/vir-biotechnology-announces-closing-of-exclusive-worldwide-license-agreement-with 2024-09-09T20:10:14+00:00 weekly 0.7 https://trial.medpath.com/news/8e50fc525f996dfb/nivolumab-plus-chemotherapy-extends-survival-in-lymph-node-only-metastatic-urothelial-cancer 2024-09-09T19:13:13+00:00 weekly 0.7 https://trial.medpath.com/news/e217e27d1bb44483/pembrolizumab-plus-ccrt-scores-in-east-asian-subgroup-with-cervical-cancer 2024-09-09T19:11:58+00:00 weekly 0.7 https://trial.medpath.com/news/d999f54ac5828256/stealth-biotherapeutics-announces-fda-advisory-committee-meeting-to-review-biospace 2024-09-09T19:11:45+00:00 weekly 0.7 https://trial.medpath.com/news/df300e5c222bc5db/bay-2927088-displays-durable-responses-in-her2-mutated-nsclc-onclive 2024-09-09T19:03:15+00:00 weekly 0.7 https://trial.medpath.com/news/3a056fae76524cd7/phase-ii-study-for-sjogren-s-syndrome-drug-cooperation-between-servier-than-and-clariness 2024-09-09T18:50:55+00:00 weekly 0.7 https://trial.medpath.com/news/02a7785db052d789/brigham-led-study-finds-weight-loss-drug-semaglutide-reduced-covid-19-related 2024-09-09T18:29:06+00:00 weekly 0.7 https://trial.medpath.com/news/4c4b09748dc52216/agenus-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-losses-morningstar 2024-09-09T18:28:49+00:00 weekly 0.7 https://trial.medpath.com/news/ad88a6021a3b3dca/study-olezarsen-effective-treatment-for-high-triglycerides-mass-general-brigham 2024-09-09T18:20:54+00:00 weekly 0.7 https://trial.medpath.com/news/849ced93341de220/psilocybin-drug-by-psilera-could-treat-frontotemporal-dementia-without-psychoactive-effects 2024-09-09T18:20:11+00:00 weekly 0.7 https://trial.medpath.com/news/bd3a678d9caba16e/md-anderson-research-highlights-special-edition-2-newswise 2024-09-09T18:11:55+00:00 weekly 0.7 https://trial.medpath.com/news/6fcfc592446a1d85/the-changing-landscape-of-clinical-trials-in-cancer-care-oncology-nursing-news 2024-09-09T18:11:33+00:00 weekly 0.7 https://trial.medpath.com/news/4106161d683d800d/directrx-pharmacy-distributing-copd-therapy-ohtuvayre-in-us 2024-09-09T17:53:33+00:00 weekly 0.7 https://trial.medpath.com/news/d0c5bfcbfa289207/biorationality-fda-clarification-provides-new-indications-and-process-change-for-biosimilars 2024-09-09T17:05:48+00:00 weekly 0.7 https://trial.medpath.com/news/e210b3c044b6fafb/phase-3-charm-results-highlight-potential-of-iv-glibenclamide-to-improve-independent 2024-09-09T17:04:56+00:00 weekly 0.7 https://trial.medpath.com/news/2270596c02f8f929/advancing-hope-udaily-university-of-delaware 2024-09-09T16:54:13+00:00 weekly 0.7 https://trial.medpath.com/news/ab541f24c5f6749b/rdca-dap-nets-new-data-to-speed-research-therapies-for-cf-cystic-fibrosis-news-today 2024-09-09T16:42:51+00:00 weekly 0.7 https://trial.medpath.com/news/0f1c2583cda6f145/fda-letter-supports-use-of-new-alpha-synuclein-assay-in-trials-parkinson-s-news-today 2024-09-09T16:42:41+00:00 weekly 0.7 https://trial.medpath.com/news/f35ab249c8bf4080/iu-research-targets-debilitating-side-effects-for-black-breast-cancer-patients 2024-09-09T16:27:22+00:00 weekly 0.7 https://trial.medpath.com/news/78475b4ba5d3d8b2/a-better-fix-for-food-allergies-the-atlantic 2024-09-09T15:31:24+00:00 weekly 0.7 https://trial.medpath.com/news/e2cdbb2063ea9bae/pierre-fabre-laboratories-receives-european-commission-approval-for-braftovi 2024-09-09T15:31:13+00:00 weekly 0.7 https://trial.medpath.com/news/f2daaadf52f33d32/zealand-pharma-announces-positive-topline-results-from-13-week-phase-1b-multiple-quantisnow 2024-09-09T15:21:20+00:00 weekly 0.7 https://trial.medpath.com/news/6a9d2016b5f60756/early-metabolic-profiling-could-identify-babies-at-risk-of-sids-inside-precision-medicine 2024-09-09T15:04:37+00:00 weekly 0.7 https://trial.medpath.com/news/0248414f92f6db52/the-highly-anticipated-fda-approvals-of-galderma-s-nemolizumab-and-eli-lilly-s-markets-insider 2024-09-09T14:55:55+00:00 weekly 0.7 https://trial.medpath.com/news/d707692873f86da9/a-diagnosis-of-triple-negative-breast-cancer-was-not-on-my-radar-the-asco-post 2024-09-09T14:51:50+00:00 weekly 0.7 https://trial.medpath.com/news/21052d7b114f8ff4/dow-jones-today-major-indexes-higher-as-stocks-look-to-rebound-from-biggest-weekly 2024-09-09T14:51:29+00:00 weekly 0.7 https://trial.medpath.com/news/5e553bb13b19a080/grail-s-potential-turnaround-seeking-fda-approval-for-galleri-nasdaq-gral 2024-09-09T14:51:06+00:00 weekly 0.7 https://trial.medpath.com/news/507c32f6de96f8ff/tubeless-insulin-patch-pump-receives-fda-clearance-for-type-1-and-type-2-diabetes-healio 2024-09-09T14:48:54+00:00 weekly 0.7 https://trial.medpath.com/news/94eea88aaa928acb/zeroing-in-on-vaginal-microbes-that-most-increase-hiv-risk-fred-hutchinson-cancer-center 2024-09-09T14:45:32+00:00 weekly 0.7 https://trial.medpath.com/news/a5cf33fb0485ac67/earnings-call-genus-reports-progress-amid-market-challenges-eyes-fda-approval 2024-09-09T14:27:26+00:00 weekly 0.7 https://trial.medpath.com/news/bddc4cb7093830b6/avacta-to-present-updated-clinical-data-on-ava6000-at-the-european-society-for-medical 2024-09-09T14:25:23+00:00 weekly 0.7 https://trial.medpath.com/news/be6e22964be01df0/psyence-biomed-announces-initiation-of-first-trial-site-in-australia-for-its-phase-iib-study-of 2024-09-09T14:19:22+00:00 weekly 0.7 https://trial.medpath.com/news/b815a01afa289eef/innovative-medical-trial-for-treatment-of-hydrocephalus-to-lead-to-safer-outcomes-for-patients 2024-09-09T14:18:44+00:00 weekly 0.7 https://trial.medpath.com/news/7ed095bca0977f9c/chinese-study-finds-radiation-alone-may-be-as-effective-as-chemoradiation-in-patients 2024-09-09T14:08:35+00:00 weekly 0.7 https://trial.medpath.com/news/ddc403768ab69545/astrazeneca-s-promising-biomarker-data-and-phase-iii-trials-buy-rating-affirmed 2024-09-09T14:01:03+00:00 weekly 0.7 https://trial.medpath.com/news/a2dca71e297cfd3c/ruxolitinib-may-be-effective-in-refractory-chronic-gvhd-hematology-advisor 2024-09-09T13:49:19+00:00 weekly 0.7 https://trial.medpath.com/news/ee3a916118abd8c4/bambusa-therapeutics-inc-announces-successful-series-seed-funding-to-advance-morningstar 2024-09-09T13:34:09+00:00 weekly 0.7 https://trial.medpath.com/news/cbd2bcedbf4417dc/actuate-therapeutics-obtains-complete-responses-and-provides-update-on-clinical-trial-of 2024-09-09T13:34:05+00:00 weekly 0.7 https://trial.medpath.com/news/79a37faeb62d4435/jazz-pharmaceuticals-to-present-advancements-in-solid-tumor-oncology-research-at-esmo-2024 2024-09-09T13:33:39+00:00 weekly 0.7 https://trial.medpath.com/news/3f87d897c4202f3c/clinical-trials-ongoing-for-asf-bird-flu-vaccines-businessworld-online 2024-09-09T13:32:58+00:00 weekly 0.7 https://trial.medpath.com/news/235430f0e38044be/candid-with-370m-sets-out-to-prove-bispecifics-worth-in-autoimmune-disease 2024-09-09T13:26:38+00:00 weekly 0.7 https://trial.medpath.com/news/19112667f1005e35/rytelotm-imetelstat-fda-approved-for-treatment-of-patients-with-low-to-intermediate-1 2024-09-09T13:25:16+00:00 weekly 0.7 https://trial.medpath.com/news/dc03eefb760733bd/t2-biosystems-provides-updates-on-its-new-product-development-pipeline-progress 2024-09-09T13:25:10+00:00 weekly 0.7 https://trial.medpath.com/news/fb82cba45aded6d9/china-s-akeso-soars-after-new-cancer-drug-beats-market-leader-in-clinical-trials 2024-09-09T13:18:26+00:00 weekly 0.7 https://trial.medpath.com/news/ffce7b60c5126b84/femasys-inc-receives-u-s-fda-clearance-to-market-femchec-r-an-innovative-diagnostic 2024-09-09T13:14:31+00:00 weekly 0.7 https://trial.medpath.com/news/64aed5fdbe199dd2/epsilogen-ltd-completes-ps12-5m-series-b-expansion-european-biotechnology-magazine 2024-09-09T13:14:30+00:00 weekly 0.7 https://trial.medpath.com/news/7582a325af58ce82/amgen-presents-new-data-for-first-in-class-imdelltratm-tarlatamab 2024-09-09T13:06:17+00:00 weekly 0.7 https://trial.medpath.com/news/247748ada827dc3c/evaxion-reports-69-overall-response-rate-in-its-phase-2-trial-on-lead-cancer-vaccine 2024-09-09T13:04:00+00:00 weekly 0.7 https://trial.medpath.com/news/7ad877e9840e79af/abbvie-showcases-advancement-of-solid-tumor-pipeline-at-esmo-2024-with-new-data-in 2024-09-09T13:02:58+00:00 weekly 0.7 https://trial.medpath.com/news/8ef5d4d804c7b4b5/chinese-monkeypox-vaccine-gets-green-light-for-clinical-trials-chinadaily-com-cn 2024-09-09T13:01:20+00:00 weekly 0.7 https://trial.medpath.com/news/11bb38ae755d6b60/september-2024-letter-to-shareholders-cytodyn-inc 2024-09-09T12:35:02+00:00 weekly 0.7 https://trial.medpath.com/news/0f8f6a6c3b7d24af/pds-biotech-to-present-updated-versatile-002-data-at-esmo-congress-2024 2024-09-09T12:34:03+00:00 weekly 0.7 https://trial.medpath.com/news/4d0a07458c2b1e88/biostock-has-published-an-article-on-the-approved-ompd-for-cs1-in-the-eu-marketscreener 2024-09-09T12:28:34+00:00 weekly 0.7 https://trial.medpath.com/news/4cccf14d56c2b5aa/fda-approves-illumina-cancer-biomarker-test-san-diego-business-journal 2024-09-09T12:28:18+00:00 weekly 0.7 https://trial.medpath.com/news/be45750698820e46/data-show-sustained-benefits-of-deucrictibant-for-hae-attacks-angioedema-news 2024-09-09T12:22:54+00:00 weekly 0.7 https://trial.medpath.com/news/86fdec85f7553213/amgen-will-test-obesity-drug-maritide-for-kidney-and-other-diseases-docwire-news 2024-09-09T12:21:37+00:00 weekly 0.7 https://trial.medpath.com/news/618ca9b72b0842c3/moleculin-announces-first-patients-treated-in-phase-2-clinical-trial-of-stat3-stock-titan 2024-09-09T12:20:26+00:00 weekly 0.7 https://trial.medpath.com/news/b4be9684e1e71cfb/agilent-unveils-biopharma-cdx-services-lab-to-accelerate-precision-medicine-stock-titan 2024-09-09T12:20:24+00:00 weekly 0.7 https://trial.medpath.com/news/c4385380bbdb29b3/ub-professor-nys-researchers-developing-immunotherapy-treatment-for-alzheimer-s 2024-09-09T12:14:32+00:00 weekly 0.7 https://trial.medpath.com/news/c8f86b032d95a555/phase-i-study-of-safety-and-efficacy-of-allogeneic-natural-killer-cell-therapy-in-relapsed 2024-09-09T12:08:45+00:00 weekly 0.7 https://trial.medpath.com/news/b82e42de461cb90d/annexon-to-present-phase-2-archer-data-on-protection-of-vision-and-photoreceptors-with 2024-09-09T12:06:09+00:00 weekly 0.7 https://trial.medpath.com/news/30b9960bca0fd700/replimune-announces-positive-pre-bla-meeting-with-fda-and-globenewswire 2024-09-09T12:04:09+00:00 weekly 0.7 https://trial.medpath.com/news/36fc15d5b365637d/rezolute-s-rz358-advances-with-fda-clearance-for-study-tipranks-com 2024-09-09T11:59:17+00:00 weekly 0.7 https://trial.medpath.com/news/06d82c091cff926d/medicenna-presents-preclinical-results-from-its-il-2-super-antagonist-and-anti-pd1-il-2 2024-09-09T11:59:08+00:00 weekly 0.7 https://trial.medpath.com/news/ffe07d57d57064ad/tonix-pharmaceuticals-presented-data-on-the-potential-mpox-vaccine-tnx-801-in-morningstar 2024-09-09T11:35:59+00:00 weekly 0.7 https://trial.medpath.com/news/fea799118ebea84a/terns-pharmaceuticals-announces-positive-phase-1-clinical-trial-results-with-tern-601 2024-09-09T11:35:57+00:00 weekly 0.7 https://trial.medpath.com/news/fdb2396715b62602/cartesian-therapeutics-receives-fda-rare-pediatric-disease-designation-for-descartes-08 2024-09-09T11:18:14+00:00 weekly 0.7 https://trial.medpath.com/news/e78f207b4f1fbb74/sab-bio-provides-sab-142-clinical-trial-progress-update-at-the-european-association-for 2024-09-09T11:13:00+00:00 weekly 0.7 https://trial.medpath.com/news/d2e6bd12b6cf2a3c/akero-therapeutics-announces-first-patient-dosed-in-phase-3-synchrony-outcomes 2024-09-09T11:04:11+00:00 weekly 0.7 https://trial.medpath.com/news/1c79d18b4ad3aa79/targeting-the-racial-disparity-in-kidney-disease 2024-09-09T11:00:41+00:00 weekly 0.7 https://trial.medpath.com/news/7018629e110db372/1104-tackling-the-root-cause-of-allergic-disease-drug-target-review 2024-09-09T10:58:08+00:00 weekly 0.7 https://trial.medpath.com/news/5431625bce448978/dr-sen-on-interim-ideate-lung01-data-in-extensive-stage-sclc-onclive 2024-09-09T10:47:13+00:00 weekly 0.7 https://trial.medpath.com/news/52004d0e42f52eda/fosun-pharma-s-new-drug-wins-approval-tipranks-com 2024-09-09T10:41:09+00:00 weekly 0.7 https://trial.medpath.com/news/6df35edca5fda803/u-ploid-announces-breakthrough-technology-to-overcome-age-related-infertility 2024-09-09T10:23:17+00:00 weekly 0.7 https://trial.medpath.com/news/30a069b5d70d4e04/bayer-receives-ema-approval-marketscreener 2024-09-09T10:16:03+00:00 weekly 0.7 https://trial.medpath.com/news/f51c402b3e157206/astrazeneca-completes-clinical-trials-for-near-zero-emission-inhalers-businessgreen-news 2024-09-09T09:11:18+00:00 weekly 0.7 https://trial.medpath.com/news/5e246bb1033bf96c/immunovant-provides-update-on-graves-disease-development-program-biospace 2024-09-09T09:09:11+00:00 weekly 0.7 https://trial.medpath.com/news/a8f099e3dcdf1185/fda-approves-leklaza-combination-therapy-what-are-the-prospects-for-monotherapy-in 2024-09-09T08:50:08+00:00 weekly 0.7 https://trial.medpath.com/news/f237419e95f643b3/tilt-biotherapeutics-presents-clinical-data-on-tilt-123-globenewswire 2024-09-09T07:03:14+00:00 weekly 0.7 https://trial.medpath.com/news/42f13768e4d14091/annual-mammograms-show-superior-outcomes-in-breast-cancer-detection-and-survival-rates 2024-09-09T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/951f0626cd1f9da1/diamyd-medical-to-pursue-accelerated-approval-pathway-for-type-1-diabetes-precision-medicine 2024-09-09T06:57:57+00:00 weekly 0.7 https://trial.medpath.com/news/296f9bc5ff88dc1e/myongji-hospital-develops-tool-to-predict-ovarian-cancer-drug-resistance-hospital-article-kbr 2024-09-09T06:47:34+00:00 weekly 0.7 https://trial.medpath.com/news/fc70e5086d8d2c25/cizzle-biotechnology-collaborates-with-moffitt-cancer-center-directorstalk-interviews 2024-09-09T06:38:48+00:00 weekly 0.7 https://trial.medpath.com/news/68e09a641d8ac144/chugai-seeks-additional-indication-approval-from-japan-mhlw-for-vabysmo-to-treat-angioid 2024-09-09T06:30:50+00:00 weekly 0.7 https://trial.medpath.com/news/b332a00d2ec546d7/hemogenyx-pharmaceuticals-plc-flt3-assay-ready-for-phase-i-trials-at-md-anderson 2024-09-09T06:28:41+00:00 weekly 0.7 https://trial.medpath.com/news/8efc8868946cf424/fda-approved-oral-jak-inhibitors-show-promise-in-treating-moderate-to-severe-atopic-dermatitis 2024-09-09T05:17:03+00:00 weekly 0.7 https://trial.medpath.com/news/683645e2a8a80c2d/global-biopharmaceutical-innovator-pharmaessentia-launches-new 2024-09-09T05:15:38+00:00 weekly 0.7 https://trial.medpath.com/news/254e5a24e2323e67/innate-pharma-sa-monalizumab-data-from-neocoast-2-phase-2-study-in-early-stage 2024-09-09T05:08:28+00:00 weekly 0.7 https://trial.medpath.com/news/f49a8b9970fbd165/poltreg-treg-cell-therapy-for-patients-with-type-1-diabetes-globenewswire 2024-09-09T05:02:17+00:00 weekly 0.7 https://trial.medpath.com/news/a7bc21edc9080761/late-stage-alzheimer-s-pipeline-goes-beyond-amyloid-and-tau-biospace 2024-09-09T04:10:58+00:00 weekly 0.7 https://trial.medpath.com/news/048261541fb1f79b/mda-kickstart-program-launches-for-ultra-rare-neuromuscular-disease-drug-development 2024-09-09T04:01:41+00:00 weekly 0.7 https://trial.medpath.com/news/edb8c25427a78f5d/healios-kk-advances-global-phase-3-ards-trial-tipranks-com 2024-09-09T03:58:53+00:00 weekly 0.7 https://trial.medpath.com/news/18da823469d1ff9e/br-6002-by-boryung-pharmaceutical-for-cardiovascular-disease-likelihood-of-approval 2024-09-09T03:09:14+00:00 weekly 0.7 https://trial.medpath.com/news/8e0020c549a67dc7/senhwa-biosciences-presents-clinical-data-abstract-on-pidnarulex-at-2024-esmo-congress 2024-09-09T02:39:41+00:00 weekly 0.7 https://trial.medpath.com/news/5defb5443cd3e09f/hutchmed-highlights-clinical-data-to-be-presented-at-esmo-congress-2024-and-the 2024-09-09T01:53:41+00:00 weekly 0.7 https://trial.medpath.com/news/2a9f6c86b17c4453/antennova-to-present-latest-data-of-atn-037-in-a-mini-oral-presentation-at-esmo-congress-2024 2024-09-09T00:52:39+00:00 weekly 0.7 https://trial.medpath.com/news/675cdaffc13334de/natera-to-present-new-signateratm-colorectal-cancer-data-at-esmo-showing-10x 2024-09-09T00:34:38+00:00 weekly 0.7 https://trial.medpath.com/news/68049c4c49c0c395/eisai-s-foscenvivint-shows-promise-in-pancreatic-cancer-development-pipeline 2024-09-09T00:12:01+00:00 weekly 0.7 https://trial.medpath.com/news/f05d5f3b3fbe157f/alfasigma-advances-filgotinib-maleate-development-for-igg4-related-disease-treatment 2024-09-09T00:03:06+00:00 weekly 0.7 https://trial.medpath.com/news/4024c50e775d2cdc/breakwater-study-shows-promise-for-encorafenib-cetuximab-plus-folfiri-in-braf-v600e-mutant-colorectal-cancer 2024-09-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/9593b111fc6192d2/update-imunons-ovarian-cancer-r-d-day-to-feature-presentations-from-imnn-001-clinical-study-investigators-immunology-and-biostatistics-experts-and-executive-management 2024-09-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f73085b85f97ee8c/hr20013-demonstrates-noninferiority-in-preventing-chemo-induced-nausea-vomiting 2024-09-08T23:26:15+00:00 weekly 0.7 https://trial.medpath.com/news/4c1d22fd23daac10/lecanemab-the-drug-giving-hope-to-people-at-risk-of-dementia-hmri 2024-09-08T23:25:01+00:00 weekly 0.7 https://trial.medpath.com/news/85d9ea5d2e73146f/anti-pd-l1-antibody-asc22-in-combination-with-a-histone-deacetylase-inhibitor-chidamide-nature 2024-09-08T23:16:58+00:00 weekly 0.7 https://trial.medpath.com/news/b4317654838bab24/macrogenics-announces-tamarack-phase-2-data-presentation-at-esmo-congress-2024 2024-09-08T23:15:07+00:00 weekly 0.7 https://trial.medpath.com/news/df619d26e10f6a9e/clinical-trial-combining-durvalumab-with-novel-agents-increases-pathological-responses-in 2024-09-08T23:10:30+00:00 weekly 0.7 https://trial.medpath.com/news/132006707e41c34b/cantargia-new-data-from-two-clinical-studies-strongly-support-nadunolimab-efficacy-after 2024-09-08T22:21:33+00:00 weekly 0.7 https://trial.medpath.com/news/5c9a91d4b6dead6f/ultimovacs-announces-updated-data-analysis-on-uv1-phase-ii-globenewswire 2024-09-08T22:18:22+00:00 weekly 0.7 https://trial.medpath.com/news/e505f892fd19965d/c4-therapeutics-to-present-preliminary-cft1946-monotherapy-phase-1-clinical-data-at-the 2024-09-08T22:12:22+00:00 weekly 0.7 https://trial.medpath.com/news/7d72367226a6321a/summit-lung-cancer-drug-shows-striking-benefit-over-keytruda-biopharma-dive 2024-09-08T22:10:49+00:00 weekly 0.7 https://trial.medpath.com/news/6e658363ce432be8/dr-spira-on-updated-mariposa-trial-data-in-egfr-advanced-nsclc-onclive 2024-09-08T22:07:11+00:00 weekly 0.7 https://trial.medpath.com/news/2e5955b9943a8438/a-biotech-going-through-the-nose-to-treat-the-brain-plots-alternative-path-to-public-markets 2024-09-08T21:52:34+00:00 weekly 0.7 https://trial.medpath.com/news/847d0690429d50c8/durvalumab-combo-maintains-pfs-benefit-in-ovarian-cancer-targeted-oncology 2024-09-08T21:04:34+00:00 weekly 0.7 https://trial.medpath.com/news/8eaf5c82469b6b6e/effectiveness-of-structured-multidisciplinary-long-term-care-for-pediatric-cancer-survivors 2024-09-08T20:32:05+00:00 weekly 0.7 https://trial.medpath.com/news/e1bfaac26cbf35c4/a-phase-ii-trial-examining-the-safety-and-preliminary-efficacy-of-repetitive-transcranial 2024-09-08T20:30:06+00:00 weekly 0.7 https://trial.medpath.com/news/3d2b20a857f8c33b/study-reports-2-year-survival-data-on-nivolumab-plus-relatlimab-in-nsclc 2024-09-08T19:22:02+00:00 weekly 0.7 https://trial.medpath.com/news/ac88531cb8c48bca/fda-oked-new-drug-application-for-novel-glioblastoma-treatment-cure-today 2024-09-08T19:10:30+00:00 weekly 0.7 https://trial.medpath.com/news/fb1115723f5de711/research-identifies-potential-biomarkers-for-treatment-response-in-psa-hcplive 2024-09-08T18:31:00+00:00 weekly 0.7 https://trial.medpath.com/news/2f7a212879a4446a/sun-pharma-s-sonidegib-shows-promise-across-multiple-cancer-indications-beyond-basal-cell-carcinoma 2024-09-08T18:28:51+00:00 weekly 0.7 https://trial.medpath.com/news/a9777d02d3959369/minovia-s-mnv-201-cell-therapy-shows-promise-for-rare-pearson-syndrome-treatment 2024-09-08T18:26:19+00:00 weekly 0.7 https://trial.medpath.com/news/a301e2357c41793c/first-in-class-cebranopadol-moving-to-phase-3-trials-managed-healthcare-executive 2024-09-08T18:14:14+00:00 weekly 0.7 https://trial.medpath.com/news/480edf2c9ed9fe75/emicizumab-shows-promise-for-acquired-hemophilia-a-treatment-in-development-pipeline 2024-09-08T17:57:42+00:00 weekly 0.7 https://trial.medpath.com/news/decac0d121f79b2f/rybrevant-r-amivantamab-vmjw-plus-lazcluzetm-lazertinib-show-strong-favorable 2024-09-08T17:49:14+00:00 weekly 0.7 https://trial.medpath.com/news/82984979b6464448/risk-adjusted-net-present-value-what-is-the-current-valuation-of-deciphera 2024-09-08T17:45:12+00:00 weekly 0.7 https://trial.medpath.com/news/333b6875bd01d1f4/perioperative-nivolumab-may-bolster-survival-over-only-neoadjuvant-nivolumab-plus 2024-09-08T17:18:32+00:00 weekly 0.7 https://trial.medpath.com/news/1f3ce1c86c9ddab7/immunotherapy-before-and-after-lung-cancer-surgery-reduces-death-risk-and-disease 2024-09-08T17:12:44+00:00 weekly 0.7 https://trial.medpath.com/news/1f866e9d5a44d75c/il-21-promises-to-revolutionize-treatment-for-glioblastoma-pembrolizumab-trials-halted-in 2024-09-08T17:03:02+00:00 weekly 0.7 https://trial.medpath.com/news/f0a3da5d14b2e9db/novel-computational-pathology-based-trop2-biomarker-for-datopotamab-deruxtecan-was 2024-09-08T16:36:17+00:00 weekly 0.7 https://trial.medpath.com/news/cd51678b43888783/global-experts-share-strategies-to-enhance-lung-cancer-screening-access-and-early-detection 2024-09-08T16:30:45+00:00 weekly 0.7 https://trial.medpath.com/news/7b0d2b56511d6c90/ivonescimab-monotherapy-reduced-the-risk-of-disease-progression-or-death-by-49-morningstar 2024-09-08T16:03:05+00:00 weekly 0.7 https://trial.medpath.com/news/31be94d9d4c3eb4f/company-announcement-markets-data 2024-09-08T15:49:26+00:00 weekly 0.7 https://trial.medpath.com/news/6d02e4c90079bdff/association-of-leucine-and-other-branched-chain-amino-acids-with-clinical-outcomes-in-nature 2024-09-08T14:58:15+00:00 weekly 0.7 https://trial.medpath.com/news/45b292b0e1992592/vaxcyte-s-broad-spectrum-pneumococcal-vaccines-poised-for-market-dominance-by-2027 2024-09-08T14:34:14+00:00 weekly 0.7 https://trial.medpath.com/news/d62ee604d3011085/lower-risk-mds-population-has-enduring-rbc-ti-following-imetelstat-therapy 2024-09-08T14:09:23+00:00 weekly 0.7 https://trial.medpath.com/news/8e80543fe6d5b391/fda-clears-think-surgical-robotic-system-for-use-with-medacta-knee-implants-healio 2024-09-08T13:57:39+00:00 weekly 0.7 https://trial.medpath.com/news/3998b2ea75e51092/childhood-antibioticination-reduces-mortality-in-africa-contagion-live 2024-09-08T13:26:31+00:00 weekly 0.7 https://trial.medpath.com/news/d280c7a29764c061/revealed-the-bowel-cancer-breakthrough-that-could-save-young-sufferers-daily-mail 2024-09-08T13:12:44+00:00 weekly 0.7 https://trial.medpath.com/news/4bca4a7780f6b341/all-about-cholesterol-american-society-for-biochemistry-and-molecular-biology 2024-09-08T12:15:17+00:00 weekly 0.7 https://trial.medpath.com/news/ba1f1e3d45d69735/alzheimer-s-drug-leqembi-promises-to-give-patients-more-time-but-they-face-a-long-road-to-treatment 2024-09-08T12:03:19+00:00 weekly 0.7 https://trial.medpath.com/news/a395dbd8c9f12bf9/longboard-pharmaceuticals-announces-positive-interim-analysis-results-from-the-stock-titan 2024-09-08T11:35:43+00:00 weekly 0.7 https://trial.medpath.com/news/86a9ef4af5c1c332/ai-platform-demonstrates-promising-results-in-treating-patient-with-rare-cancer 2024-09-08T11:31:44+00:00 weekly 0.7 https://trial.medpath.com/news/fca420c351f2fba1/savara-announces-new-data-from-pivotal-phase-3-impala-2-trial-of-molgramostim-morningstar 2024-09-08T11:02:45+00:00 weekly 0.7 https://trial.medpath.com/news/1d70a24e0a3a954d/celcuity-s-gedatolisib-projected-to-reach-155m-annual-revenue-by-2034-for-breast-cancer-treatment 2024-09-08T09:14:13+00:00 weekly 0.7 https://trial.medpath.com/news/07a625fc84222334/tenaya-therapeutics-gene-therapy-tn-201-shows-promise-with-projected-165m-revenue-for-cardiomyopathy-treatment 2024-09-08T09:13:04+00:00 weekly 0.7 https://trial.medpath.com/news/2bc2eaa32063819a/bristol-myers-squibb-s-myk-224-for-hypertrophic-cardiomyopathy-projects-41m-revenue-by-2035 2024-09-08T09:11:56+00:00 weekly 0.7 https://trial.medpath.com/news/38ac429c7949b8e3/regulus-therapeutics-rgls-8429-projected-to-reach-213m-annual-revenue-by-2037-for-adpkd-treatment 2024-09-08T09:10:46+00:00 weekly 0.7 https://trial.medpath.com/news/59e990fe8f78dd48/jcr-pharmaceuticals-laronidase-for-hurler-syndrome-expected-to-generate-38m-by-2040 2024-09-08T09:08:24+00:00 weekly 0.7 https://trial.medpath.com/news/e6dcb7ccbf336c42/iteos-therapeutics-tigit-inhibitor-belrestotug-projects-366m-peak-revenue-for-solid-tumors-by-2038 2024-09-08T09:06:16+00:00 weekly 0.7 https://trial.medpath.com/news/82fc6e0e490685af/insmed-s-treprostinil-palmitil-shows-promise-for-rare-pulmonary-disorders-with-projected-66m-revenue-by-2037 2024-09-08T09:05:20+00:00 weekly 0.7 https://trial.medpath.com/news/2f738073001add72/altimmune-s-pemvidutide-projected-to-reach-759m-in-global-sales-by-2039 2024-09-08T09:03:31+00:00 weekly 0.7 https://trial.medpath.com/news/16325984afb65ccf/dupilumab-treatment-effective-for-chronic-rhinosinusitis-with-nasal-polyps-hcplive 2024-09-08T08:42:07+00:00 weekly 0.7 https://trial.medpath.com/news/e975c84519e282f3/beigene-s-bgb-16673-shows-promise-in-blood-cancer-treatment-with-projected-9m-revenue-by-2037 2024-09-08T08:39:51+00:00 weekly 0.7 https://trial.medpath.com/news/00a2ce65f349f559/amgen-s-maridebart-cafraglutide-projected-to-reach-527-million-in-us-sales-by-2039 2024-09-08T08:33:30+00:00 weekly 0.7 https://trial.medpath.com/news/d76c6589dcf8a6eb/novartis-s-atrasentan-shows-promise-with-projected-229m-revenue-by-2033-for-kidney-diseases 2024-09-08T08:32:18+00:00 weekly 0.7 https://trial.medpath.com/news/bc81b00d58e7bd0b/ideaya-s-ide-397-shows-promise-in-multiple-solid-tumors-with-47m-revenue-projection-by-2037 2024-09-08T08:29:17+00:00 weekly 0.7 https://trial.medpath.com/news/0ea368c047f7d7e0/study-shows-how-nanorobots-could-prevent-strokes-newsbytes 2024-09-08T08:24:53+00:00 weekly 0.7 https://trial.medpath.com/news/4efe3bb58f3cbbe6/fda-rejection-of-mdma-could-fuel-black-market-demand-warns-ceo-of-women-s 2024-09-08T08:08:56+00:00 weekly 0.7 https://trial.medpath.com/news/a7bee1bb97991de0/mesa-lab-testing-new-leg-wound-care-products-eastvalleytribune-com 2024-09-08T07:07:26+00:00 weekly 0.7 https://trial.medpath.com/news/bea71e7f8f310ff7/non-invasive-optoacoustic-imaging-of-glycogen-storage-and-muscle-degeneration-in-late 2024-09-08T06:45:42+00:00 weekly 0.7 https://trial.medpath.com/news/bc267b4cf8a48f73/spain-pharma-company-key-in-life-saving-drug-euro-weekly-news 2024-09-08T05:31:54+00:00 weekly 0.7 https://trial.medpath.com/news/26f35e92ca7184dc/first-comprehensive-review-of-sma-drugs-offers-long-term-insights-outcome-gaps 2024-09-08T02:49:33+00:00 weekly 0.7 https://trial.medpath.com/news/e4d6fa96367b43c7/dose-justification-for-asciminib-in-patients-with-philadelphia-chromosome-positive-chronic 2024-09-08T01:39:53+00:00 weekly 0.7 https://trial.medpath.com/news/079a4b4290554e80/levicept-levi-04-reduces-osteoarthritis-pain-2-minute-medicine 2024-09-07T23:48:11+00:00 weekly 0.7 https://trial.medpath.com/news/b2ece1e1b2ef4262/antibody-drug-conjugate-i-dxd-shows-meaningful-response-in-patients-with-extensive-stage 2024-09-07T22:18:04+00:00 weekly 0.7 https://trial.medpath.com/news/fd37c143f8d58819/semaglutide-hydrogel-may-cut-diabetes-shots-to-monthly-mirage-news 2024-09-07T22:03:23+00:00 weekly 0.7 https://trial.medpath.com/news/76bd06c04cfd1fdc/merck-daiichi-post-trial-data-for-lung-cancer-drug-nyse-mrk-seeking-alpha 2024-09-07T21:13:37+00:00 weekly 0.7 https://trial.medpath.com/news/27d6b8a767ce1da9/this-week-in-ophthalmology-week-of-september-1-2024 2024-09-07T21:06:17+00:00 weekly 0.7 https://trial.medpath.com/news/d6c6bb4c2bac2e85/high-risk-cll-subgroups-see-benefits-with-liso-cel-targeted-oncology 2024-09-07T21:05:27+00:00 weekly 0.7 https://trial.medpath.com/news/7bf45a43c1abd911/tryptamine-therapeutics-sets-date-for-agm-advances-clinical-trials-tipranks-com 2024-09-07T19:24:16+00:00 weekly 0.7 https://trial.medpath.com/news/8bf9889bab701eec/recreational-drug-use-tied-to-repeat-cardiovascular-events-medical-xpress 2024-09-07T19:21:14+00:00 weekly 0.7 https://trial.medpath.com/news/f1fddc883ce33086/effect-of-adding-electroacupuncture-to-standard-triple-antiemetic-therapy-on-pubmed 2024-09-07T18:49:55+00:00 weekly 0.7 https://trial.medpath.com/news/a4d88b4e158bc522/brentuximab-vedotin-triplet-continues-to-improve-r-r-diffuse-large-b-cell-lymphoma-outcomes 2024-09-07T18:39:20+00:00 weekly 0.7 https://trial.medpath.com/news/822036c393fb2411/multicenter-radio-multiomic-analysis-for-predicting-breast-cancer-outcome-and-unravelling 2024-09-07T18:36:43+00:00 weekly 0.7 https://trial.medpath.com/news/15c3bd0a7f504204/buy-rating-maintained-for-unicycive-therapeutics-amidst-olc-nda-submission-and-strong 2024-09-07T18:07:51+00:00 weekly 0.7 https://trial.medpath.com/news/5a846a4db7d61f07/immunic-drug-targeting-post-covid-syndrome-in-phase-2-trial-icymi-nasdaq-imux 2024-09-07T17:16:26+00:00 weekly 0.7 https://trial.medpath.com/news/716f62e8f063cd64/global-survey-reveals-persistent-barriers-to-lung-cancer-biomarker-testing-despite-growing-recognition 2024-09-07T17:07:12+00:00 weekly 0.7 https://trial.medpath.com/news/591ef7eb4f852203/frontline-golcadomide-r-chop-combo-elicits-antitumor-activity-in-aggressive-b-cell-lymphoma 2024-09-07T17:06:41+00:00 weekly 0.7 https://trial.medpath.com/news/258904c9829461c2/health-ministry-approves-introduction-of-new-shorter-more-efficacious-treatment-regimen-for 2024-09-07T16:38:36+00:00 weekly 0.7 https://trial.medpath.com/news/12bfbcc0c307e42d/intelligent-bio-solutions-advances-in-fda-approval-process-tipranks-com 2024-09-07T16:35:22+00:00 weekly 0.7 https://trial.medpath.com/news/a72b38c0ff23c7fc/baseline-characteristics-and-maintenance-therapy-choice-on-symptom-control-reliever 2024-09-07T16:27:49+00:00 weekly 0.7 https://trial.medpath.com/news/e979835adc317aa0/fda-official-clarifies-cgmp-expectations-for-investigational-drugs-raps 2024-09-07T16:00:21+00:00 weekly 0.7 https://trial.medpath.com/news/4b21fd1d64b0a3c1/alzheimer-s-new-csu-treatment-could-be-game-changing-tool-the-denver-post 2024-09-07T15:48:23+00:00 weekly 0.7 https://trial.medpath.com/news/2d3f436e521eda14/ifinatamab-deruxtecan-continues-to-demonstrate-promising-objective-response-rates-in 2024-09-07T15:35:45+00:00 weekly 0.7 https://trial.medpath.com/news/a012eb092beaca76/cbd-could-effectively-treat-leigh-syndrome-prolong-life-legal-reader 2024-09-07T15:13:57+00:00 weekly 0.7 https://trial.medpath.com/news/d52743743fdb9212/the-oncfive-top-oncology-articles-for-the-week-of-9-1-onclive 2024-09-07T13:58:51+00:00 weekly 0.7 https://trial.medpath.com/news/cb7d71b02616cd14/real-world-experience-with-duchenne-muscular-dystrophy-gene-therapy-cgtlive-r 2024-09-07T13:09:25+00:00 weekly 0.7 https://trial.medpath.com/news/9a46f1bd04e1b2ee/us-ipo-week-ahead-a-pair-of-biotechs-plan-to-complete-200-million-deals 2024-09-07T11:49:18+00:00 weekly 0.7 https://trial.medpath.com/news/1ac5c852eb799582/ers-congress-2024-addresses-critical-ethical-challenges-of-ai-in-clinical-decision-making 2024-09-07T11:44:35+00:00 weekly 0.7 https://trial.medpath.com/news/3f100fd1a89e26fa/bowel-cancer-trial-sees-all-patients-disease-free-in-huge-breakthrough-ladbible 2024-09-07T11:15:36+00:00 weekly 0.7 https://trial.medpath.com/news/14052e009ac267d0/fda-grants-breakthrough-therapy-designation-to-sanbexin-for-acute-ischemic-stroke 2024-09-07T10:58:46+00:00 weekly 0.7 https://trial.medpath.com/news/51c1d05bc040fa88/the-evolution-and-clinical-applications-of-mrd-testing-in-lymphoma-pharmacy-times 2024-09-07T10:58:46+00:00 weekly 0.7 https://trial.medpath.com/news/8f3d880fd95e8647/what-happened-in-optometry-this-week-september-2-september-6 2024-09-07T10:49:20+00:00 weekly 0.7 https://trial.medpath.com/news/7308cf016b70199e/how-rheumatoid-arthritis-and-down-syndrome-are-helping-researchers-find-treatments-for-alzheimer-s 2024-09-07T10:48:08+00:00 weekly 0.7 https://trial.medpath.com/news/49a62986a403afdc/spidol-study-protocol-for-the-assessment-of-intrathecal-ziconotide-antalgic-efficacy-for-trials 2024-09-07T10:35:20+00:00 weekly 0.7 https://trial.medpath.com/news/faf8e1a0a5cd6159/csf-proteomics-hints-at-how-apoe4-promotes-ad-and-how-a-drug-hinders-it-alzforum 2024-09-07T10:29:59+00:00 weekly 0.7 https://trial.medpath.com/news/9fba2508ed08188f/ai-deep-learning-models-show-promise-in-accelerating-lung-cancer-biomarker-detection 2024-09-07T10:01:19+00:00 weekly 0.7 https://trial.medpath.com/news/20db5cd893689f65/an-excellent-outcome-tavr-safe-and-effective-for-patients-in-their-nineties 2024-09-07T09:42:16+00:00 weekly 0.7 https://trial.medpath.com/news/973bca848058b190/novel-gene-therapies-and-transplant-options-reshape-sickle-cell-disease-treatment-landscape 2024-09-07T09:42:00+00:00 weekly 0.7 https://trial.medpath.com/news/bc45f3737f06ba0e/2024-nccn-prostate-cancer-guidelines-updates-in-m1-cspc-treatment-urotoday 2024-09-07T09:32:43+00:00 weekly 0.7 https://trial.medpath.com/news/76b240b1dfc42271/billionaires-are-buying-viking-therapeutics-stock-left-and-right-should-you-follow-their-lead 2024-09-07T09:29:33+00:00 weekly 0.7 https://trial.medpath.com/news/f66df19e585ad108/study-compares-safety-of-jak-inhibitors-between-adolescent-adult-patients-hcplive 2024-09-07T09:23:34+00:00 weekly 0.7 https://trial.medpath.com/news/19c41e381e2e6739/weekly-review-neffy-pre-ordering-launches-trofinetide-data-and-more 2024-09-07T08:44:05+00:00 weekly 0.7 https://trial.medpath.com/news/8203fdb992eede4d/research-suggests-psychedelics-are-well-tolerated-but-calls-for-improved-monitoring 2024-09-07T08:28:01+00:00 weekly 0.7 https://trial.medpath.com/news/464b5317d813ca02/bioxcel-therapeutics-earns-buy-rating-on-promising-clinical-trials-and-market-potential 2024-09-07T08:27:14+00:00 weekly 0.7 https://trial.medpath.com/news/57c27d747dfab067/sec-form-424b4-filed-by-qualigen-therapeutics-inc-quantisnow 2024-09-07T08:03:34+00:00 weekly 0.7 https://trial.medpath.com/news/af1ecee33c15ddc8/reagan-udall-foundation-for-fda-facilitates-discussion-on-urgent-needs-in-ptsd-therapy 2024-09-07T08:01:48+00:00 weekly 0.7 https://trial.medpath.com/news/579e2490701a4991/managing-toxicities-in-cll-treatment-expert-insights-on-bcl2-and-btk-inhibitor-selection 2024-09-07T08:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/99d28269cd6bb453/depression-anxiety-improve-in-patients-enrolled-in-care-personalized-to-their-symptoms 2024-09-07T07:56:17+00:00 weekly 0.7 https://trial.medpath.com/news/0f0271301c6ce36b/neurologylive-r-friday-5-september-6-2024 2024-09-07T07:10:45+00:00 weekly 0.7 https://trial.medpath.com/news/251b484d52ca5868/cgtlive-r-s-weekly-rewind-september-6-2024 2024-09-07T07:06:38+00:00 weekly 0.7 https://trial.medpath.com/news/d8672b8346f6d316/mrna-car-t-descartes-08-s-potential-for-treating-myasthenia-gravis-cgtlive-r 2024-09-07T06:33:51+00:00 weekly 0.7 https://trial.medpath.com/news/f28c96b891de989c/longer-duration-of-adjuvant-trastuzumab-may-further-improve-dfs-rates-in-erbb2 2024-09-07T06:03:11+00:00 weekly 0.7 https://trial.medpath.com/news/09abc168ae0ab823/gene-silencer-drug-shows-promise-in-treating-heart-condition-laboratory-equipment 2024-09-07T05:37:50+00:00 weekly 0.7 https://trial.medpath.com/news/0a6ed4d444fe9469/d-vrd-improves-mrd-negativity-rates-in-newly-diagnosed-transplant-eligible-myeloma 2024-09-07T05:14:09+00:00 weekly 0.7 https://trial.medpath.com/news/fcbefa593c112287/dr-ornstein-on-the-use-of-io-tki-doublets-in-non-ccrcc-onclive 2024-09-07T05:14:07+00:00 weekly 0.7 https://trial.medpath.com/news/1a096f97afb81506/access-to-care-issues-complicate-prescribing-obesity-medications-clinical-advisor 2024-09-07T04:34:46+00:00 weekly 0.7 https://trial.medpath.com/news/6d7db8aa73a1ef0c/vor-biopharma-s-promising-clinical-trials-and-strategic-developments-merit-a-buy-rating 2024-09-07T04:24:57+00:00 weekly 0.7 https://trial.medpath.com/news/8ab78bb329e6dfbc/nccn-adds-denileukin-diftitox-to-ctcl-clinical-practice-guidelines-in-oncology-onclive 2024-09-07T04:08:30+00:00 weekly 0.7 https://trial.medpath.com/news/31d23008cf0eba26/new-fda-approved-device-offers-hope-for-chronic-pain-sufferers 2024-09-07T04:00:04+00:00 weekly 0.7 https://trial.medpath.com/news/5615563e85d1d599/study-reveals-higher-healthcare-barriers-for-chronic-liver-disease-patients-compared-to-other-chronic-conditions 2024-09-07T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fcdfa2f4d458ef20/text-messaging-shows-promise-for-lung-cancer-screening-eligibility-assessment-but-equity-gaps-persist 2024-09-07T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/3ba6b4eba3b7800c/obesity-drug-startup-raises-67m-vor-s-shielded-transplant-shows-promise 2024-09-07T03:54:39+00:00 weekly 0.7 https://trial.medpath.com/news/d8a44dd853901961/long-term-safety-and-efficacy-evaluation-of-travoprost-intracameral-implant-based-on 2024-09-07T03:10:30+00:00 weekly 0.7 https://trial.medpath.com/news/4051df5b7b6789f7/advisory-committee-meeting-for-oral-sulopenem-occurring-september-9-2024 2024-09-07T03:04:22+00:00 weekly 0.7 https://trial.medpath.com/news/a0e2beb372113ad3/data-support-increased-subcutaneous-rituximab-use-in-non-hodgkin-lymphoma 2024-09-07T03:00:54+00:00 weekly 0.7 https://trial.medpath.com/news/9e5e5f0a8ddcad7e/advanced-treatment-strategies-show-promise-in-improving-ptcl-patient-outcomes 2024-09-07T03:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d6894a6eb49f92b4/donor-human-milk-for-preventing-necrotising-enterocolitis-in-very-preterm-or-very-low-pubmed 2024-09-07T02:43:46+00:00 weekly 0.7 https://trial.medpath.com/news/c1cb43d95cfb497a/managing-drug-drug-interactions-so-many-drugs-so-little-evidence-jama-network 2024-09-07T01:43:53+00:00 weekly 0.7 https://trial.medpath.com/news/5d71ac5670f58676/acurastem-receives-cirm-grant-for-targeted-therapeutic-program-for-als-ftd-aftd 2024-09-07T01:14:34+00:00 weekly 0.7 https://trial.medpath.com/news/5439961f784ac6e2/fda-approves-neoadjuvant-adjuvant-imfinzi-for-resectable-nsclc-the-cancer-letter 2024-09-07T00:18:36+00:00 weekly 0.7 https://trial.medpath.com/news/19beabbb70153da3/i-can-t-imagine-doing-anything-else-as-a-nurse-meet-robin-dobbins-pediatric-oncology 2024-09-06T22:51:53+00:00 weekly 0.7 https://trial.medpath.com/news/2917cf70079b67b7/are-you-a-healthy-adult-above-18-years-of-age-you-may-be-qualified-to-take-part-in-a-uab 2024-09-06T21:59:04+00:00 weekly 0.7 https://trial.medpath.com/news/7ce8a777dd4beef7/lundbeck-tests-its-most-promising-potential-migraine-candidate-in-ph1-combination-trial 2024-09-06T21:57:09+00:00 weekly 0.7 https://trial.medpath.com/news/19b1c148df4ad736/legendary-breast-cancer-researcher-carol-fabian-reflects-on-the-progress-of-research-and 2024-09-06T21:38:21+00:00 weekly 0.7 https://trial.medpath.com/news/96460d220a426f21/fda-reviewers-voice-concerns-over-novel-uti-treatment-medpage-today 2024-09-06T21:33:10+00:00 weekly 0.7 https://trial.medpath.com/news/69b515c805c79e82/autolus-start-thinking-about-obe-cel-pdufa-and-the-baby-bull-case-seeking-alpha 2024-09-06T21:12:19+00:00 weekly 0.7 https://trial.medpath.com/news/5141775efbc77971/elutia-celebrates-first-year-morningstar 2024-09-06T20:47:26+00:00 weekly 0.7 https://trial.medpath.com/news/d8c0813e89b3c9d3/relay-therapeutics-announces-webcast-to-report-rly-2608-data-on-september-9-2024 2024-09-06T20:08:43+00:00 weekly 0.7 https://trial.medpath.com/news/3e2e40a22d3c3c4f/gsk-announces-positive-results-from-phase-iii-trial-of-nucala-mepolizumab-in-copd 2024-09-06T19:44:54+00:00 weekly 0.7 https://trial.medpath.com/news/615879793784bdcf/fda-roundup-novavax-covid-19-vaccine-first-digital-therapeutic-for-gad-drug-topics 2024-09-06T19:38:33+00:00 weekly 0.7 https://trial.medpath.com/news/cb5b9f8e982fb819/exploring-afamelanotide-for-vitiligo-insights-into-the-cuv-105-phase-3-clinical-trial 2024-09-06T19:11:07+00:00 weekly 0.7 https://trial.medpath.com/news/60dd3227c627dec0/first-on-podium-data-from-21-vascular-and-venous-clinical-trials-to-be-presented-pr-newswire 2024-09-06T19:00:51+00:00 weekly 0.7 https://trial.medpath.com/news/29b0887adf5b88a0/fda-approves-nymalize-in-prefilled-enfit-syringes-drug-topics 2024-09-06T18:33:13+00:00 weekly 0.7 https://trial.medpath.com/news/1fdb16cb5a2ad981/boehringer-ingelheim-to-advance-potential-new-treatment-for-geographic-atrophy-following 2024-09-06T18:23:53+00:00 weekly 0.7 https://trial.medpath.com/news/7fae6f5007e68262/splash-clinical-announces-partnership-with-cambridge-cognition-globenewswire 2024-09-06T18:03:15+00:00 weekly 0.7 https://trial.medpath.com/news/65128c327d085b4a/development-of-a-core-outcome-set-for-studies-assessing-interventions-for-diabetes 2024-09-06T17:32:38+00:00 weekly 0.7 https://trial.medpath.com/news/4b7d0b167b7988f7/cartesian-therapeutics-doses-first-patient-with-mrna-car-t-descartes-15-in-trial-for-r-r 2024-09-06T17:19:15+00:00 weekly 0.7 https://trial.medpath.com/news/66b54703dbaf1ebb/eli-lilly-shares-keep-buy-rating-on-successful-phase-iii-trial-results-investing-com 2024-09-06T17:03:25+00:00 weekly 0.7 https://trial.medpath.com/news/d3a4d0552cf02f18/dr-patel-on-the-fda-approval-of-durvalumab-plus-chemotherapy-for-nsclc-onclive 2024-09-06T17:02:39+00:00 weekly 0.7 https://trial.medpath.com/news/cf958389f3fb810f/milestone-partner-ji-xing-pharmaceuticals-ltd-announces-positive-topline-results-from-the 2024-09-06T16:56:15+00:00 weekly 0.7 https://trial.medpath.com/news/aa0ecfa3798d7b7e/alopexx-announces-investment-from-biotech-consortia-inc-biospace 2024-09-06T16:56:15+00:00 weekly 0.7 https://trial.medpath.com/news/4c6a231d847d97ae/ventyx-biosciences-announces-initiation-of-dosing-in-a-phase-2a-trial-of-vtx3232-in-biospace 2024-09-06T16:56:12+00:00 weekly 0.7 https://trial.medpath.com/news/de3db8153c44e7e3/phase-3-keynote-789-trial-evaluates-pembrolizumab-plus-chemotherapy-in-egfr 2024-09-06T16:52:29+00:00 weekly 0.7 https://trial.medpath.com/news/9421616fd75b771e/fda-confirms-acceptability-of-palatin-s-remaining-phase-3-pivotal-clinical-trials-for-pl9643-in-ded 2024-09-06T16:46:43+00:00 weekly 0.7 https://trial.medpath.com/news/7f578244992accfb/amid-shortages-us-allows-expanded-production-of-adhd-drug-vyvanse-clinical-advisor 2024-09-06T16:34:59+00:00 weekly 0.7 https://trial.medpath.com/news/3ebada2e96dd7b20/new-clinical-studies-and-classification-criteria-advance-understanding-of-axial-psa-treatment 2024-09-06T16:00:24+00:00 weekly 0.7 https://trial.medpath.com/news/74e354c4927de07e/ai-drug-discovery-trial-reveals-promise-and-challenges-of-using-the-tech-pymnts-com 2024-09-06T15:48:22+00:00 weekly 0.7 https://trial.medpath.com/news/1cc1a46df92a7925/eu-court-halts-commission-s-ban-on-drug-for-rare-liver-disease-yahoo-news-uk 2024-09-06T15:44:28+00:00 weekly 0.7 https://trial.medpath.com/news/b2efc3cb4758d7f9/strides-gains-usfda-approval-for-theophylline-extended-release-tablets-300-mg-and-450-mg 2024-09-06T15:17:10+00:00 weekly 0.7 https://trial.medpath.com/news/d8c68253f8aaa60f/drug-drug-interactions-and-the-clinical-tolerability-of-colchicine-among-patients-with-covid-19 2024-09-06T15:15:57+00:00 weekly 0.7 https://trial.medpath.com/news/1673c9cd2eec5987/milk-elimination-diet-shows-promise-as-first-line-therapy-for-children-with-eoe 2024-09-06T15:13:48+00:00 weekly 0.7 https://trial.medpath.com/news/65f96d1241f4a7be/florida-cancer-specialists-presents-real-world-evidence-research-on-multiple-myeloma-at-international-meeting 2024-09-06T14:59:00+00:00 weekly 0.7 https://trial.medpath.com/news/41023d8f71a20c4e/prescription-digital-therapeutic-reduces-monthly-migraine-days-phase-3-study-shows 2024-09-06T14:51:13+00:00 weekly 0.7 https://trial.medpath.com/news/38837417ad00fe74/findings-from-cobalt-trial-including-external-control-arm-globenewswire 2024-09-06T14:32:52+00:00 weekly 0.7 https://trial.medpath.com/news/e950ca1b4df4aecf/gastrointestinal-chemotherapy-tweak-can-reduce-side-effects-inside-precision-medicine 2024-09-06T14:29:32+00:00 weekly 0.7 https://trial.medpath.com/news/596e295a7fe93108/future-of-crispr-gene-editing-technologies-herald-landmark-clinical-trials 2024-09-06T14:23:37+00:00 weekly 0.7 https://trial.medpath.com/news/bd6025da768edaf3/deuterium-depletion-is-the-key-to-getting-a-breakthrough-in-cancer-therapy 2024-09-06T14:17:00+00:00 weekly 0.7 https://trial.medpath.com/news/01c4a09599025f5b/twice-yearly-azithromycin-distribution-reduces-childhood-mortality-in-rural-niger 2024-09-06T14:05:05+00:00 weekly 0.7 https://trial.medpath.com/news/1bf805a707a3f759/duke-professor-s-research-leads-to-first-drug-for-type-of-liver-disease-the-chronicle 2024-09-06T13:26:16+00:00 weekly 0.7 https://trial.medpath.com/news/6c8d9dfd39e26ac7/lenvatinib-and-pembrolizumab-combo-breaks-new-ground-in-non-clear-cell-rcc 2024-09-06T13:04:44+00:00 weekly 0.7 https://trial.medpath.com/news/a1bdf4ab376c36a8/cytonics-announces-completion-of-enrollment-for-phase-1-clinical-study-evaluating-cyt 2024-09-06T12:57:56+00:00 weekly 0.7 https://trial.medpath.com/news/e29b95fbba79ae3a/akeso-to-present-data-from-13-clinical-studies-at-esmo-2024-featuring-its-pr-newswire 2024-09-06T12:54:46+00:00 weekly 0.7 https://trial.medpath.com/news/8c703b9254c782f0/novel-cell-free-dna-assays-expand-the-reach-of-mrd-detection-in-lymphoma-onclive 2024-09-06T12:42:33+00:00 weekly 0.7 https://trial.medpath.com/news/3277f79104505fc1/craig-hallum-initiated-coverage-on-cardiff-oncology-with-a-new-price-target-quantisnow 2024-09-06T12:16:26+00:00 weekly 0.7 https://trial.medpath.com/news/b3b8ab67c066b618/shingles-episodes-linked-to-20-higher-risk-of-cognitive-decline-brigham-study-reveals 2024-09-06T12:08:37+00:00 weekly 0.7 https://trial.medpath.com/news/eca73900c1e8d575/puretech-founded-entity-vor-bio-announces-new-clinical-data-validating-approach-of 2024-09-06T12:00:15+00:00 weekly 0.7 https://trial.medpath.com/news/b2189d45f329a6c3/psyence-biomed-announces-the-signing-of-a-conditional-binding-term-sheet-for-the-morningstar 2024-09-06T11:57:40+00:00 weekly 0.7 https://trial.medpath.com/news/2d4b1ce6f52f2f23/aurinia-doses-first-subject-in-phase-ia-trial-of-aur200-for-autoimmune-diseases 2024-09-06T11:52:46+00:00 weekly 0.7 https://trial.medpath.com/news/0620e608df545a47/the-marcus-foundation-makes-major-25-9-million-award-to-advance-lifesaving-stroke 2024-09-06T11:13:17+00:00 weekly 0.7 https://trial.medpath.com/news/4bdaecc8e30864c0/cell-therapy-weekly-fda-grants-odd-for-retinal-gene-therapy-regmednet 2024-09-06T11:06:21+00:00 weekly 0.7 https://trial.medpath.com/news/b26665929e19b4ad/cd47-inhibitor-drug-clinical-trials-market-outlook-to-2028-globenewswire 2024-09-06T10:51:39+00:00 weekly 0.7 https://trial.medpath.com/news/66c9671e50fe53eb/kalvista-pharmaceuticals-presents-sebetralstat-data-at-bradykinin-symposium-2024 2024-09-06T10:33:57+00:00 weekly 0.7 https://trial.medpath.com/news/ae7ab03a6d8ba16a/living-with-multiple-myeloma-doctor-becomes-powerful-resource-and-patient-advocate 2024-09-06T10:23:34+00:00 weekly 0.7 https://trial.medpath.com/news/f2099b16ad5e3f62/next-generation-precision-medicine-for-suicidality-prevention-translational-psychiatry 2024-09-06T09:38:38+00:00 weekly 0.7 https://trial.medpath.com/news/6c63a0f5d2dca6bc/neutrophil-exhaustion-and-impaired-functionality-in-psoriatic-arthritis-patients-frontiers 2024-09-06T09:10:19+00:00 weekly 0.7 https://trial.medpath.com/news/8aa05c94ee20b54c/strides-pharma-hits-all-time-high-after-usfda-approval-for-this-drug-news-on-markets 2024-09-06T08:31:40+00:00 weekly 0.7 https://trial.medpath.com/news/9e3d10461c9d398f/fda-drug-approval-decisions-expected-in-october-2024-mpr-empr-com 2024-09-06T08:27:35+00:00 weekly 0.7 https://trial.medpath.com/news/93580d14dac967b3/in8bio-cuts-staff-and-pipeline-to-focus-on-aml-cell-therapy-clinical-trials-arena 2024-09-06T08:23:21+00:00 weekly 0.7 https://trial.medpath.com/news/60a64d0312327459/sun-pharma-and-israel-based-moebius-medical-announce-usfda-grant-of-fast-track 2024-09-06T08:20:52+00:00 weekly 0.7 https://trial.medpath.com/news/e95a98c80858f779/gsk-asthma-drug-shows-promise-in-treating-chronic-lung-disease-bnn-bloomberg 2024-09-06T08:10:00+00:00 weekly 0.7 https://trial.medpath.com/news/11daae1952c0bcb0/lykos-ceo-to-depart-after-fda-rejection-layoffs-biopharma-dive 2024-09-06T07:52:54+00:00 weekly 0.7 https://trial.medpath.com/news/9a71448b70242c4d/atopic-dermatitis-market-set-to-reach-16-7b-by-2030-driving-innovation-in-treatment-options 2024-09-06T07:37:31+00:00 weekly 0.7 https://trial.medpath.com/news/adf707b63e52096e/sept-5-2024-clinical-trials-hope-to-curb-and-reverse-alzheimer-s-evs-drive-a-shift-for-firefighters 2024-09-06T07:25:40+00:00 weekly 0.7 https://trial.medpath.com/news/769f4f146520a2df/first-patient-enrolled-in-phase-1b-2-triplet-therapy-trial-of-rezlidhia-in-midh1-aml 2024-09-06T07:09:41+00:00 weekly 0.7 https://trial.medpath.com/news/e9608ddafd7999c5/international-consensus-supports-asthma-biologic-use-during-pregnancy-with-shared-decision-making 2024-09-06T07:00:24+00:00 weekly 0.7 https://trial.medpath.com/news/0ded9e19ff65a6ea/verastem-s-path-to-fda-approval-high-risk-high-reward-oncology-opportunity 2024-09-06T06:25:57+00:00 weekly 0.7 https://trial.medpath.com/news/0f67e504b8e34173/fda-grants-orphan-drug-designation-to-certepetide-in-cholangiocarcinoma-onclive 2024-09-06T06:24:13+00:00 weekly 0.7 https://trial.medpath.com/news/9c9e37b9a65d5265/a-small-step-towards-a-big-mission-world-s-first-ultradx-received-first-clinical-approval 2024-09-06T06:20:13+00:00 weekly 0.7 https://trial.medpath.com/news/a096d753fb175073/fda-s-new-drug-approvals-in-august-include-a-dupixent-competitor-a-targeted-glioma 2024-09-06T06:15:37+00:00 weekly 0.7 https://trial.medpath.com/news/7e02d88e6147d39b/pyrotinib-plus-metronomic-vinorelbine-is-active-in-her2-advanced-breast-cancer-after 2024-09-06T06:06:29+00:00 weekly 0.7 https://trial.medpath.com/news/599da84ce2e53334/global-bispecific-antibody-drug-conjugates-bispecific-adc-clinical-trials-commercial 2024-09-06T05:53:37+00:00 weekly 0.7 https://trial.medpath.com/news/8e049319206749be/breakthrough-in-broad-spectrum-malaria-therapy-hunt-mirage-news 2024-09-06T05:25:00+00:00 weekly 0.7 https://trial.medpath.com/news/b558c5346dc7a835/vanda-s-struggles-persist-despite-new-drug-launches-and-takeover-bids-seeking-alpha 2024-09-06T05:24:46+00:00 weekly 0.7 https://trial.medpath.com/news/78267a5e608ae7d0/breakthrough-hope-a-revolutionary-advance-in-treating-brain-cancer-called-glioma-survivornet 2024-09-06T05:06:09+00:00 weekly 0.7 https://trial.medpath.com/news/58127bb319a5d98b/ocuphire-pharma-doses-first-patient-in-phase-3-vega-3-clinical-trial-ophthalmology-times 2024-09-06T04:40:36+00:00 weekly 0.7 https://trial.medpath.com/news/e2694f0faa152b4a/atsena-therapeutics-announces-12-month-safety-and-efficacy-data-from-phase-i-ii-clinical 2024-09-06T04:32:00+00:00 weekly 0.7 https://trial.medpath.com/news/3d75884684dbf40a/hilleman-and-bharat-biotech-launch-oral-cholera-vaccine-in-india-bioprocess-international 2024-09-06T04:06:50+00:00 weekly 0.7 https://trial.medpath.com/news/638334066c5f145e/think-surgical-receives-fda-510-k-clearance-for-zimmer-biomet-persona-knee-on-tmini 2024-09-06T04:05:57+00:00 weekly 0.7 https://trial.medpath.com/news/012ef29309b002dc/moderna-mpox-mrna-vaccine-shows-early-promise-in-monkey-study-clinical-trials-arena 2024-09-06T03:28:01+00:00 weekly 0.7 https://trial.medpath.com/news/477e2a7e92dc16d4/largest-ever-phage-therapy-trial-shows-promise-for-uti-treatment-c-en 2024-09-06T03:16:59+00:00 weekly 0.7 https://trial.medpath.com/news/704e45d6750dd65a/lupin-share-price-hits-52-week-high-on-launch-of-overactive-bladder-drug-in-us-mint 2024-09-06T02:54:31+00:00 weekly 0.7 https://trial.medpath.com/news/5b1d745e98237713/clinical-study-explores-efficacy-of-light-activated-therapy-in-adolescents-undergoing 2024-09-06T02:53:53+00:00 weekly 0.7 https://trial.medpath.com/news/7d6d6fd5a407ddaf/tisagenlecleucel-moves-to-earlier-lines-of-therapy-for-pediatric-young-adults-with 2024-09-06T02:23:24+00:00 weekly 0.7 https://trial.medpath.com/news/885c1584a0d84582/nimmune-and-biotherapeutics-form-strategic-alliance-to-accelerate-precision-medicine-development-for-autoimmune-diseases 2024-09-06T02:09:20+00:00 weekly 0.7 https://trial.medpath.com/news/74168ec5744f3678/advancing-nox-inhibitors-for-treating-fibrotic-diseases-and-cancer 2024-09-06T02:04:56+00:00 weekly 0.7 https://trial.medpath.com/news/3111aec795bedaac/new-partners-for-phase-2-trial-of-next-gen-lithium-therapy-al001-alzheimer-s-news-today 2024-09-06T01:43:28+00:00 weekly 0.7 https://trial.medpath.com/news/b4583eb6d992904e/esc-congress-recap-high-impact-clinical-trials-with-deepak-bhatt-md-mph-mba 2024-09-06T01:36:34+00:00 weekly 0.7 https://trial.medpath.com/news/2f8916030ba638c1/researchers-aim-to-confirm-benefits-of-non-hormonal-therapy-for-certain-prostate-cancer-patients 2024-09-06T01:32:39+00:00 weekly 0.7 https://trial.medpath.com/news/fd7b12b88cfe7b27/egenesis-lands-191m-to-advance-xenotransplantation-into-clinical-trials 2024-09-06T01:31:26+00:00 weekly 0.7 https://trial.medpath.com/news/64bbee999df1fbe4/travere-therapeutics-announces-full-fda-approval-of-filspari-r-sparsentan-the-only 2024-09-06T01:19:50+00:00 weekly 0.7 https://trial.medpath.com/news/16b2c2eac6a857df/oppenheimer-upgrades-ascendis-pharma-shares-on-potential-drug-launches 2024-09-06T01:04:27+00:00 weekly 0.7 https://trial.medpath.com/news/15a2e9e8042df318/decentralized-clinical-trials-show-significant-growth-in-2024-driving-improved-patient-diversity-and-retention 2024-09-06T00:41:50+00:00 weekly 0.7 https://trial.medpath.com/news/b1edb36a7b221748/real-world-study-measures-lenire-s-effectiveness-in-treating-tinnitus 2024-09-06T00:21:42+00:00 weekly 0.7 https://trial.medpath.com/news/ee175ad63aa26da1/amneal-gains-fda-approval-for-new-oncology-drug-boruzu-investing-com 2024-09-06T00:00:23+00:00 weekly 0.7 https://trial.medpath.com/news/cdb56e4ca36bc8dd/hoth-stock-up-as-lead-drug-heals-skin-toxicities-in 2024-09-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/c79957ea4a720875/cleo-commences-u-s-clinical-trials 2024-09-05T23:29:25+00:00 weekly 0.7 https://trial.medpath.com/news/ee8273987e4e816d/tempo-therapeutics-announces-first-patient-dosed-in-clinical-trial-of-tt101-for-tissue 2024-09-05T23:27:04+00:00 weekly 0.7 https://trial.medpath.com/news/db107571519baa5f/vesper-bio-reports-data-from-phase-i-frontotemporal-dementia-treatment-trial 2024-09-05T22:57:54+00:00 weekly 0.7 https://trial.medpath.com/news/8e4fc94379f5f8f8/usf-researcher-led-clinical-trial-for-new-parkinson-s-medication-tampa-bay-times 2024-09-05T22:54:43+00:00 weekly 0.7 https://trial.medpath.com/news/7c854f34b5488df0/clinical-trial-restores-quality-of-life-for-concord-township-woman-news-herald 2024-09-05T22:53:10+00:00 weekly 0.7 https://trial.medpath.com/news/f64b9a02e8a51569/changes-in-skeletal-muscle-mass-in-the-first-3-months-following-gastrointestinal-cancer-surgery 2024-09-05T22:48:46+00:00 weekly 0.7 https://trial.medpath.com/news/79f08d815627a7e7/efsitora-demonstrates-non-inferiority-vs-insulin-glargine-degludec-for-type-2-diabetes 2024-09-05T22:33:29+00:00 weekly 0.7 https://trial.medpath.com/news/c16c832fbeca7251/in-this-month-s-e-news-september-2024-health-care-compliance-association-hcca 2024-09-05T21:59:56+00:00 weekly 0.7 https://trial.medpath.com/news/8b203adc00a14abd/stifel-initiates-coverage-on-oric-pharmaceuticals-with-buy-rating-and-20-target 2024-09-05T21:08:50+00:00 weekly 0.7 https://trial.medpath.com/news/d5236d0d949f0a08/fda-approves-new-covid-19-vaccine-for-fall-and-winter-wsaz 2024-09-05T20:55:29+00:00 weekly 0.7 https://trial.medpath.com/news/099929bfdbdf1c7a/ai-tools-help-avoid-patient-dropouts-nonadherence-in-clinical-trials-inside-health-policy 2024-09-05T20:51:22+00:00 weekly 0.7 https://trial.medpath.com/news/2919e1af0a3c040b/incyte-wins-fda-approval-for-niktimvo-considers-future-delaware-business-times 2024-09-05T20:29:21+00:00 weekly 0.7 https://trial.medpath.com/news/688a3cae8e7cb787/immuron-plans-phase-2-trial-for-imm-529-following-fda-review-biospace 2024-09-05T20:19:04+00:00 weekly 0.7 https://trial.medpath.com/news/036720fc859eeff5/sacituzumab-govitecan-in-advanced-urothelial-cancer-after-ici-therapy-the-asco-post 2024-09-05T20:13:28+00:00 weekly 0.7 https://trial.medpath.com/news/35e5587bdb312964/fda-approves-foundationone-tests-for-olaparib-combo-in-brca-mutated-mcrpc 2024-09-05T20:08:55+00:00 weekly 0.7 https://trial.medpath.com/news/86040e949820b447/fda-awards-orphan-drug-designation-to-abd-147-for-neuroendocrine-carcinoma 2024-09-05T20:01:15+00:00 weekly 0.7 https://trial.medpath.com/news/797e9c48e7b414e2/fda-approved-new-covid-19-vaccines-here-s-what-to-know-and-where-to-get-them 2024-09-05T19:35:53+00:00 weekly 0.7 https://trial.medpath.com/news/d3781c7692b944e1/kalvista-pharmaceuticals-reports-first-fiscal-quarter-results-and-provides-operational-update 2024-09-05T19:07:11+00:00 weekly 0.7 https://trial.medpath.com/news/9dfba71c959b5398/biogen-s-nusinersen-shows-efficacy-compared-to-sham-treatment-at-experimental-higher-dose 2024-09-05T19:05:40+00:00 weekly 0.7 https://trial.medpath.com/news/b6e2cae0326c1986/palisade-bio-reports-data-demonstrating-pde4b-expression-in-patient-cohorts-could-be 2024-09-05T18:54:12+00:00 weekly 0.7 https://trial.medpath.com/news/54a136cdc2e5edf8/clinical-research-focus-32nd-edition-cromos-pharma 2024-09-05T18:35:50+00:00 weekly 0.7 https://trial.medpath.com/news/fcadff205c628cb5/innovent-receives-us-fda-fast-track-designation-for-ibi363-as-monotherapy-for-advanced-melanoma 2024-09-05T18:30:56+00:00 weekly 0.7 https://trial.medpath.com/news/3645e3fda427da13/safe-pro-ai-completes-united-nations-development-programme-s-purchase-order-accesswire 2024-09-05T18:30:26+00:00 weekly 0.7 https://trial.medpath.com/news/fe511ad556658e55/skyline-therapeutics-receives-orphan-drug-designation-from-fda-for-skg1108 2024-09-05T18:26:20+00:00 weekly 0.7 https://trial.medpath.com/news/bd39b89b29d9e262/um-cancer-treatment-reaches-human-clinical-trials-news-montanakaimin-com 2024-09-05T18:16:03+00:00 weekly 0.7 https://trial.medpath.com/news/f2759cbddf133230/ractigen-garners-orphan-drug-designation-for-sarna-therapy-rag-18-cgtlive-r 2024-09-05T18:14:17+00:00 weekly 0.7 https://trial.medpath.com/news/29ef074140f1078b/bird-influenza-study-clinical-trial-rochester-clinical-research 2024-09-05T17:28:55+00:00 weekly 0.7 https://trial.medpath.com/news/5c97c4c41eb9ecc9/arsenal-biosciences-raises-325m-in-series-c-financing-round 2024-09-05T17:12:05+00:00 weekly 0.7 https://trial.medpath.com/news/0b1b546e5846861c/eli-lilly-says-experimental-insulin-could-mean-313-fewer-injections-per-year-quartz 2024-09-05T17:10:20+00:00 weekly 0.7 https://trial.medpath.com/news/7696bd96ac8f2979/fda-clears-medigene-s-ind-for-tcr-t-therapy-in-certain-advanced-solid-tumors 2024-09-05T16:51:55+00:00 weekly 0.7 https://trial.medpath.com/news/295bf789f35f0c41/fda-grants-fast-track-designation-to-vmt01-for-unresectable-metastatic-mc1r-melanoma 2024-09-05T16:26:30+00:00 weekly 0.7 https://trial.medpath.com/news/3cbc02e3f115df1a/balloon-angioplasty-vs-medical-management-for-intracranial-artery-stenosis-jama-network 2024-09-05T15:56:19+00:00 weekly 0.7 https://trial.medpath.com/news/269c79a7f9df842f/study-aims-to-find-new-ways-of-alleviating-the-long-term-effects-of-covid-19-news-medical 2024-09-05T15:47:37+00:00 weekly 0.7 https://trial.medpath.com/news/fb8e338bedffc6e3/race-ethnicity-and-sex-in-pediatric-eye-disease-investigator-group-clinical-studies 2024-09-05T15:05:36+00:00 weekly 0.7 https://trial.medpath.com/news/34016296cd95efd2/hoth-therapeutics-announces-expansion-of-clinical-sites-for-ht-001-phase-2a-trial 2024-09-05T14:47:39+00:00 weekly 0.7 https://trial.medpath.com/news/58c753e831cfd7c8/french-biotech-candidate-for-cannabis-use-disorder-fails-phase-2b-clinical-trial-indivior 2024-09-05T14:35:14+00:00 weekly 0.7 https://trial.medpath.com/news/48542ba5c24f1523/dmid-nextgen-covid-19-vaccines-fill-finish-a-platform-trial-to-evaluate-next 2024-09-05T14:34:17+00:00 weekly 0.7 https://trial.medpath.com/news/f35014302edc2931/moderna-chmp-gives-green-light-to-new-covid-vaccine-marketscreener 2024-09-05T14:26:03+00:00 weekly 0.7 https://trial.medpath.com/news/019784f55c8630b4/prokidney-drops-phase-iii-ckd-study-to-focus-on-us-market-and-save-up-to-175m 2024-09-05T14:25:10+00:00 weekly 0.7 https://trial.medpath.com/news/f79d9a89af209e9e/clinical-trial-cbd-dosing-reduces-daytime-fatigue-compared-to-placebo-norml 2024-09-05T14:07:18+00:00 weekly 0.7 https://trial.medpath.com/news/466c80ec8dae4d94/pantheon-vision-pioneers-bioengineered-solutions-to-combat-global-corneal-blindness 2024-09-05T14:00:30+00:00 weekly 0.7 https://trial.medpath.com/news/068c9cedb61741e4/tofu-like-psychedelic-gets-fda-nod-mindstate-s-ai-designed-therapy-to-begin-human-trials 2024-09-05T13:16:10+00:00 weekly 0.7 https://trial.medpath.com/news/5dc2535f8191aa9c/webinar-provides-details-on-compass-pws-clinical-trial 2024-09-05T12:39:54+00:00 weekly 0.7 https://trial.medpath.com/news/9cfe81d8157a26a3/sophia-genetics-announces-validation-of-novel-clinical-trial-assay-together-pr-newswire 2024-09-05T12:30:55+00:00 weekly 0.7 https://trial.medpath.com/news/73183c2f19dcb8ac/roche-s-btk-inhibitor-shines-in-multiple-sclerosis-trial-clinical-trials-arena 2024-09-05T12:03:43+00:00 weekly 0.7 https://trial.medpath.com/news/b2f39b55eaca37df/ai-driven-insights-soms-boosts-clinical-trial-success-outsourcing-pharma-com 2024-09-05T11:09:31+00:00 weekly 0.7 https://trial.medpath.com/news/d9f3fdc922a9938c/unitedhealthcare-launches-nationwide-gold-card-program-to-streamline-prior-authorization-process 2024-09-05T08:59:58+00:00 weekly 0.7 https://trial.medpath.com/news/d17c430dbedc59ff/first-time-disclosures-from-rome 2024-09-05T08:49:06+00:00 weekly 0.7 https://trial.medpath.com/news/7262cbacaa2902e6/first-patient-enrolled-in-a-clinical-trial-to-evaluate-brain-next-generation-cognitive-training 2024-09-05T07:50:10+00:00 weekly 0.7 https://trial.medpath.com/news/ebf2c460ce06574c/crestone-announces-positive-data-from-phase-2-clinical-trial-of-crs3123-for-c-difficile 2024-09-05T07:44:32+00:00 weekly 0.7 https://trial.medpath.com/news/faef6c02a1fb4e3e/clinical-trial-for-groundbreaking-alzheimer-s-disease-drug-begins-in-middle-tennessee 2024-09-05T02:50:32+00:00 weekly 0.7 https://trial.medpath.com/news/b9278614dc1ff3dc/uk-takes-bold-step-to-ban-xylazine-and-21-other-substances-in-major-drug-control-initiative 2024-09-05T02:22:02+00:00 weekly 0.7 https://trial.medpath.com/news/b31960004cb75539/blinatumomab-improves-survival-in-pediatric-high-risk-b-all-post-transplant 2024-09-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/3f925ff3a8a51941/hoth-therapeutics-announces-positive-data-from-first-of-its-kind-human 2024-09-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/9a5ddeb02b809b00/evommune-enrols-first-subject-in-chronic-inducible-urticaria-therapy-trial 2024-09-04T23:49:27+00:00 weekly 0.7 https://trial.medpath.com/news/7adeb91b66768d89/clinical-trial-to-investigate-causes-of-diabetes-obesity-in-individuals-with-spinal-cord-injury 2024-09-04T22:19:24+00:00 weekly 0.7 https://trial.medpath.com/news/a2429e116d12f3c8/emapalumab-extends-intervention-free-survival-for-children-with-hlh 2024-09-04T22:07:14+00:00 weekly 0.7 https://trial.medpath.com/news/f11adcbf14210a61/adding-anti-clotting-drugs-to-stroke-care-ineffective-clinical-trial-finds 2024-09-04T21:07:40+00:00 weekly 0.7 https://trial.medpath.com/news/0914b78b90e488b1/axsome-therapeutics-announces-fda-acceptance-of-nda-resubmission-for-axs-07-for-the-acute-treatment-of-migraine 2024-09-04T20:09:25+00:00 weekly 0.7 https://trial.medpath.com/news/ec6db9de5296c76b/btcrc-lun17-127-published-in-lung-cancer-journal 2024-09-04T19:29:43+00:00 weekly 0.7 https://trial.medpath.com/news/50f1561b956c3a12/regenxbio-s-mpsii-gene-therapy-rgx-121-continues-to-show-efficacy-in-long-term-trial-data 2024-09-04T18:59:57+00:00 weekly 0.7 https://trial.medpath.com/news/a6f95151e2c627e5/marshall-university-launches-latest-clinical-trial-cohort-for-non-opioid-treatment-of-neonatal 2024-09-04T18:27:17+00:00 weekly 0.7 https://trial.medpath.com/news/7f5d43a101fbbc64/a-phase-ib-ii-randomized-clinical-trial-of-oleclumab-with-or-without-durvalumab-aacr-journals 2024-09-04T18:10:35+00:00 weekly 0.7 https://trial.medpath.com/news/924ef14a9b9673e3/enhancing-patient-selection-in-sepsis-clinical-trials-design-through-an-ai-enrichment-strategy 2024-09-04T17:28:46+00:00 weekly 0.7 https://trial.medpath.com/news/b98c655a15479eac/fda-activity-recap-august-2024-features-tcr-t-cell-therapy-approval-rems 2024-09-04T17:18:02+00:00 weekly 0.7 https://trial.medpath.com/news/d7f5cc50c1d0b2f1/bill-gates-optimistic-of-progress-in-tb-vaccine-clinical-trial-news-agency-of-nigeria 2024-09-04T15:59:06+00:00 weekly 0.7 https://trial.medpath.com/news/d5c006d26a7abef4/clinical-trial-a-study-to-assess-the-safety-and-efficacy-of-lacosamide-versus-placebo-a 2024-09-04T15:55:10+00:00 weekly 0.7 https://trial.medpath.com/news/55c38f5641e3ada0/heart-drug-improves-exercise-tolerance-in-clinical-trial-of-patients-with-hypertrophic 2024-09-04T15:29:47+00:00 weekly 0.7 https://trial.medpath.com/news/cdf05349e6e2c8a8/outlook-therapeutics-r-announces-completion-of-enrollment-in-norse-eight-clinical-trial 2024-09-04T14:58:52+00:00 weekly 0.7 https://trial.medpath.com/news/6f57f1e430c48657/radiation-oncology-research-and-clinical-trial-res-newswise 2024-09-04T14:20:50+00:00 weekly 0.7 https://trial.medpath.com/news/78b56dcebf6a836f/i-wanted-to-change-the-outcomes-sholler-s-career-leads-to-neuroblastoma-breakthrough 2024-09-04T13:46:29+00:00 weekly 0.7 https://trial.medpath.com/news/b9c23134f1e52151/abbott-initiates-clinical-study-to-evaluate-the-use-of-its-deep-brain-stimulation-system-to 2024-09-04T13:07:31+00:00 weekly 0.7 https://trial.medpath.com/news/40829037798f169b/nh-theraguix-advances-phase-ii-brain-metastases-treatment-trial 2024-09-04T11:48:02+00:00 weekly 0.7 https://trial.medpath.com/news/03990d50f74a645e/eledon-announces-completion-of-enrollment-in-phase-2-bestow-clinical-trial-assessing 2024-09-04T11:29:16+00:00 weekly 0.7 https://trial.medpath.com/news/60ab92687d1bf3ac/avenzo-gilead-partner-for-breast-cancer-combination-regimen-trial 2024-09-04T11:22:47+00:00 weekly 0.7 https://trial.medpath.com/news/3f74ae805d0533f8/invivyd-doses-first-participants-in-phase-1-clinical-trial-of-vyd2311-a-next-generation 2024-09-04T11:08:46+00:00 weekly 0.7 https://trial.medpath.com/news/0a881e4bc2b8df49/fda-clears-bluerock-s-ind-for-photoreceptor-diseases-therapy-trial 2024-09-04T11:08:44+00:00 weekly 0.7 https://trial.medpath.com/news/a3f008b2c9c0a285/merck-and-eyebio-announce-initiation-of-phase-2b-3-clinical-trial-for-restorettm-for-the 2024-09-04T10:54:27+00:00 weekly 0.7 https://trial.medpath.com/news/e2aa11ef0db9438d/immunic-announces-first-patient-enrolled-in-investigator-sponsored-phase-2-clinical-trial 2024-09-04T10:30:30+00:00 weekly 0.7 https://trial.medpath.com/news/49ef7657032b18b1/wearable-heart-monitor-ups-detection-of-a-fib-by-more-than-50 2024-09-04T10:09:32+00:00 weekly 0.7 https://trial.medpath.com/news/3937aa34b57599be/september-4-2024-nih-heal-initiative-supports-new-funding-opportunity-for-pragmatic 2024-09-04T08:01:46+00:00 weekly 0.7 https://trial.medpath.com/news/40d20b07e6e9d9aa/exciting-developments-in-clinical-research-axcellant-s-groundbreaking-global-study 2024-09-04T07:20:15+00:00 weekly 0.7 https://trial.medpath.com/news/4e27f24e4635f27b/phase-i-ib-clinical-trial-of-sabatolimab-an-anti-tim-3-antibody-alone-and-in-combination 2024-09-04T04:35:45+00:00 weekly 0.7 https://trial.medpath.com/news/3740422c9f60c7a9/end-of-trial-declaration-clinical-trials-toolkit 2024-09-04T01:55:17+00:00 weekly 0.7 https://trial.medpath.com/news/9444a6167acf2670/denali-therapeutics-plans-accelerated-approval-for-mps-ii-treatment 2024-09-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ff41d4f6e3cd5f9c/irlab-strengthens-patent-portfolio-for-parkinson-s-drug-candidates-mesdopetam-and-pirepemat 2024-09-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/67f72c5f7aa89aa3/new-hope-for-progressive-supranuclear-palsy-with-innovative-trial-uc-san-francisco 2024-09-03T23:40:14+00:00 weekly 0.7 https://trial.medpath.com/news/fa2022b3f0a27c61/giving-resources-to-low-income-children-to-enhance-recovery-clinical-trial-identifier 2024-09-03T21:54:30+00:00 weekly 0.7 https://trial.medpath.com/news/a316a153c2559888/fda-authorizes-ind-for-phase-2-clinical-trial-evaluating-treatment-for-post-covid-19-condition 2024-09-03T21:49:22+00:00 weekly 0.7 https://trial.medpath.com/news/a1a779e72ef33268/ascendis-pharma-reports-second-quarter-2024-financial-results-and-updates-on-clinical-trials 2024-09-03T21:04:00+00:00 weekly 0.7 https://trial.medpath.com/news/aa8dce936653d8cb/theolytics-secures-grant-from-innovate-uk-for-phase-i-trial-of-ovarian-cancer-drug 2024-09-03T20:47:09+00:00 weekly 0.7 https://trial.medpath.com/news/475fe13e78abf86a/grit-biotechnology-s-til-therapy-gt201-cleared-for-us-trial-in-advanced-solid-tumors 2024-09-03T20:35:04+00:00 weekly 0.7 https://trial.medpath.com/news/daaa635d071b2ae0/kalvista-announces-fda-acceptance-of-new-drug-application-for-sebetralstat-for-oral-on-demand-treatment-of-hereditary-angioedema 2024-09-03T20:09:29+00:00 weekly 0.7 https://trial.medpath.com/news/3455629560c261cc/athira-pharma-announces-topline-results-from-phase-2-3-lift-ad-clinical-trial-of 2024-09-03T20:06:46+00:00 weekly 0.7 https://trial.medpath.com/news/0a21dc06890ee086/kezar-study-evaluates-potential-new-treatment-for-people-with-lupus-nephritis 2024-09-03T19:14:15+00:00 weekly 0.7 https://trial.medpath.com/news/718e13242534eca4/structural-news-clinical-trials-scai 2024-09-03T18:58:40+00:00 weekly 0.7 https://trial.medpath.com/news/53a369a0b7f4b61b/new-experimental-drug-aims-to-extend-dogs-lives-pill-available-locally-in-clinical-trial 2024-09-03T18:25:13+00:00 weekly 0.7 https://trial.medpath.com/news/407a0005ff67f305/7-hills-pharma-safely-doses-first-patient-in-phase-1b-2a-clinical-trial-testing-alintegimod 2024-09-03T18:08:32+00:00 weekly 0.7 https://trial.medpath.com/news/1485460241ce3633/vaxcyte-shares-boom-as-one-of-biotech-s-big-david-vs-goliath-stories-heats-up 2024-09-03T17:35:39+00:00 weekly 0.7 https://trial.medpath.com/news/d33e68d1b1801cf0/exclusive-to-roswell-park-armored-car-clinical-trial-targets-cd19-hematologic-malignancies 2024-09-03T17:33:54+00:00 weekly 0.7 https://trial.medpath.com/news/fa9822539a7262a3/spectral-medical-provides-august-tigris-trial-update-biospace 2024-09-03T17:24:31+00:00 weekly 0.7 https://trial.medpath.com/news/9ae133be0913a4d0/dyne-therapeutics-announces-positive-new-clinical-data-from-phase-1-2-deliver-trial-of 2024-09-03T17:16:52+00:00 weekly 0.7 https://trial.medpath.com/news/add4eda6e8f22bae/jcr-pharmaceuticals-announces-completion-of-clinical-trial-notification-process-in-japan 2024-09-03T16:46:20+00:00 weekly 0.7 https://trial.medpath.com/news/3c0cf3002bdbc123/apolipoprotein-a-i-infusions-and-cardiovascular-outcomes-in-acute-myocardial-infarction 2024-09-03T16:13:09+00:00 weekly 0.7 https://trial.medpath.com/news/a7502d8341dfc941/gc-biopharma-and-hanmi-pharmaceutical-receives-ind-clearance-for-phase-1-2-clinical 2024-09-03T15:58:35+00:00 weekly 0.7 https://trial.medpath.com/news/f89d9b0714cd22da/recursion-presents-mixed-data-on-lead-ai-derived-drug-candidate-for-potentially-fatal-brain-condition 2024-09-03T15:30:29+00:00 weekly 0.7 https://trial.medpath.com/news/3082eb08ab10ed89/ozempic-wegovy-won-t-raise-user-s-suicide-risk-study-finds 2024-09-03T15:09:31+00:00 weekly 0.7 https://trial.medpath.com/news/4acb5fec85872996/antabio-completes-phase-1-clinical-study-of-mem-ant3310-for-severe-hospital-infections 2024-09-03T15:08:30+00:00 weekly 0.7 https://trial.medpath.com/news/779896c44f59615a/vaxcyte-reports-positive-topline-data-from-phase-1-2-study-of-vax-31-its-31-valent 2024-09-03T14:37:23+00:00 weekly 0.7 https://trial.medpath.com/news/b64bd74c9d9ed502/adaptimmune-s-journey-to-pioneering-tcr-t-therapy-for-cancer-treatment 2024-09-03T13:12:33+00:00 weekly 0.7 https://trial.medpath.com/news/330a6e5322b4acc3/biomx-to-present-positive-phase-1b-2a-clinical-trial-data-for-bx004-at-the-european 2024-09-03T12:41:26+00:00 weekly 0.7 https://trial.medpath.com/news/16f7b6e61a3f8c77/clinical-accelerator-partners-with-tau-medical-for-early-feasibility-study-of-pivot-extend-in 2024-09-03T10:52:56+00:00 weekly 0.7 https://trial.medpath.com/news/403de24c686826a9/astrazeneca-advances-ambition-to-improve-standards-of-care-in-multiple-cancer-types-at 2024-09-03T06:05:39+00:00 weekly 0.7 https://trial.medpath.com/news/7e84b61b8fa9d8f6/gsk-aims-to-redefine-the-future-of-respiratory-medicine-at-the-european-respiratory-society 2024-09-03T06:03:39+00:00 weekly 0.7 https://trial.medpath.com/news/9bc0af6b31c98433/valneva-and-pfizer-report-further-positive-phase-2-booster-results-for-lyme-disease 2024-09-03T05:02:16+00:00 weekly 0.7 https://trial.medpath.com/news/1e454d9aef12c392/quality-of-life-measures-to-become-commonplace-in-cancer-clinical-trials 2024-09-03T05:00:08+00:00 weekly 0.7 https://trial.medpath.com/news/11723bc8289db716/quanthealth-215-million-in-financial-returns-and-85-clinical-trial-accuracy 2024-09-03T02:39:25+00:00 weekly 0.7 https://trial.medpath.com/news/da2365caad1e0ac2/evaluation-of-efficacy-of-cholecalciferol-and-silymarin-in-improving-lower-urinary-tract 2024-09-03T02:28:55+00:00 weekly 0.7 https://trial.medpath.com/news/60a21213f41fa0fa/emyria-announces-interim-clinical-trial-results-for-ptsd-program-biotech-dispatch 2024-09-03T01:40:21+00:00 weekly 0.7 https://trial.medpath.com/news/d71258aca546da8d/signed-agreement-for-the-clinical-trial-of-bnct-with-national-cancer-center-stella 2024-09-03T01:11:48+00:00 weekly 0.7 https://trial.medpath.com/news/5ce20953a0260329/unicycive-therapeutics-announces-submission-of-the-new-drug-application-nda-to-the-u-s-fda-for-oxylanthanum-carbonate-olc-for-the-treatment-of-hyperphosphatemia-in-patients-with-chronic-kidney-disease-on-dialysis 2024-09-03T01:09:22+00:00 weekly 0.7 https://trial.medpath.com/news/18052dc613d57752/urticaria-emerges-as-concern-in-phase-1-trial-of-hiv-mrna-vaccines 2024-09-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/83b72acc86669a5d/longeveron-r-announces-positive-type-c-meeting-with-u-s-fda-regarding-pathway-to-bla-for-lomecel-btm-in-hypoplastic-left-heart-syndrome-hlhs 2024-09-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f52fbfef5daf748d/fda-grants-fast-track-designations-to-caribou-biosciences-cb-010-and-cb-012-for-refractory-sle-and-aml 2024-09-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/defe275070a6254f/challenges-and-opportunities-in-developing-an-oncology-clinical-trial-network-in-the-urotoday 2024-09-02T22:08:43+00:00 weekly 0.7 https://trial.medpath.com/news/59dc5317cc389f06/gnrh-a-based-fertility-sparing-treatment-of-atypical-endometrial-hyperplasia-aeh-and 2024-09-02T21:57:17+00:00 weekly 0.7 https://trial.medpath.com/news/ab1b1b40d908bfe9/first-dengue-vaccine-phase-3-clinical-trial-kicks-off-at-kims-odisha-diary 2024-09-02T19:42:00+00:00 weekly 0.7 https://trial.medpath.com/news/34a48bc395402fc5/nxera-wins-35m-after-phase-ii-schizophrenia-trial-success-clinical-trials-arena 2024-09-02T16:45:14+00:00 weekly 0.7 https://trial.medpath.com/news/a180bf1cd8cfd629/re-engineering-the-clinical-approach-to-suspected-cardiac-chest-pain-assessment-in-the 2024-09-02T16:11:33+00:00 weekly 0.7 https://trial.medpath.com/news/52cc92494a1aeb05/pipeline-moves-investigator-led-oncology-cell-therapy-trial-terminated 2024-09-02T15:42:47+00:00 weekly 0.7 https://trial.medpath.com/news/ae0c769e52e77e2c/medtronic-has-positive-long-term-extravascular-icd-study-results-massdevice 2024-09-02T15:39:01+00:00 weekly 0.7 https://trial.medpath.com/news/ddf1e04081931480/multiple-sclerosis-pill-succeeds-in-key-trial-sanofi-says-stat-news 2024-09-02T15:02:21+00:00 weekly 0.7 https://trial.medpath.com/news/e4e07c5398170982/clinical-experience-with-a-new-solvent-detergent-treated-intravenous-immunoglobulin-free-of 2024-09-02T14:20:20+00:00 weekly 0.7 https://trial.medpath.com/news/055794e8ca30ee51/proteus-trial-suggests-ai-for-heart-scans-may-benefit-decision-making-for-less 2024-09-02T14:18:03+00:00 weekly 0.7 https://trial.medpath.com/news/6a0408595356ddf5/minimal-residual-disease-status-may-be-linked-with-progression-free-survival-in-cll 2024-09-02T14:06:24+00:00 weekly 0.7 https://trial.medpath.com/news/e15ca4eaa7e9bb85/association-between-in-vitro-susceptibility-and-clinical-outcomes-in-fungal-keratitis 2024-09-02T13:37:17+00:00 weekly 0.7 https://trial.medpath.com/news/3d9bcb3e13abd72f/optical-coherence-tomography-guided-coronary-intervention-in-patients-with-complex-lesions 2024-09-02T13:29:06+00:00 weekly 0.7 https://trial.medpath.com/news/5323901aae27164e/drug-coated-balloon-angioplasty-with-rescue-stenting-versus-intended-stenting-for-the 2024-09-02T13:29:06+00:00 weekly 0.7 https://trial.medpath.com/news/2337f999dc4c1e10/esc-congress-2024-infinity-swedeheart-trial-of-elixir-medical-s-dynamx-bioadaptor 2024-09-02T13:20:09+00:00 weekly 0.7 https://trial.medpath.com/news/7b349c1b30294fcf/arrowhead-teeing-up-drug-trials-los-angeles-business-journal 2024-09-02T13:02:16+00:00 weekly 0.7 https://trial.medpath.com/news/e7e4eda3470b49eb/artificial-intelligence-guided-screening-for-cardiomyopathies-in-an-obstetric-population 2024-09-02T12:28:52+00:00 weekly 0.7 https://trial.medpath.com/news/b099b90245d7284d/dr-noah-biotech-s-ai-driven-als-medicine-receives-u-s-fda-approval-for-phase-1 2024-09-02T11:23:02+00:00 weekly 0.7 https://trial.medpath.com/news/13ce781ea022925a/pulmonary-vein-isolation-vs-sham-intervention-in-symptomatic-atrial-fibrillation 2024-09-02T10:55:47+00:00 weekly 0.7 https://trial.medpath.com/news/a1cb26f211625aba/johnson-johnson-seeks-fda-approval-for-nipocalimab-in-generalized-myasthenia-gravis 2024-09-02T10:25:01+00:00 weekly 0.7 https://trial.medpath.com/news/bd206b43ce76b29e/io-biotech-updates-on-pivotal-phase-3-trial-of-io102-io103-in-combination-with-biospace 2024-09-02T10:04:05+00:00 weekly 0.7 https://trial.medpath.com/news/a25b399cd659a445/comparative-efficacy-of-probing-with-or-without-intubation-and-or-inferior-turbinate-fracture-in 2024-09-02T09:49:18+00:00 weekly 0.7 https://trial.medpath.com/news/c020cb4334ae8178/we-will-be-forever-grateful-mother-s-joy-as-son-s-leukaemia-stays-in-remission-for-five-years 2024-09-02T09:47:55+00:00 weekly 0.7 https://trial.medpath.com/news/15459836af8507dc/bristol-myers-squibb-s-camzyos-offers-benefits-in-ohcm-trial 2024-09-02T08:46:19+00:00 weekly 0.7 https://trial.medpath.com/news/e144d15579cf66e5/global-progress-in-clinical-research-on-human-respiratory-syncytial-virus-vaccines-frontiers 2024-09-02T08:19:01+00:00 weekly 0.7 https://trial.medpath.com/news/3c7f92e50d3afd15/effects-of-meridian-sinew-tuina-after-identifying-the-treatment-area-under-ultrasound-frontiers 2024-09-02T08:19:00+00:00 weekly 0.7 https://trial.medpath.com/news/028cfe7c56d0e574/press-release-tolebrutinib-meets-primary-endpoint-in-hercules-phase-3-study-the-first-sanofi 2024-09-02T05:08:08+00:00 weekly 0.7 https://trial.medpath.com/news/6043de24dc93e434/arrowhead-pharmaceuticals-presents-new-pivotal-phase-3-data-at-esc-2024-from-palisade-study-of-plozasiran-in-patients-with-familial-chylomicronemia-syndrome 2024-09-02T04:09:24+00:00 weekly 0.7 https://trial.medpath.com/news/357fa6d3aa441733/innovent-annouces-multiple-clinical-study-results-of-mazdutide-to-be-presented-at-the-easd-2024 2024-09-02T00:19:00+00:00 weekly 0.7 https://trial.medpath.com/news/f8392cf514992f4f/a-phase-ii-clinical-trial-of-toripalimab-in-advanced-solid-tumors-with-polymerase-epsilon 2024-09-02T00:03:06+00:00 weekly 0.7 https://trial.medpath.com/news/60dc8bc505ae23b4/incorporating-a-stepped-care-approach-into-internet-based 2024-09-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/b3498aa8775e60d6/roche-s-piasky-approved-in-eu-as-first-monthly-self-administered-treatment-for-paroxysmal-nocturnal-haemoglobinuria 2024-09-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/1644d69c2c361e8a/esc-2024-cathedral-hf-trial-results-have-the-potential-to-reduce-polypharmacy 2024-09-01T23:46:35+00:00 weekly 0.7 https://trial.medpath.com/news/2a382432e561dd90/closing-the-loop-with-transcranial-electrical-stimulation-for-depression-psychiatry-online 2024-09-01T22:51:28+00:00 weekly 0.7 https://trial.medpath.com/news/b7feb08625a2442c/matterhorn-trial-finds-teer-non-inferior-to-surgery-for-secondary-mitral-regurgitation 2024-09-01T22:02:08+00:00 weekly 0.7 https://trial.medpath.com/news/7fa9f2438edcd0a0/scoff-trial-confirms-that-fasting-is-not-needed-before-cath-lab-procedures 2024-09-01T21:19:29+00:00 weekly 0.7 https://trial.medpath.com/news/db23f590132b8fd5/research-suggests-flexible-approach-to-antiplatelet-management-after-coronary-drug-eluting 2024-09-01T18:20:10+00:00 weekly 0.7 https://trial.medpath.com/news/085498e4902dd268/irhythm-technologies-announces-results-of-guard-af-trial-globenewswire 2024-09-01T17:36:52+00:00 weekly 0.7 https://trial.medpath.com/news/c812cbac94334a39/fentanyl-vaccine-created-in-texas-heads-for-clinical-trials-with-goal-of-saving-lives 2024-09-01T15:40:30+00:00 weekly 0.7 https://trial.medpath.com/news/2450aaf840acbe93/dr-chris-kramer-on-the-clinical-importance-of-finerenone-for-patients-with-heart-failure 2024-09-01T15:32:27+00:00 weekly 0.7 https://trial.medpath.com/news/4ae5ac7639916fbe/sglt2-inhibitor-empagliflozin-is-shown-to-be-safe-newswise 2024-09-01T14:09:20+00:00 weekly 0.7 https://trial.medpath.com/news/0797db78eb1f059d/long-term-ixekizumab-similarly-efficacious-in-challenging-body-areas-healio 2024-09-01T13:51:27+00:00 weekly 0.7 https://trial.medpath.com/news/7027b808e7bf72ec/abata-therapeutics-treg-therapy-aba-101-garners-fda-fast-track-designation 2024-09-01T13:11:27+00:00 weekly 0.7 https://trial.medpath.com/news/2e3a154f75854d98/the-targeted-pulse-good-news-for-advanced-cll-sll-with-bgb-16673-receiving-fast 2024-09-01T11:03:20+00:00 weekly 0.7 https://trial.medpath.com/news/8c10cadbb2777a85/cytokinetics-presents-additional-data-from-sequoia-hcm-at-the-european-society-morningstar 2024-09-01T08:02:50+00:00 weekly 0.7 https://trial.medpath.com/news/3ad1231cfb84ce8e/ozempic-reduces-risk-of-heart-failure-by-27pc-study-afr 2024-09-01T07:18:34+00:00 weekly 0.7 https://trial.medpath.com/news/3533c5dd1b60b135/dedicated-trial-in-women-demonstrates-the-superiority-of-transcatheter-vs-surgical-aortic 2024-09-01T05:24:26+00:00 weekly 0.7 https://trial.medpath.com/news/66746d5ddd94df97/events-for-september-10-2024-rethinking-clinical-trials 2024-09-01T04:22:21+00:00 weekly 0.7 https://trial.medpath.com/news/c71b631634b81810/pause-or-keep-ras-inhibitors-before-surgery-take-your-pick-medpage-today 2024-09-01T04:13:40+00:00 weekly 0.7 https://trial.medpath.com/news/3c7011586f683102/aggressive-supportive-care-following-novel-agents-may-reduce-infection 2024-09-01T03:58:30+00:00 weekly 0.7 https://trial.medpath.com/news/865e293bffca38e7/fda-grants-priority-review-to-new-drug-application-of-neurofibromatosis-agent-mirdametinib 2024-09-01T02:28:08+00:00 weekly 0.7 https://trial.medpath.com/news/0ba7aff7ef8094af/novel-drug-development-advances-in-metastatic-colorectal-cancer-focus-on-kras-targeting-and-immunotherapy 2024-09-01T02:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/89a9e96e393983a3/these-highlights-do-not-include-all-the-information-needed-to-use 2024-09-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/6dfed882c68a991a/phase-iii-study-of-socazolimab-as-first-line-treatment-in-persistent-recurrent-or-metastatic-cervical-cancer 2024-09-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/123970cb133b5481/school-based-prevention-of-teacher-and-parental-violence-against-children-bmc-public-health 2024-08-31T23:34:41+00:00 weekly 0.7 https://trial.medpath.com/news/d4b232e1d0c8abed/nivolumab-plus-neoadjuvant-chemoradiation-fails-to-enhance-pcr-rate-in-esophageal 2024-08-31T22:02:32+00:00 weekly 0.7 https://trial.medpath.com/news/e0854128afc94a55/oncolytic-peptide-vp-315-reduces-tumor-size-in-patients-with-basal-cell-carcinoma 2024-08-31T21:07:26+00:00 weekly 0.7 https://trial.medpath.com/news/91fcc6d74fa0f599/esc-2024-study-highlights-potential-for-novartis-to-differentiate-in-hf-space 2024-08-31T18:42:50+00:00 weekly 0.7 https://trial.medpath.com/news/ef791214170201ba/esc-2024-sacubitril-valsartan-continues-to-impress-in-heart-failure-clinical-trials-arena 2024-08-31T18:10:39+00:00 weekly 0.7 https://trial.medpath.com/news/82ec85f5df0cf583/potassium-supplementation-and-prevention-of-atrial-fibrillation-after-cardiac-surgery 2024-08-31T16:21:04+00:00 weekly 0.7 https://trial.medpath.com/news/25bffd0bb363f9f9/a-clinical-trial-on-no-touch-vein-graft-in-coronary-surgery-swedegraft 2024-08-31T16:16:43+00:00 weekly 0.7 https://trial.medpath.com/news/dd4b9b7f13549bb0/dr-dizman-on-future-efforts-to-elucidate-benefit-with-cbm588-in-first-line-rcc-onclive 2024-08-31T15:55:38+00:00 weekly 0.7 https://trial.medpath.com/news/aba7d36d9a2e7875/dr-dipti-itchhaporia-on-health-equity-clinical-trials-and-emerging-therapies-at-esc 2024-08-31T13:29:58+00:00 weekly 0.7 https://trial.medpath.com/news/6231b7768e0d3b29/the-promise-of-il-21-engineered-nk-cells-in-glioblastoma-treatment-targeted-oncology 2024-08-31T12:36:23+00:00 weekly 0.7 https://trial.medpath.com/news/67ca802c988b7eeb/fda-grants-priority-review-to-mirdametinib-for-nf1-associated-plexiform-neurofibromas 2024-08-31T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/1d1d258272adbef5/more-drug-does-not-always-lead-to-more-efficacy-dr-mark-bleackley-on-the-progress-of 2024-08-31T11:41:57+00:00 weekly 0.7 https://trial.medpath.com/news/4355afb5c7f67a48/foundation-fighting-blindness-to-conduct-a-natural-history-study-of-usher-syndrome-type-3 2024-08-31T11:33:39+00:00 weekly 0.7 https://trial.medpath.com/news/25a20f33ef1f4307/novel-low-dose-3-in-1-blood-pressure-pill-significantly-outperforms-standard-care-study-shows 2024-08-31T10:18:26+00:00 weekly 0.7 https://trial.medpath.com/news/49c76b9b9e4283ce/low-dose-triple-pill-vs-standard-care-protocols-for-hypertension-treatment-in-nigeria 2024-08-31T09:54:25+00:00 weekly 0.7 https://trial.medpath.com/news/8da7593c9de25434/abemaciclib-monotherapy-elicits-no-response-in-advanced-rcc-onclive 2024-08-31T08:10:53+00:00 weekly 0.7 https://trial.medpath.com/news/f83b9d45908ad896/esc-2024-obicetrapib-a-promising-breakthrough-for-dyslipidemia-treatment 2024-08-31T08:04:30+00:00 weekly 0.7 https://trial.medpath.com/news/2d16475a9c17de18/cgtlive-r-s-weekly-rewind-august-30-2024 2024-08-31T07:17:34+00:00 weekly 0.7 https://trial.medpath.com/news/2c6b4ee61eac3749/european-study-reveals-harmful-impact-of-delayed-myasthenia-gravis-diagnosis 2024-08-31T05:51:32+00:00 weekly 0.7 https://trial.medpath.com/news/b567a20b0fc2a494/nxp800-gains-fda-orphan-drug-status-in-arid1a-deficient-ovarian-cancers 2024-08-31T04:08:17+00:00 weekly 0.7 https://trial.medpath.com/news/f00c26be0e20fc9c/clinical-trial-in-ireland-challenges-beliefs-about-ozempic-and-similar-new-obesity-treatments 2024-08-31T00:45:08+00:00 weekly 0.7 https://trial.medpath.com/news/cd9272b7153a91e2/esc-2024-select-trial-provides-promising-results-for-obesity-related-hfpef-treatment 2024-08-30T21:34:14+00:00 weekly 0.7 https://trial.medpath.com/news/0c235743598d2417/phase-i-clinical-trial-of-nh130-and-the-prediction-of-its-pharmacokinetics-using-frontiers 2024-08-30T20:39:34+00:00 weekly 0.7 https://trial.medpath.com/news/73adcdc388d9abcc/phase-3-clinical-trial-commences-for-oral-myasthenia-gravis-treatment-healio 2024-08-30T18:54:12+00:00 weekly 0.7 https://trial.medpath.com/news/a4be97d917a6fafa/cellprothera-inches-closer-to-phase-iii-trial-for-heart-attack-cell-therapy-clinical-trials-arena 2024-08-30T17:41:34+00:00 weekly 0.7 https://trial.medpath.com/news/29a6b12aa69494b3/orgenesis-car-t-org-101-demonstrates-efficacy-and-safety-in-acute-lymphoblastic 2024-08-30T17:14:39+00:00 weekly 0.7 https://trial.medpath.com/news/6d827ce78f3c8de8/an-obesity-drug-prevents-covid-deaths-study-suggests-the-new-york-times 2024-08-30T17:08:04+00:00 weekly 0.7 https://trial.medpath.com/news/47c248196c3602da/esc-2024-retatrutide-improves-lipid-and-cardiovascular-risk-profile-in-phase-ii-trial 2024-08-30T16:44:42+00:00 weekly 0.7 https://trial.medpath.com/news/58654bc86d28273d/mother-frantic-to-save-clinical-trial-that-could-cure-her-daughter-the-treatment-is-sitting-in-a-fridge 2024-08-30T16:37:55+00:00 weekly 0.7 https://trial.medpath.com/news/0f3b9096cbf2362a/abyss-trial-no-difference-in-outcomes-continuing-or-stopping-beta-blockers-following-mi 2024-08-30T16:30:50+00:00 weekly 0.7 https://trial.medpath.com/news/ab6ba070c879da27/nih-grants-funds-to-establish-network-for-nursing-home-trials 2024-08-30T15:15:21+00:00 weekly 0.7 https://trial.medpath.com/news/53fe44bf87e8e09b/benefits-of-dark-chocolate-intake-on-retinal-vessels-functionality-nature 2024-08-30T14:58:18+00:00 weekly 0.7 https://trial.medpath.com/news/f3735cbde12afca7/ozempic-wegovy-have-health-benefits-beyond-weight-loss-studies-find 2024-08-30T14:08:39+00:00 weekly 0.7 https://trial.medpath.com/news/676c9338bedfd301/australian-first-clinical-trial-of-personalised-immunotherapy-used-on-two-perth-cancer-patients-abc 2024-08-30T13:48:35+00:00 weekly 0.7 https://trial.medpath.com/news/4721f689b7826aa4/an-oral-small-molecule-pcsk9-inhibitor-disclosed-by-astrazeneca 2024-08-30T13:45:00+00:00 weekly 0.7 https://trial.medpath.com/news/420a991d3efdd86d/leading-cardiologist-deepak-bhatt-highlights-critical-challenges-in-clinical-trial-interpretation 2024-08-30T11:17:25+00:00 weekly 0.7 https://trial.medpath.com/news/b286b28be4590a2e/community-oncologists-face-growing-decision-support-crisis-amid-cancer-care-complexity 2024-08-30T10:00:02+00:00 weekly 0.7 https://trial.medpath.com/news/0d151427d93f809c/us-leads-global-cancer-vaccine-research-with-47-of-clinical-trials 2024-08-30T08:12:50+00:00 weekly 0.7 https://trial.medpath.com/news/113d69a96eb574b4/clinical-trial-diversity-gap-costs-healthcare-system-11-trillion-nasem-report-reveals 2024-08-30T07:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/f2d2dd19d84fa878/new-pooled-analysis-published-in-the-lancet-demonstrated-reduced-risk-of-combined-cv-death-or-worsening-heart-failure-with-semaglutide 2024-08-30T03:09:52+00:00 weekly 0.7 https://trial.medpath.com/news/7d7e9c0b22cb6afc/clinical-ink-unveils-edcxtra-integrated-data-capture-platform-to-streamline-clinical-trials 2024-08-30T02:27:33+00:00 weekly 0.7 https://trial.medpath.com/news/f933f4f53d0bfe07/and-medium-term-outcomes-of-novel-biologics-and-lightweight-synthetic-mesh-for-pubmed 2024-08-30T00:32:26+00:00 weekly 0.7 https://trial.medpath.com/news/160d318d84419ac1/novavax-2024-2025-formula-covid-19-vaccine-now-authorized-and-recommended-for-use-in-the-u-s 2024-08-30T00:08:42+00:00 weekly 0.7 https://trial.medpath.com/news/1931994efcd264c2/aclarion-launches-second-clinical-utility-and-economic-clue-trial-site-with-first 2024-08-29T23:46:48+00:00 weekly 0.7 https://trial.medpath.com/news/8e58355bfa063c80/arizona-bioscience-news-u-of-a-president-salary-journey-venture-studio-ivy-brian-center 2024-08-29T23:29:19+00:00 weekly 0.7 https://trial.medpath.com/news/8bb7946b308f9144/inari-medical-announces-peerless-data-to-be-presented-during-the-late-breaking-morningstar 2024-08-29T20:28:50+00:00 weekly 0.7 https://trial.medpath.com/news/25bc9671b733bdf8/four-new-clinical-trials-grants-from-the-cihr-for-ri-muhc-researchers-health-e-news 2024-08-29T19:36:42+00:00 weekly 0.7 https://trial.medpath.com/news/4d348e7ad7272b19/dr-hantel-on-eligibility-criteria-associated-with-racial-ethnic-disparities-in-clinical-trial 2024-08-29T19:22:54+00:00 weekly 0.7 https://trial.medpath.com/news/a24d3bbd5a1d0f7e/efficacy-and-safety-of-ensitrelvir-for-asymptomatic-or-mild-covid-19-an-exploratory 2024-08-29T19:12:48+00:00 weekly 0.7 https://trial.medpath.com/news/1391a27de1808463/health-matters-mental-health-edition-methamphetamine-addiction-a-larc-clinical-trial 2024-08-29T18:22:18+00:00 weekly 0.7 https://trial.medpath.com/news/ce124d8727bbbfd5/researchers-attempt-to-emulate-a-clinical-trial-using-data-from-real-patients-medical-xpress 2024-08-29T18:03:16+00:00 weekly 0.7 https://trial.medpath.com/news/30507ef949df96b5/fda-tackles-clinical-trial-diversity-is-congress-next-national-health-council 2024-08-29T17:47:39+00:00 weekly 0.7 https://trial.medpath.com/news/dd388d781499b51b/clinical-trial-aims-to-test-tolerability-of-felodipine-in-hd-rare-disease-advisor 2024-08-29T17:36:49+00:00 weekly 0.7 https://trial.medpath.com/news/37fcce472153ceef/keytruda-fails-lung-and-skin-cancer-trials-limiting-further-expansion-biopharma-dive 2024-08-29T16:53:30+00:00 weekly 0.7 https://trial.medpath.com/news/aadbad3495ad4c37/merck-provides-update-on-phase-3-keynote-867-and-keynote-630-trials-merck-com 2024-08-29T16:46:46+00:00 weekly 0.7 https://trial.medpath.com/news/ef36ff71d3d7f1cd/ireland-steps-up-efforts-to-boost-clinical-trial-performance-by-standardizing-ctas 2024-08-29T16:07:49+00:00 weekly 0.7 https://trial.medpath.com/news/c02814a92eb6fa0f/nih-r01-grant-awarded-to-dr-vajravelu-for-novel-clinical-trial 2024-08-29T16:04:33+00:00 weekly 0.7 https://trial.medpath.com/news/ffe4145c37afbb11/cambridgeshire-boy-takes-part-in-brain-tumour-drug-trial-cambridge-children-s 2024-08-29T15:00:57+00:00 weekly 0.7 https://trial.medpath.com/news/ee865bb9a9f6af8b/jazz-fails-phase-3-trial-in-japan-bat-set-to-see-growth-from-cannabis-investment 2024-08-29T14:42:18+00:00 weekly 0.7 https://trial.medpath.com/news/ca38a2ceb9c5b34b/clinical-trial-assesses-the-efficacy-of-suvorexant-in-reducing-delirium-in-older-adults 2024-08-29T14:34:53+00:00 weekly 0.7 https://trial.medpath.com/news/f10f2231a7229526/neura-launches-world-s-largest-clinical-trial-for-phantom-limb-pain-news-hub 2024-08-29T14:09:32+00:00 weekly 0.7 https://trial.medpath.com/news/b44c2b1db5e7535e/melodi-health-announces-10-75-million-in-series-a-funding-first-enrollment-in-pivotal-clinical-trial 2024-08-29T13:16:22+00:00 weekly 0.7 https://trial.medpath.com/news/7d4e768a5d745da1/mindbio-ceo-provides-video-update-to-shareholders-on-progress-of-world-first-thenewswire 2024-08-29T13:05:45+00:00 weekly 0.7 https://trial.medpath.com/news/db8b76c305b73b3b/innovent-to-present-clinical-data-of-multiple-novel-molecules-at-wclc-and-esmo-2024 2024-08-29T11:59:34+00:00 weekly 0.7 https://trial.medpath.com/news/1f9e995bede4ec8c/neurocrine-reports-positive-data-from-phase-ii-schizophrenia-treatment-trial 2024-08-29T11:43:16+00:00 weekly 0.7 https://trial.medpath.com/news/ee8744d07a244185/gain-therapeutics-announces-positive-topline-results-from-the-phase-1-clinical-trial-of-gt 2024-08-29T11:40:46+00:00 weekly 0.7 https://trial.medpath.com/news/a57c0d92b2ec8164/don-t-delay-covid-19-booster-vaccination-study-reveals-doherty-website 2024-08-29T10:21:57+00:00 weekly 0.7 https://trial.medpath.com/news/3620c2e509e1f525/migraine-drug-ubrelvy-may-stop-headaches-before-they-start 2024-08-29T10:08:48+00:00 weekly 0.7 https://trial.medpath.com/news/6afdd429da314d2b/repare-therapeutics-announces-strategic-reprioritization-to-focus-on-broad-clinical-portfolio 2024-08-29T10:04:34+00:00 weekly 0.7 https://trial.medpath.com/news/2351bbce5ff026e0/offering-peace-of-mind-peanut-immunotherapy-clinical-trials-at-lurie-children-s-eurekalert 2024-08-29T08:15:26+00:00 weekly 0.7 https://trial.medpath.com/news/7cc79f9808e1a7a2/transcenta-holding-limited-stock-code-6628-hk-announce-2024-interim-results 2024-08-29T07:54:59+00:00 weekly 0.7 https://trial.medpath.com/news/b6eb9f34ed3dfa46/around-the-helix-cell-and-gene-therapy-company-updates-august-28-2024-cgtlive-r 2024-08-29T07:17:22+00:00 weekly 0.7 https://trial.medpath.com/news/d68608ed0eae9238/human-papillomavirus-hpv-trials-a-cross-sectional-analysis-of-clinical-trials-registries-pubmed 2024-08-29T04:59:18+00:00 weekly 0.7 https://trial.medpath.com/news/239aea512cfa25c6/emergent-biosolutions-acam2000-smallpox-and-mpox-vaccinia-vaccine-live-receives-u-s-fda-approval-for-mpox-indication 2024-08-29T04:08:02+00:00 weekly 0.7 https://trial.medpath.com/news/e5b65a7d7e137f6b/umass-chan-scientist-shan-lu-reports-on-effectiveness-of-dna-vaccine-to-prevent-hiv 2024-08-29T04:06:39+00:00 weekly 0.7 https://trial.medpath.com/news/9813f55e89f8f717/randomized-controlled-trial-assessing-vitamin-d-s-role-in-reducing-bppv-recurrence-pubmed 2024-08-29T00:47:01+00:00 weekly 0.7 https://trial.medpath.com/news/196b766a2aa948ee/first-patient-dosed-in-guard-therapeutics-phase-2b-study-pointer 2024-08-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/8dcbd0bfd3a85ac8/qlife-holding-ab-interim-report-q2-april-to-june-2024 2024-08-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/29e3b87a6558fad2/expert-reaction-to-observational-study-claiming-certain-diabetes-drugs-might-prevent-dementia 2024-08-28T22:59:29+00:00 weekly 0.7 https://trial.medpath.com/news/d4d28e54305a63c2/university-of-utah-health-participates-in-groundbreaking-pain-management-research-study 2024-08-28T20:04:50+00:00 weekly 0.7 https://trial.medpath.com/news/d9ec313a6c19a16f/estimating-cure-proportion-in-cancer-clinical-trials-using-flexible-parametric-cure-models 2024-08-28T19:49:56+00:00 weekly 0.7 https://trial.medpath.com/news/55c2e1569083c284/gatc-mci-team-on-ai-clinical-trial-funding-and-insurance-model-informa-connect 2024-08-28T19:40:17+00:00 weekly 0.7 https://trial.medpath.com/news/8e393c087ba2f492/participant-visits-complete-in-phase-2b-trial-of-cls-ax-for-wet-amd-healio 2024-08-28T19:37:43+00:00 weekly 0.7 https://trial.medpath.com/news/a94b8e5b2bcfb320/news-dosing-underway-in-world-s-first-in-vivo-crispr-trial-for-primary-hyperoxaluria 2024-08-28T19:13:17+00:00 weekly 0.7 https://trial.medpath.com/news/2c77e9620aedbe1e/verve-therapeutics-investor-sues-over-clinical-trial-stoppage-bloomberg-law-news 2024-08-28T18:36:51+00:00 weekly 0.7 https://trial.medpath.com/news/3d730fb102d49659/phase-ii-trial-of-her-vaxx-a-b-cell-peptide-based-vaccine-in-her2-overexpressing 2024-08-28T17:45:49+00:00 weekly 0.7 https://trial.medpath.com/news/6861eb67b77724bf/glp-1-therapies-a-new-frontier-in-mash-treatment-clinical-trials-arena 2024-08-28T17:16:05+00:00 weekly 0.7 https://trial.medpath.com/news/ed39762a0dcbd8ef/optimi-health-atma-receive-no-objection-letter-from-health-canada-for-phase-2-clinical-trial 2024-08-28T16:29:49+00:00 weekly 0.7 https://trial.medpath.com/news/2cf21bfa5288ab9f/uk-secures-ps400-million-investment-to-boost-clinical-trials-gov-uk 2024-08-28T16:09:29+00:00 weekly 0.7 https://trial.medpath.com/news/7a2db7d23d39f5a2/new-brain-tumor-drug-hits-market-16-years-after-duke-neurosurgeon-s-discovery-abc11 2024-08-28T15:55:53+00:00 weekly 0.7 https://trial.medpath.com/news/6db8e502522e317e/promising-mpox-drug-fails-in-trials-as-virus-spreads-wired 2024-08-28T15:37:18+00:00 weekly 0.7 https://trial.medpath.com/news/e9d1dfef5090858f/immix-biopharma-expands-u-s-clinical-sites-for-relapsed-refractory-al-amyloidosis-trial 2024-08-28T14:08:12+00:00 weekly 0.7 https://trial.medpath.com/news/31306303c1073393/emvenio-s-clinical-research-sites-at-prime-healthcare-hospitals-now-open-in-dallas-and-atlanta 2024-08-28T14:06:43+00:00 weekly 0.7 https://trial.medpath.com/news/8f4bdc3c8e6fba33/notable-uh-and-cwru-clinician-researcher-and-educator-robert-salata-md-facp 2024-08-28T14:06:41+00:00 weekly 0.7 https://trial.medpath.com/news/fb7e504b134b4383/hyundai-bioscience-to-conduct-phase-3-clinical-trial-for-high-risk-group-of-covid-19-patients 2024-08-28T13:37:00+00:00 weekly 0.7 https://trial.medpath.com/news/810e5dad2dc74a5e/novartis-twice-yearly-leqvio-r-demonstrated-clinically-meaningful-statistically-significant 2024-08-28T13:06:04+00:00 weekly 0.7 https://trial.medpath.com/news/4e014fca49e57487/game-changer-take-home-blood-cancer-drug-to-be-offered-by-nhs-england 2024-08-28T12:33:04+00:00 weekly 0.7 https://trial.medpath.com/news/213d2a493c61f9dd/experts-call-for-technology-driven-solutions-to-boost-minority-representation-in-cll-clinical-trials 2024-08-28T11:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/5856e031c8ccc5e4/leading-experts-to-host-webinar-on-scientific-storytelling-in-medical-publications 2024-08-28T07:30:48+00:00 weekly 0.7 https://trial.medpath.com/news/6ff633db4624fb75/crf-announces-tct-2024-late-breaking-clinical-trials-and-science 2024-08-28T07:20:38+00:00 weekly 0.7 https://trial.medpath.com/news/176b4d4aaa245504/wanted-t1d-participants-for-clinical-trial-to-test-semaglutide-jdrf-australia 2024-08-28T06:52:31+00:00 weekly 0.7 https://trial.medpath.com/news/c6ea76d65ae4f529/clinical-trial-taking-place-in-houston-for-those-who-want-to-stop-smoking-lose-weight 2024-08-28T03:30:26+00:00 weekly 0.7 https://trial.medpath.com/news/df31949ef1a1cea1/telix-submits-nda-for-tlx101-cdx-pixclara-brain-cancer-imaging-agent 2024-08-28T03:08:56+00:00 weekly 0.7 https://trial.medpath.com/news/aec19bb1f01b11ce/trailblazers-in-innovation-medical-college-of-wisconsin 2024-08-28T02:36:56+00:00 weekly 0.7 https://trial.medpath.com/news/e32dffbb3c45e2e8/waiver-of-local-clinical-trial-requirements-by-csdso-a-well-deliberated-move-shweta-rai 2024-08-28T02:31:03+00:00 weekly 0.7 https://trial.medpath.com/news/b940aa5d44226c93/eli-lilly-introduces-lower-cost-single-dose-zepbound-vials-to-expand-obesity-treatment-access 2024-08-28T00:49:26+00:00 weekly 0.7 https://trial.medpath.com/news/00653b9f73db0598/i-mab-reports-1h-2024-financial-results-pipeline-progress-and 2024-08-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/1588128268fe8b43/eshunt-r-system-receives-fda-breakthrough-device-designation 2024-08-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/091352a771fed87f/european-commission-approves-astellas-padcev-tm-enfortumab-vedotin-in 2024-08-27T23:34:47+00:00 weekly 0.7 https://trial.medpath.com/news/ccaf9745035b61f6/nebulized-enriched-heparin-improves-respiratory-parameters-in-patients-with-covid-19 2024-08-27T22:47:51+00:00 weekly 0.7 https://trial.medpath.com/news/7dc991a7fdb7b7c3/projenx-announces-formation-of-clinical-advisory-board-pr-newswire 2024-08-27T21:10:22+00:00 weekly 0.7 https://trial.medpath.com/news/8aa9348ce71f2728/investigating-immune-tolerance-in-celiac-disease-avalon-clinical-trial 2024-08-27T20:05:11+00:00 weekly 0.7 https://trial.medpath.com/news/83938ddfed4ab228/next-level-breast-reconstruction-after-cancer-university-of-houston 2024-08-27T19:48:35+00:00 weekly 0.7 https://trial.medpath.com/news/9221ca114bef07b4/limited-impact-of-cannabidiol-on-health-related-quality-of-life-of-people-with-long-term-controlled-hiv 2024-08-27T19:37:55+00:00 weekly 0.7 https://trial.medpath.com/news/e8b2764546f31182/enrollment-dosing-complete-in-phase-1-trial-of-aiv007-for-amd-diabetic-macular-edema 2024-08-27T19:11:06+00:00 weekly 0.7 https://trial.medpath.com/news/a189ffb78ef72aed/novo-nordisk-registers-clinical-trial-on-wegovy-s-long-term-effects-on-teens-quartz 2024-08-27T18:41:22+00:00 weekly 0.7 https://trial.medpath.com/news/fd0c9d76d3556412/jw-therapeutics-relma-cell-approved-in-china-for-r-r-mantle-cell-lymphoma 2024-08-27T18:22:25+00:00 weekly 0.7 https://trial.medpath.com/news/0a2ee7b37a8fce44/xlhed-clinical-trial-opens-new-site-in-los-angeles 2024-08-27T17:26:46+00:00 weekly 0.7 https://trial.medpath.com/news/6b52da2417756aae/thoracic-oncology-program-research-ucsf 2024-08-27T16:43:55+00:00 weekly 0.7 https://trial.medpath.com/news/b4cac47f94bc7cb5/new-insights-on-brain-spinal-communication-in-opioid-withdrawal-lead-to-a-clinical-trial 2024-08-27T16:32:55+00:00 weekly 0.7 https://trial.medpath.com/news/7e3259e93d572361/fda-approves-engineered-cell-therapy-for-advanced-synovial-sarcoma-national-cancer-institute 2024-08-27T16:26:41+00:00 weekly 0.7 https://trial.medpath.com/news/eee35aee5a5ca03f/covid-19-nasal-vaccine-ready-for-clinical-trials-inside-precision-medicine 2024-08-27T15:18:54+00:00 weekly 0.7 https://trial.medpath.com/news/bc8085f854e309c4/harvard-apparatus-regenerative-technology-secures-5m-to-continue-clinical-trial 2024-08-27T14:57:01+00:00 weekly 0.7 https://trial.medpath.com/news/1860fcef750eeb7d/oculis-closes-phase-iii-eye-drop-trial-due-to-third-party-administrative-error-biospace 2024-08-27T14:50:52+00:00 weekly 0.7 https://trial.medpath.com/news/d266c3435ec7355d/atlantic-veterinary-college-initiates-clinical-trial-for-treatment-of-cardiac-tumours-in-dogs 2024-08-27T14:41:17+00:00 weekly 0.7 https://trial.medpath.com/news/0788a8fc0d28b280/clinical-trials-for-first-lung-cancer-vaccine-underway-where-in-va-and-md-is-it-being-tested 2024-08-27T13:05:04+00:00 weekly 0.7 https://trial.medpath.com/news/41ad226361b10684/astellas-initiates-phase-3-clinical-study-of-fezolinetant-for-vms-in-women-with-breast 2024-08-27T13:04:25+00:00 weekly 0.7 https://trial.medpath.com/news/f3202ed912d49b14/mabwell-receives-approval-for-phase-iii-trial-of-urothelial-carcinoma-drug-in-china 2024-08-27T12:34:17+00:00 weekly 0.7 https://trial.medpath.com/news/be095048598fc8cc/fda-clears-first-automated-device-to-deliver-insulin-to-people-with-type-2-diabetes 2024-08-27T12:08:50+00:00 weekly 0.7 https://trial.medpath.com/news/45b162c376642dd7/gi-innovation-and-msd-partner-for-trial-of-gi-102-and-keytruda-regimen-for-cancer 2024-08-27T11:39:32+00:00 weekly 0.7 https://trial.medpath.com/news/ba247e991852bf1e/diakonos-oncology-secures-funds-for-phase-ii-trial-of-dendritic-cell-vaccine 2024-08-27T11:39:32+00:00 weekly 0.7 https://trial.medpath.com/news/8f7756d4c91d3761/merck-announces-phase-3-trial-initiation-for-bomedemstat-an-investigational-candidate-for 2024-08-27T10:50:51+00:00 weekly 0.7 https://trial.medpath.com/news/1020fb84187c9578/opna-bio-doses-first-subject-in-phase-i-trial-of-treatment-for-multiple-myeloma 2024-08-27T10:03:06+00:00 weekly 0.7 https://trial.medpath.com/news/4257dba91caf8cdf/omny-ire-clinical-trial-completes-enrolment-cardiac-rhythm-news 2024-08-27T09:03:57+00:00 weekly 0.7 https://trial.medpath.com/news/e4f74e07015a1b1f/microbiotica-doses-first-patient-in-phase-1b-trial-of-mb097-microbiome-therapy-for-advanced-melanoma 2024-08-27T09:00:56+00:00 weekly 0.7 https://trial.medpath.com/news/be8a56c85de9d8d6/vaderis-announces-positive-clinical-proof-of-concept-trial-in-hht-morningstar 2024-08-27T07:48:32+00:00 weekly 0.7 https://trial.medpath.com/news/17230eb58c760113/c-difficile-vaccine-candidate-fails-to-meet-primary-end-point-in-phase-3-trial-cidrap 2024-08-27T07:35:28+00:00 weekly 0.7 https://trial.medpath.com/news/467226e8c302a5cd/unm-launches-clinical-trial-using-heated-chemo-for-ovarian-cancer-new-mexico-sun 2024-08-27T06:53:06+00:00 weekly 0.7 https://trial.medpath.com/news/e1199f0fa88a5097/clinical-trials-in-phoenix-offering-hope-for-brain-cancer-patients-azfamily 2024-08-27T06:16:48+00:00 weekly 0.7 https://trial.medpath.com/news/4133220335c3434b/mytomorrows-and-pancreatic-cancer-europe-unite-to-enhance-clinical-trial-access-across-europe 2024-08-27T05:26:43+00:00 weekly 0.7 https://trial.medpath.com/news/091fc8c0773a66a1/soleno-therapeutics-announces-u-s-fda-acceptance-for-filing-and-priority-review-of-nda-for-dccr-diazoxide-choline-extended-release-tablets-in-prader-willi-syndrome 2024-08-27T05:08:33+00:00 weekly 0.7 https://trial.medpath.com/news/8081599029e8e4e4/walgreens-and-barda-enter-partnership-to-progress-decentralized-clinical-research-program 2024-08-27T05:00:08+00:00 weekly 0.7 https://trial.medpath.com/news/b1090618124f9667/par-24-274-nci-research-specialist-clinician-scientist-award-r50-clinical-trial-not-allowed 2024-08-27T04:56:25+00:00 weekly 0.7 https://trial.medpath.com/news/2641175127bdecdc/intermittent-energy-restriction-for-adolescents-with-obesity-the-fast-track-to-health 2024-08-27T00:09:19+00:00 weekly 0.7 https://trial.medpath.com/news/c9501dbeb13c776c/low-intensity-blood-stem-cell-transplants-for-sickle-cell-appear-safe-for-lung-health 2024-08-27T00:08:32+00:00 weekly 0.7 https://trial.medpath.com/news/470681c6ecc55137/johnson-johnson-is-transforming-solid-tumor-cancer-outcomes-with 2024-08-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/83cc57ae8b3a6afe/fda-releases-important-information-about-risk-of-covid-19-due-to-sars-cov-2-viral-variants-with-substantially-reduced-susceptibility-to-pemgarda-pemivibart 2024-08-26T23:08:08+00:00 weekly 0.7 https://trial.medpath.com/news/0bd2bbb175e1da9e/new-approach-helps-more-people-with-rectal-cancers-avoid-surgery 2024-08-26T09:08:30+00:00 weekly 0.7 https://trial.medpath.com/news/44297bc9a420a046/an-alzheimer-s-drug-may-also-slow-lewy-body-dementia 2024-08-26T09:08:28+00:00 weekly 0.7 https://trial.medpath.com/news/0e10eb1c902bf03f/mckesson-acquires-2-49-billion-controlling-stake-in-florida-cancer-specialists-to-expand-community-oncology-platform 2024-08-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/7def087e35283a0c/si-bone-sibn-receives-fda-nod-for-its-tnt-implant-system 2024-08-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/0984ecad50bd0603/rhythm-pharmaceuticals-announces-fda-acceptance-for-globenewswire 2024-08-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/7f1c955a8778a79d/celltrion-s-steqeyma-gets-ec-approval-for-inflammatory-diseases 2024-08-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/00497c7b52788adb/xaluritamig-a-promising-new-therapeutic-for-metastatic-castration-resistant-prostate-cancer 2024-08-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/0be21e95bf5cbcce/izotropic-plans-regulatory-approval-for-izoview-breast-ct-in-u-s-and-eu 2024-08-23T13:46:57+00:00 weekly 0.7 https://trial.medpath.com/news/52fa7dd5e2fabfb6/wegovy-helps-patients-with-heart-failure-avoid-heart-attack-stroke 2024-08-23T09:08:50+00:00 weekly 0.7 https://trial.medpath.com/news/da8af4bf8a54d4de/no-link-found-between-migraines-parkinson-s-disease 2024-08-23T09:08:13+00:00 weekly 0.7 https://trial.medpath.com/news/2fc5d43c3e2255fd/mrna-cancer-vaccine-clinical-trials-insight 2024-08-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/762ff7d39617ad4d/lixte-biotechnology-faces-nasdaq-delisting-over-equity 2024-08-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/78d0e91fd5319104/the-journal-of-american-medical-association-jama-publishes-elinzanetant-phase-iii-data 2024-08-22T22:08:53+00:00 weekly 0.7 https://trial.medpath.com/news/9b03727dde3cda9b/moderna-receives-u-s-fda-approval-for-updated-covid-19-vaccine-targeting-kp-2-variant-of-sars-cov-2 2024-08-22T22:08:14+00:00 weekly 0.7 https://trial.medpath.com/news/1ff9fc27e1c75530/bayer-initiates-phase-ii-study-of-soluble-guanylate-cyclase-activator-bay3283142-in-patients-with-chronic-kidney-disease 2024-08-22T22:08:11+00:00 weekly 0.7 https://trial.medpath.com/news/6fea4959bf98e9fd/nice-rejects-alzheimer-s-drug-lecanemab-despite-mhra-approval-creating-two-tier-access-system 2024-08-22T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a06e2a839e0f4231/key-leadership-changes-reshape-pharmaceutical-services-landscape-in-july-2024 2024-08-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ee8edfa49e1ace94/federal-circuit-reverses-patent-invalidation-for-allergan-s-ibs-d-drug-viberzi-in-landmark-double-patenting-case 2024-08-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/5a24734c3b8fa1e3/molecule-one-pager-kt-474-sar444656 2024-08-21T21:56:07+00:00 weekly 0.7 https://trial.medpath.com/news/71615b2fc7a19650/leclaza-in-combination-with-rybrevant-receives-first-u-s-fda-approval-for-a-korea-born-anticancer-drug 2024-08-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/548afe1648aa869f/lexicon-pharmaceuticals-announces-fda-advisory-committee-globenewswire 2024-08-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/9b0cb3d40dbca7f6/fda-approves-rybrevant-amivantamab-vmjw-plus-lazcluze-lazertinib-for-patients-with-egfr-mutated-advanced-lung-cancer 2024-08-20T21:08:58+00:00 weekly 0.7 https://trial.medpath.com/news/c0c4b049b43fb2be/ftc-orange-book-patent-challenge-initiative-shows-mixed-results-as-most-listings-remain-in-force 2024-08-20T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cf965fc5ac9a597b/tirzepatide-reduced-the-risk-of-developing-type-2-diabetes-by-94-in-adults-with-pre-diabetes-and-obesity-or-overweight 2024-08-20T05:08:04+00:00 weekly 0.7 https://trial.medpath.com/news/d80b89b3311e15bf/regeneron-provides-update-on-biologics-license-application-for-linvoseltamab 2024-08-20T02:08:46+00:00 weekly 0.7 https://trial.medpath.com/news/a2d6c868c407c757/gsk-receives-us-fda-breakthrough-therapy-designation-for-b7-h3-targeted-antibody-drug-conjugate-gsk5764227-in-relapsed-or-refractory-extensive-stage-small-cell-lung-cancer 2024-08-20T02:08:04+00:00 weekly 0.7 https://trial.medpath.com/news/d9bc375240b73124/u-s-fda-grants-tentative-approval-of-yutrepia-treprostinil-inhalation-powder-for-patients-with-pulmonary-arterial-hypertension-pah-and-pulmonary-hypertension-associated-with-interstitial-lung-disease-ph-ild 2024-08-19T21:08:41+00:00 weekly 0.7 https://trial.medpath.com/news/448a9a6dbc1504ae/moma-therapeutics-initiates-phase-1-trial-for-novel-dna-repair-inhibitor-moma-313 2024-08-19T11:09:39+00:00 weekly 0.7 https://trial.medpath.com/news/998f42d7e9db2c01/arthrosi-therapeutics-receives-fda-fast-track-designation-for-ar882-in-tophaceous-gout 2024-08-19T02:08:55+00:00 weekly 0.7 https://trial.medpath.com/news/71a45e7e410100b9/tafasitamab-regimen-shows-promise-in-improving-pfs-for-advanced-follicular-lymphoma-patients 2024-08-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a4ecd7201a517390/who-announces-new-treatment-regimens-for-drug-resistant-tuberculosis 2024-08-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/5e4330972f3c1573/pfizer-biontech-covid-flu-combo-vaccine-faces-setback-due-to-influenza-b-response 2024-08-18T23:38:51+00:00 weekly 0.7 https://trial.medpath.com/news/3e7e75add04b5718/enrollment-completed-for-phase-2-clinical-trial-evaluating-vg081821ac-for-the-treatment-of-parkinson-s-disease 2024-08-18T22:08:00+00:00 weekly 0.7 https://trial.medpath.com/news/18e16807a445883e/cilta-cel-for-functional-high-risk-myeloma-healthtree 2024-08-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/0824874e03a1dfb6/imfinzi-approved-in-the-us-for-the-treatment-of-resectable-non-small-cell-lung-cancer-before-and-after-surgery 2024-08-16T23:08:36+00:00 weekly 0.7 https://trial.medpath.com/news/e560f490569321e2/u-s-food-and-drug-administration-accepts-for-priority-review-decipheras-new-drug-application-for-vimseltinib-for-the-treatment-of-patients-with-tenosynovial-giant-cell-tumor-tgct 2024-08-16T23:08:14+00:00 weekly 0.7 https://trial.medpath.com/news/05b3aeb3abd8e853/pfizer-and-biontech-provide-update-on-mrna-based-combination-vaccine-program-against-influenza-and-covid-19-in-individuals-18-64-years-of-age 2024-08-16T02:08:20+00:00 weekly 0.7 https://trial.medpath.com/news/4acc364baded7292/ptab-invalidates-multiple-regeneron-eylea-patents-as-biosimilar-competition-intensifies 2024-08-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/3bf37a1394803196/expanding-treatment-options-for-her2-breast-cancer-patients 2024-08-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/c714a839d1e6c6c4/citius-oncology-launches-following-fda-approval-of-lymphir 2024-08-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fd09e651f2d36987/vericel-announces-fda-approval-of-nexobrid-for-the-treatment-of-pediatric-patients-with-severe-thermal-burns 2024-08-15T20:08:46+00:00 weekly 0.7 https://trial.medpath.com/news/42177ec928be1616/sanofi-s-genzyme-sues-sarepta-over-elevidys-gene-therapy-patent-infringement 2024-08-15T16:56:07+00:00 weekly 0.7 https://trial.medpath.com/news/7b7afbfec05a1880/cresilon-receives-fda-clearance-for-traumagel 2024-08-15T13:32:49+00:00 weekly 0.7 https://trial.medpath.com/news/8c71ff828afffa9b/medicare-drug-price-negotiations-deliver-6-billion-in-savings-with-22-79-discounts-on-10-blockbuster-medications 2024-08-15T08:35:46+00:00 weekly 0.7 https://trial.medpath.com/news/51ad11208d954378/tecovirimat-is-safe-but-did-not-improve-clade-i-mpox-resolution-in-democratic-republic-of-the-congo 2024-08-15T02:08:24+00:00 weekly 0.7 https://trial.medpath.com/news/1d1385a86592e57e/prota-therapeutics-announces-publication-in-allergy-of-long-term-peanut-allergy-study-confirming-clinical-remission-as-the-optimal-treatment-outcome 2024-08-15T00:08:44+00:00 weekly 0.7 https://trial.medpath.com/news/df34b809b841dd69/tempest-announces-successful-end-of-phase-2-meeting-with-fda-for-amezalpat-tpst-1120-to-treat-first-line-hepatocellular-carcinoma 2024-08-15T00:08:35+00:00 weekly 0.7 https://trial.medpath.com/news/187ea723e8de8f76/imfinzi-granted-priority-review-and-breakthrough-therapy 2024-08-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/0e612a1d6b37f2db/a-randomized-double-blind-placebo-controlled-phase-3 2024-08-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/355f36504702ce4c/fda-grants-orphan-drug-and-rare-pediatric-disease-designations-to-atsn-201-for-x-linked-retinoschisis 2024-08-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/c1fd87e1b461994e/fda-approves-niktimvo-axatilimab-csfr-for-the-treatment-of-chronic-graft-versus-host-disease-gvhd 2024-08-14T22:08:53+00:00 weekly 0.7 https://trial.medpath.com/news/549c8e834e3c18e9/fda-grants-accelerated-approval-for-livdelzi-seladelpar-for-the-treatment-of-primary-biliary-cholangitis 2024-08-14T22:08:15+00:00 weekly 0.7 https://trial.medpath.com/news/ac01b3753b7fb5bc/precigen-announces-second-quarter-and-first-half-2024-financial-results-and-business-updates 2024-08-14T16:05:00+00:00 weekly 0.7 https://trial.medpath.com/news/7222aff7fcf5782b/evolution-of-pnh-treatment-new-therapies-transform-management-of-rare-blood-disorder 2024-08-14T11:24:32+00:00 weekly 0.7 https://trial.medpath.com/news/8627a62928eb9760/nhs-launches-personalised-cancer-vaccine-program-across-england-with-thousands-expected-to-enroll 2024-08-14T06:50:07+00:00 weekly 0.7 https://trial.medpath.com/news/469cb60d8e8d99f8/ai-and-multi-omics-drive-breakthrough-advances-in-anti-aging-drug-development 2024-08-14T05:25:28+00:00 weekly 0.7 https://trial.medpath.com/news/aa0a313961490c68/first-clinical-trial-of-paradoxical-intervention-for-cancer-to-begin-soon 2024-08-14T05:00:08+00:00 weekly 0.7 https://trial.medpath.com/news/a8eb361577ec9ac7/accutar-biotechnology-receives-fda-fast-track-designation-for-ac699-in-er-her2-breast-cancer 2024-08-14T01:08:46+00:00 weekly 0.7 https://trial.medpath.com/news/b89a6aba78c4f39a/candidate-malaria-vaccine-provides-lasting-protection-in-nih-sponsored-trials 2024-08-14T01:08:46+00:00 weekly 0.7 https://trial.medpath.com/news/56c1c6f9b8f3d01b/urogen-submits-completed-ugn-102-nda-seeking-approval-as-the-first-fda-approved-treatment-for-low-grade-intermediate-risk-non-muscle-invasive-bladder-cancer 2024-08-14T01:08:20+00:00 weekly 0.7 https://trial.medpath.com/news/05824ad8d89e81fc/acelyrin-stock-rating-downgraded-amid-pipeline-shift 2024-08-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/7c5c2ea37a54f01d/moleculin-advances-aml-treatment-with-positive-fda-feedback-and-plans-for-phase-3-miracle-trial 2024-08-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/6f270f6a9946a5d4/acelyrin-inc-announces-positive-phase-3-data-for-izokibep-biospace 2024-08-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/766a432b563fd878/enrollment-completed-for-the-sad-part-1-of-phase-1-clinical-trial-evaluating-da-1726-for-the-treatment-of-obesity 2024-08-13T23:08:31+00:00 weekly 0.7 https://trial.medpath.com/news/e08fa05f054686ce/fda-approves-nemluvio-nemolizumab-for-the-treatment-of-adult-patients-with-prurigo-nodularis 2024-08-13T21:08:43+00:00 weekly 0.7 https://trial.medpath.com/news/47fc65b965d9041c/acelyrin-announces-layoffs-strategy-shift-after-late-stage-trial-results-for-anti-inflammatory-drug 2024-08-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4b6a3c1060c847a4/real-world-evidence-platforms-transform-precision-medicine-development-through-advanced-data-analytics 2024-08-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fa12237a3a675702/heparegenix-lands-eur15m-to-advance-liver-regeneration-drug-into-clinical 2024-08-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/3ba7b63c7c0d38b7/federal-court-denies-novartis-injunction-against-entresto-generic-clearing-path-for-msn-launch 2024-08-12T22:53:32+00:00 weekly 0.7 https://trial.medpath.com/news/b6fc7b350aa9fb65/fda-lifts-clinical-hold-on-4d-molecular-therapeutics-fabry-disease-gene-therapy-trial 2024-08-12T15:00:11+00:00 weekly 0.7 https://trial.medpath.com/news/f8729660e29aa64b/kymera-therapeutics-reports-progress-in-q2-2024-earnings-call 2024-08-12T14:12:51+00:00 weekly 0.7 https://trial.medpath.com/news/616eb4783a98bd78/amylyx-s-amx0035-shows-promise-in-alzheimer-s-disease-biomarker-study 2024-08-12T13:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/7169887fc504dba3/pharmacosmos-group-acquires-g1-therapeutics-for-405-million-to-expand-cosela-access-for-cancer-patients 2024-08-12T09:26:28+00:00 weekly 0.7 https://trial.medpath.com/news/64091514d6aa5aef/fda-approves-enzeevu-aflibercept-abzv-a-biosimilar-to-eylea 2024-08-12T06:08:24+00:00 weekly 0.7 https://trial.medpath.com/news/8cd159b463f0da5c/scpharmaceuticals-announces-fda-approval-of-supplemental-new-drug-application-expanding-the-furoscix-indication-in-heart-failure 2024-08-12T01:08:47+00:00 weekly 0.7 https://trial.medpath.com/news/7109e97d86224266/lenz-therapeutics-announces-submission-of-new-drug-application-to-u-s-food-and-drug-administration-for-lnz100-for-the-treatment-of-presbyopia 2024-08-12T01:08:26+00:00 weekly 0.7 https://trial.medpath.com/news/1ffb95fd9d88540d/viva-biotech-s-portfolio-companies-make-significant-strides-in-biopharmaceutical-innovation 2024-08-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/00ba648734d9890a/brazil-cancer-drugs-market-clinical-trials-report-2024-brazil-emerges-as-a-leading-force-in-cancer-drug-clinical-trials 2024-08-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/7f178b939e018cba/key-developments-in-biosimilars-and-pharmaceuticals-in-2024 2024-08-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a02b642785fa2cdb/iaso-bio-secures-fda-approval-for-bcma-car-t-therapy-in-multiple-autoimmune-diseases 2024-08-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fc3458632d2a821e/study-shows-sglt2-inhibitors-improve-renal-function-in-non-diabetic-ckd-patients 2024-08-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/912a3293f0731570/neurotech-provides-update-on-bla-for-nt-501-as-a 2024-08-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/af418e21ab0fa215/sanofis-sarclisa-wins-in-transplant-eligible-multiple-myeloma-trial 2024-08-10T17:11:25+00:00 weekly 0.7 https://trial.medpath.com/news/5cefe7d8e94da589/lykos-therapeutics-announces-complete-response-letter-for-midomafetamine-capsules-for-ptsd 2024-08-09T21:08:38+00:00 weekly 0.7 https://trial.medpath.com/news/2a5d47ea2b86b668/first-patients-enrolled-in-us-pivotal-study-of-ai-based-image-analysis-module-for-lung-cancer 2024-08-09T21:08:37+00:00 weekly 0.7 https://trial.medpath.com/news/c605be8119bcf412/fda-approves-neffy-epinephrine-nasal-spray-needle-free-treatment-for-type-i-allergic-reactions-including-anaphylaxis 2024-08-09T07:08:41+00:00 weekly 0.7 https://trial.medpath.com/news/348060929f4433b5/fda-rejects-psychedelic-mdma-as-treatment-for-ptsd-calling-for-additional-study 2024-08-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/327dd119171f166a/fda-approves-lymphir-denileukin-diftitox-cxdl-immunotherapy-for-the-treatment-of-adults-with-relapsed-or-refractory-cutaneous-t-cell-lymphoma 2024-08-08T22:08:26+00:00 weekly 0.7 https://trial.medpath.com/news/0267bbe3b0d19361/westgene-to-advance-clinical-trials-following-dual-ind-approvals-for-world-s-first-eb-virus-related-mrna-therapeutic-cancer-vaccine 2024-08-08T22:08:00+00:00 weekly 0.7 https://trial.medpath.com/news/882327dcd8ccaa79/kymera-therapeutics-shares-price-target-rises-on-positive-development 2024-08-08T11:28:08+00:00 weekly 0.7 https://trial.medpath.com/news/240836ebea8aa506/nanoviricides-provides-an-update-on-its-clinical-program 2024-08-08T11:14:20+00:00 weekly 0.7 https://trial.medpath.com/news/2c487b686960e2cd/blarcamesine-shows-significant-slowing-of-alzheimer-disease-in-phase-2-3-trial 2024-08-08T10:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/1fe300141c6cf0e6/policy-change-alone-wont-achieve-equity-in-clinical-trial-participation 2024-08-08T09:00:09+00:00 weekly 0.7 https://trial.medpath.com/news/d63600fbac5c7868/novartis-receives-fda-accelerated-approval-for-fabhalta-iptacopan-for-the-reduction-of-proteinuria-in-primary-iga-nephropathy-igan 2024-08-08T06:08:46+00:00 weekly 0.7 https://trial.medpath.com/news/4b603fda6eb07a5e/aldeyra-therapeutics-achieves-primary-endpoint-in-phase-3-dry-eye-disease-clinical-trial-of-reproxalap 2024-08-08T06:08:04+00:00 weekly 0.7 https://trial.medpath.com/news/233babda28bd8eb1/merck-provides-update-on-phase-3-keyvibe-008-trial-evaluating-an-investigational-fixed-dose-combination-of-vibostolimab-and-pembrolizumab-in-patients-with-extensive-stage-small-cell-lung-cancer 2024-08-08T06:08:01+00:00 weekly 0.7 https://trial.medpath.com/news/892c50491c833ee6/stoke-therapeutics-eyes-phase-iii-dravet-syndrome-trial-as-fda 2024-08-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/53d879fc71da838f/verona-pharma-reports-second-quarter-2024-financial-results-and 2024-08-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/1dc0af6b9ab16eaa/upstream-bio-announces-200m-series-b-financing-to-advance-upb-101-for 2024-08-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/0e24d66e8da4c803/kura-oncology-announces-fda-clearance-of-ind-application-for-menin-inhibitor-ziftomenib-in-advanced-gastrointestinal-stromal-tumors-gist 2024-08-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ce38edaec43cb76c/fractyl-health-announces-clinical-results-from-german-real-world-registry 2024-08-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/444bf7a8da1611c5/nhs-england-approves-first-crispr-gene-editing-therapy-for-beta-thalassaemia-treatment 2024-08-07T23:17:32+00:00 weekly 0.7 https://trial.medpath.com/news/07c52a9c951551e6/fda-approves-zurnai-nalmefene-hydrochloride-auto-injector-for-the-emergency-treatment-of-known-or-suspected-opioid-overdose 2024-08-07T21:08:47+00:00 weekly 0.7 https://trial.medpath.com/news/f75ed78820286c20/fda-approves-crexont-carbidopa-and-levodopa-extended-release-capsules-for-the-treatment-of-parkinsons-disease 2024-08-07T08:08:01+00:00 weekly 0.7 https://trial.medpath.com/news/761f599659777234/groundbreaking-nipocalimab-study-of-pregnant-individuals-at-high-risk-for-early-onset-severe-hemolytic-disease-of-the-fetus-and-newborn-published-in-the-new-england-journal-of-medicine 2024-08-07T05:08:13+00:00 weekly 0.7 https://trial.medpath.com/news/01a529c6f5b7d3bd/nice-approves-eladynos-for-postmenopausal-osteoporosis-but-nhs-diagnostic-gaps-pose-access-challenges 2024-08-07T01:46:35+00:00 weekly 0.7 https://trial.medpath.com/news/6b79ef13e10a2031/4sc-announces-half-year-report-2024-and-provides-update 2024-08-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/5ee1466f64b02a1a/olema-oncology-reports-second-quarter-2024-financial-results-and-corporate-update 2024-08-06T21:50:00+00:00 weekly 0.7 https://trial.medpath.com/news/5a6b9ea044cb2d16/julys-molecules-on-the-move 2024-08-06T21:48:21+00:00 weekly 0.7 https://trial.medpath.com/news/e31753b4f424665a/fda-approves-voranigo-vorasidenib-for-the-treatment-of-grade-2-idh-mutant-glioma 2024-08-06T19:08:49+00:00 weekly 0.7 https://trial.medpath.com/news/984342701b8ea80c/xdemvy-the-first-fda-approved-treatment-for-demodex-blepharitis 2024-08-06T16:34:31+00:00 weekly 0.7 https://trial.medpath.com/news/5c526ac67cc08b69/eo-3021-shows-promise-in-treating-advanced-solid-tumors-expressing-cldn18-2 2024-08-06T16:12:06+00:00 weekly 0.7 https://trial.medpath.com/news/352ade440464ae72/dr-gerds-on-unmet-needs-in-low-risk-myelofibrosis 2024-08-06T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fe251c7d37b371c5/safe-and-intriguing-natures-drugs-taking-on-complex-diseases 2024-08-06T09:00:07+00:00 weekly 0.7 https://trial.medpath.com/news/d8fc197a325d7173/daiichi-sankyo-and-merck-expand-collaboration-to-develop-novel-dll3-targeting-t-cell-engager-for-small-cell-lung-cancer 2024-08-06T06:45:00+00:00 weekly 0.7 https://trial.medpath.com/news/bf86ba4147db7449/bayer-s-kerendia-and-nubeqa-drive-strong-pharmaceutical-growth-q2-sales-hit-eur11-1-billion 2024-08-06T03:20:58+00:00 weekly 0.7 https://trial.medpath.com/news/4755a4db04e53628/george-medicines-announces-gmrx2-nda-filing-to-fda 2024-08-06T02:08:34+00:00 weekly 0.7 https://trial.medpath.com/news/1b82447dec626341/glp-1-receptor-agonists-show-survival-benefit-in-cancer-patients-with-type-2-diabetes 2024-08-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/e39826d94e1e5969/abivax-s-abtect-phase-3-trial-reaches-key-enrollment-milestone 2024-08-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/66be1e0d88455769/shanton-pharma-completes-enrollment-for-phase-2b-trial-of-sap-001-in-refractory-gout 2024-08-05T13:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bde90c40f2be2551/turn-therapeutics-topical-atopic-dermatitis-candidate-significantly-inhibits-key-cytokines-in-expansion-study-of-flagship-formula 2024-08-05T11:08:43+00:00 weekly 0.7 https://trial.medpath.com/news/77c1b46ad75ced3e/novel-nanoparticle-immunotherapy-shows-promise-in-delaying-prostate-cancer-treatment-resistance 2024-08-05T09:41:00+00:00 weekly 0.7 https://trial.medpath.com/news/9b992a9b36b0ea36/jak-inhibitors-boost-immunotherapy-response-rates-in-lung-cancer-and-lymphoma-trials 2024-08-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/7d433d16d4c5ba5d/3d-printing-revolutionizes-microneedle-manufacturing-for-enhanced-transdermal-drug-delivery 2024-08-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/b9cd015ec9cd3025/ocugen-inc-announces-fda-approval-of-expanded-access-program-for-patients-with-retinitis-pigmentosa 2024-08-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/2231b7dc91ae53e8/car-e-platform-shows-promise-in-preventing-car-t-cell-therapy-relapse 2024-08-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/e997a14a9e7c267b/cell-and-gene-therapy-shows-early-promise-against 2024-08-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/880f73b38d7a75b7/enzene-biosciences-establishes-50-million-new-jersey-manufacturing-facility-with-continuous-biologics-platform 2024-08-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/75206dcdbb6819ae/innovent-and-sanegenebio-announce-first-participant-dosed-in-a-phase-1-clinical-trial-of-ibi3016 2024-08-04T02:08:58+00:00 weekly 0.7 https://trial.medpath.com/news/a5b5b020500772fe/fda-advisory-committee-votes-favorably-that-the-data-support-arimoclomol-as-effective-treatment-for-patients-with-niemann-pick-disease-type-c 2024-08-02T21:08:09+00:00 weekly 0.7 https://trial.medpath.com/news/77b5ca55725edc5b/fda-awards-orphan-drug-designation-to-avutometinib-plus-defactinib-for-pancreatic-cancer-treatment 2024-08-02T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/91f07f4dee1ff24a/eli-lilly-s-weight-loss-drug-tirzepatide-approved-in-china 2024-08-02T08:00:40+00:00 weekly 0.7 https://trial.medpath.com/news/1df8cf19097a0c2a/fda-s-july-2024-roundup-breakthroughs-and-milestones 2024-08-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/934ddd48b76402bf/gene-therapy-pioneer-jim-wilson-departs-upenn-to-launch-two-new-companies 2024-08-01T13:18:19+00:00 weekly 0.7 https://trial.medpath.com/news/e0a921d478b9b53a/ideate-lung02-phase-3-trial-of-ifinatamab-deruxtecan-initiated-in-patients-with-relapsed-small-cell-lung-cancer 2024-08-01T06:08:38+00:00 weekly 0.7 https://trial.medpath.com/news/c47476b2d6c08356/fda-expands-jemperli-dostarlimab-gxly-plus-chemotherapy-approval-to-all-adult-patients-with-primary-advanced-or-recurrent-endometrial-cancer 2024-08-01T04:08:09+00:00 weekly 0.7 https://trial.medpath.com/news/9477ed49ab3baeae/resmetirom-and-glp-1-agonists-show-promise-in-treating-mash 2024-08-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/2328b81b4e2c96ed/targeted-therapy-in-high-grade-serous-ovarian-cancer 2024-08-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ce44bcefacf7ef06/dose-dense-chemotherapy-preferred-for-node-positive-breast-cancer-patients-regardless-of-bmi 2024-08-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ea32ea5f54131b92/biotech-startup-airna-raises-60m-for-rna-editing-medicines 2024-07-31T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/15ae013f2489823e/citryll-completes-phase-i-dosing-for-novel-anti-inflammatory-drug-cit-013-targeting-neutrophil-extracellular-traps 2024-07-31T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/194fe1cfd0e45ca5/fibrogen-terminates-pamrevlumab-development-after-failed-pancreatic-cancer-trials-announces-major-workforce-reduction 2024-07-31T02:58:57+00:00 weekly 0.7 https://trial.medpath.com/news/b72da56280071f12/hispanic-patients-with-alcohol-use-disorder-at-higher-risk-for-liver-diseases 2024-07-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fa8a80b6a58f8da5/biontech-announces-positive-topline-phase-2-results-for-mrna-immunotherapy-candidate-bnt111-in-patients-with-advanced-melanoma 2024-07-30T21:08:58+00:00 weekly 0.7 https://trial.medpath.com/news/922655a40caed8d9/fractyl-health-s-revita-system-receives-fda-breakthrough-device-designation 2024-07-30T11:27:28+00:00 weekly 0.7 https://trial.medpath.com/news/3705a9f49eaf1e1c/fda-clears-compugen-s-phase-i-trial-for-solid-tumour-treatment 2024-07-30T10:51:51+00:00 weekly 0.7 https://trial.medpath.com/news/2803548b33fe1390/pfizer-discontinues-duchenne-gene-therapy-development-following-phase-3-trial-failure 2024-07-30T10:18:00+00:00 weekly 0.7 https://trial.medpath.com/news/89842022f95f084b/psoriasis-drug-ustekinumab-shows-promise-in-preserving-insulin-production-in-young-type-1-diabetes-patients 2024-07-30T09:18:14+00:00 weekly 0.7 https://trial.medpath.com/news/d71e41822920f843/high-court-rules-on-moderna-pfizer-biontech-covid-19-vaccine-patent-dispute-setting-precedent-for-mrna-technology-rights 2024-07-30T08:27:00+00:00 weekly 0.7 https://trial.medpath.com/news/ecf9eea73bac38fa/vertex-announces-fda-acceptance-of-new-drug-application-for-suzetrigine-for-the-treatment-of-moderate-to-severe-acute-pain 2024-07-30T02:07:51+00:00 weekly 0.7 https://trial.medpath.com/news/2158098fd277f0e0/darzalex-faspro-daratumumab-and-hyaluronidase-fihj-based-quadruplet-regimen-approved-in-the-u-s-for-patients-with-newly-diagnosed-multiple-myeloma-who-are-transplant-eligible 2024-07-30T02:07:08+00:00 weekly 0.7 https://trial.medpath.com/news/3194dcf507dfcd05/fda-expands-blinatumomab-approval-in-early-stage 2024-07-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/6cd4edea5089ea2b/syndax-announces-pdufa-action-date-extension-for-revumenib-nda-for-relapsed-or-refractory-kmt2ar-acute-leukemia 2024-07-29T21:07:40+00:00 weekly 0.7 https://trial.medpath.com/news/c2b110845420c045/fda-approves-zunveyl-benzgalantamine-for-the-treatment-of-alzheimer-s-disease 2024-07-29T20:07:22+00:00 weekly 0.7 https://trial.medpath.com/news/f65d26167d6f1beb/nt-0796 2024-07-29T14:38:52+00:00 weekly 0.7 https://trial.medpath.com/news/919f4e4aa1fe07b7/gsk-and-flagship-pioneering-launch-7-billion-strategic-alliance-for-novel-therapeutics-development 2024-07-29T12:44:30+00:00 weekly 0.7 https://trial.medpath.com/news/3b453bfcf02a7bb3/promis-reports-positive-phase-ia-trial-results-for-alzheimer-s-treatment 2024-07-29T08:36:48+00:00 weekly 0.7 https://trial.medpath.com/news/a621882c011d3a8f/grifols-receives-approval-for-expanded-xembify-immune-globulin-subcutaneous-human-klhw-label-in-u-s 2024-07-29T05:07:20+00:00 weekly 0.7 https://trial.medpath.com/news/e09eb2298cd300bd/topline-data-from-pivotal-phase-3-brooklyn-clinical-trial-evaluating-efficacy-safety-and-tolerability-of-obicetrapib-in-patients-with-heterozygous-familial-hypercholesterolemia 2024-07-29T02:08:32+00:00 weekly 0.7 https://trial.medpath.com/news/35423da97ca66f0c/volunteers-needed-for-the-dog-aging-project 2024-07-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d8a030939c43e867/fda-approves-blood-based-cancer-test-in-medical-breakthrough 2024-07-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d0a07dd5de28fb4f/novartis-scemblix-r-granted-fda-priority-review-for-the 2024-07-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/34e6537f2672a1d1/lomecel-b-meets-key-objectives-in-phase-iia-alzheimer-s 2024-07-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/7d2115419dea6e4c/fnih-study-validates-blood-tests-for-alzheimer-s-detection-potentially-replacing-invasive-spinal-taps 2024-07-28T11:53:00+00:00 weekly 0.7 https://trial.medpath.com/news/5566945ecf1e50a0/fda-approves-erzofri-paliperidone-palmitate-for-the-treatment-of-schizophrenia-and-schizoaffective-disorder 2024-07-28T01:07:32+00:00 weekly 0.7 https://trial.medpath.com/news/033b4ad6ad0ff305/alector-presents-baseline-characteristics-for-invoke-2-phase-2-clinical-trial-of-al002-at-the-alzheimer-s-association-international-conference-r-2024-aaic-r 2024-07-28T01:07:20+00:00 weekly 0.7 https://trial.medpath.com/news/9a8d78e44ff8307a/fda-approves-palforzia-peanut-arachis-hypogaea-allergen-powder-dnfp-for-use-in-individuals-ages-1-through-3-years-with-a-confirmed-diagnosis-of-peanut-allergy 2024-07-26T23:07:07+00:00 weekly 0.7 https://trial.medpath.com/news/98eeddc4347c1d76/fda-approves-leqselvi-deuruxolitinib-an-oral-jak-inhibitor-for-the-treatment-of-severe-alopecia-areata 2024-07-26T21:07:11+00:00 weekly 0.7 https://trial.medpath.com/news/c5f4a708bfbf7c13/xspray-pharma-shares-new-information-on-dasynoc-a-novel-cml-treatment-in-development 2024-07-26T20:07:16+00:00 weekly 0.7 https://trial.medpath.com/news/efcb3a24ebc41fcb/cbm588-may-improve-clinical-outcomes-in-metastatic-rcc 2024-07-26T14:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/2d8dcf1760c2cf86/nicox-completes-u-s-recruitment-for-phase-3-glaucoma-trial-of-ncx-470 2024-07-26T10:12:01+00:00 weekly 0.7 https://trial.medpath.com/news/67cf6b106f7bf653/third-arc-secures-165m-series-a-to-advance-novel-t-cell-engager-platform-for-cancer-and-inflammation 2024-07-26T03:12:05+00:00 weekly 0.7 https://trial.medpath.com/news/c6f7e1024a585d3e/nih-researchers-discover-potential-therapeutic-target-for-degenerative-eye-disease 2024-07-26T03:07:27+00:00 weekly 0.7 https://trial.medpath.com/news/834f625b13e7b467/guardant-health-invests-in-obviohealth-to-accelerate-digital-oncology-clinical-trials 2024-07-26T02:47:34+00:00 weekly 0.7 https://trial.medpath.com/news/c0b92319062a5527/presage-biosciences-announces-first-patient-dosing-of-pure-biologics-ror1-targeting-antibody-for-treatment-of-cancer 2024-07-26T02:07:31+00:00 weekly 0.7 https://trial.medpath.com/news/54e397e819d3711c/five-key-strategies-to-revolutionize-clinical-trial-patient-recruitment-in-biopharma 2024-07-26T01:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/da2cb17f0084aaab/ema-approves-second-covid-19-vaccine-as-moderna-receives-conditional-marketing-authorization-in-eu 2024-07-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/7177c6e69b81b3f9/jacobio-completes-first-patient-dosage-of-p53-y220c-activator-in-clinical-trial 2024-07-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4349ac9ba878a876/walgreens-receives-project-award-oracle-announces-new-ai-capabilities-for-trials-n-power-merck-collaborate-on-oncology-clinical-research-more 2024-07-25T09:00:01+00:00 weekly 0.7 https://trial.medpath.com/news/a3cf41439717e62a/mirums-livmarli-now-approved-for-pfic-in-patients-12-months-and-older 2024-07-25T01:07:08+00:00 weekly 0.7 https://trial.medpath.com/news/77e216b02725c4c7/briacell-announces-clinical-supply-agreement-with 2024-07-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ca9683ba35363cff/windtree-therapeutics-provides-update-on-istaroxime-clinical-development-and-upcoming-clinical-trial-data 2024-07-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/5df631c2c1f81152/evidence-meta-analysis-evaluating-minimal-residual-disease-as-an 2024-07-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/37c6b8b831e4fd76/final-results-from-a-phase-2-study-of-tpn-101-for-the-treatment-of-c9orf72-related-amyotrophic-lateral-sclerosis-and-or-frontotemporal-dementia 2024-07-24T21:07:35+00:00 weekly 0.7 https://trial.medpath.com/news/4c69f006fec6abb9/sage-therapeutics-and-biogen-announce-topline-results-from-phase-2-kinetic-2-study-of-sage-324-biib124-for-the-treatment-of-essential-tremor 2024-07-24T20:07:46+00:00 weekly 0.7 https://trial.medpath.com/news/6034fefd46e56035/triastek-and-biontech-partner-to-develop-3d-printed-oral-rna-therapeutics-in-1-2-billion-deal 2024-07-24T10:27:25+00:00 weekly 0.7 https://trial.medpath.com/news/75b7e0019ddd2f85/pfizer-announces-positive-topline-results-from-phase-3-study-of-hemophilia-a-gene-therapy-candidate-giroctocogene-fitelparvovec 2024-07-24T03:07:27+00:00 weekly 0.7 https://trial.medpath.com/news/11505938aa3a0140/vivacelle-bio-initiates-phase-3-trial-for-lead-asset-vbi-s-to-treat-patients-with-hypovolemia-due-to-septic-shock 2024-07-24T03:07:02+00:00 weekly 0.7 https://trial.medpath.com/news/6eff67cd2ccbbee1/u-s-food-and-drug-administration-approves-biomarin-s-brineura-cerliponase-alfa-for-children-under-3-years-with-cln2-disease 2024-07-24T01:07:11+00:00 weekly 0.7 https://trial.medpath.com/news/906384b131f665a1/consynance-therapeutics-receives-fda-rare-pediatric-disease-designation-for-csti-500-in-prader-willi-syndrome 2024-07-24T01:07:11+00:00 weekly 0.7 https://trial.medpath.com/news/fa87711707f6c021/glecirasib-a-promising-novel-kras-g12c-inhibitor-in-clinical 2024-07-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/1d3742fd714c3aad/bio-thera-solutions-announces-regulatory-filing-acceptance-for-bat2206-a-proposed-biosimilar-to-stelara-r-in-the-us-and-eu 2024-07-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a4d6608c891a786f/nci-launches-cervical-cancer-last-mile-initiative-to-expand-screening-access 2024-07-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/8d28f8f5b1d41ad0/new-gene-therapy-approach-shows-promise-for-duchenne-muscular-dystrophy 2024-07-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a9ec7722eba720c8/spectral-medical-provides-tigris-trial-update-biospace 2024-07-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/b6e32f589d6e13bb/fda-approves-femlyv-norethindrone-acetate-and-ethinyl-estradiol-orally-disintegrating-birth-control-pill 2024-07-23T23:07:51+00:00 weekly 0.7 https://trial.medpath.com/news/1b357c3f90be3a35/merz-aesthetics-announces-fda-approval-of-xeomin-incobotulinumtoxina-as-the-first-and-only-u-s-neurotoxin-for-the-simultaneous-treatment-of-upper-facial-lines 2024-07-23T22:07:08+00:00 weekly 0.7 https://trial.medpath.com/news/5f7eb5d8a921e986/iopofosine-i-131-achieves-major-response-rate-in-relapsed-refractory-waldenstrom-macroglobulinemia 2024-07-23T16:22:41+00:00 weekly 0.7 https://trial.medpath.com/news/4b2cfeafe3cc80e1/millions-more-brits-could-get-weight-loss-jabs-on-nhs-to-prevent-heart-attack-and-stroke-are-you-e 2024-07-23T16:20:20+00:00 weekly 0.7 https://trial.medpath.com/news/9579160e74d4d1d8/fda-accepts-resubmission-of-bla-for-remestemcel-l-in-pediatric-steroid-refractory-acute-graft-vs-host-disease 2024-07-23T15:23:40+00:00 weekly 0.7 https://trial.medpath.com/news/9eee2c6e7fb5cfbd/fda-accepts-sbla-for-susvimo-in-diabetic-eye-diseases-following-promising-phase-3-results 2024-07-23T14:45:56+00:00 weekly 0.7 https://trial.medpath.com/news/7fc99235bba86b78/an-isolated-viral-load-test-may-generate-false-positive-results-for-people-using-long-acting-prep 2024-07-23T04:07:43+00:00 weekly 0.7 https://trial.medpath.com/news/35e651dd927b6ef0/long-acting-injectable-cabotegravir-for-hiv-prevention-is-safe-in-pregnancy 2024-07-23T04:07:35+00:00 weekly 0.7 https://trial.medpath.com/news/6a044ed4bd93805f/merck-announces-topline-results-from-phase-2b-3-trial-of-clesrovimab-mk-1654-an-investigational-respiratory-syncytial-virus-preventative-monoclonal-antibody-for-infants 2024-07-23T04:07:30+00:00 weekly 0.7 https://trial.medpath.com/news/3a144962044b511d/ema-issues-precautionary-measures-for-valproate-use-in-male-patients-due-to-potential-neurodevelopmental-risks 2024-07-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/8c617cf3fa368ca9/reunion-neuroscience-initiates-phase-2-trial-of-fast-acting-psychedelic-re104-for-postpartum-depression 2024-07-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/9337ebeb65fa38c9/fda-approves-epysqli-eculizumab-aagh-a-biosimilar-to-soliris 2024-07-22T20:07:08+00:00 weekly 0.7 https://trial.medpath.com/news/6df45410b360d1eb/synaptixbio-secures-second-fda-orphan-drug-designation-for-tubb4a-leukodystrophy-variant 2024-07-22T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/be656e0394ad02d7/60-degrees-pharmaceuticals-initiates-clinical-trials-for-babesiosis-treatment 2024-07-22T08:14:24+00:00 weekly 0.7 https://trial.medpath.com/news/d9a7c6edc50c7bb1/ai-and-predictive-analytics-set-to-transform-cancer-patient-care-and-treatment-outcomes 2024-07-22T01:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/75bdb021b6002f33/fda-grants-new-heart-failure-implant-its-breakthrough-device 2024-07-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/09559c8c5d520edb/zymeworks-announces-fda-clearance-of-investigational-new-drug-application-for-zw191-a-novel-folate-receptor-targeted-topoisomerase-i-inhibitor-antibody-drug-conjugate 2024-07-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a4754dc742ab4d63/once-daily-gildeuretinol-acetate-shows-promise-in-halting-early-stage-stargardt-disease-progression 2024-07-21T18:48:09+00:00 weekly 0.7 https://trial.medpath.com/news/d7848d15bcb7bd1e/passage-bio-receives-fda-positive-feedback-for-expanding-gene-therapy-trial-to-include-ftd-c9orf72-patients 2024-07-19T22:00:46+00:00 weekly 0.7 https://trial.medpath.com/news/d89b87fcd751cc03/fda-approves-zituvimet-xr-sitagliptin-and-metformin-hydrochloride-extended-release-tablets-for-adults-with-type-2-diabetes 2024-07-19T19:07:56+00:00 weekly 0.7 https://trial.medpath.com/news/b8d143f411485a41/clinical-trial-data-explosion-industry-grapples-with-283-increase-in-phase-iii-data-collection 2024-07-19T01:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/0ea60eaeab51c4db/rezatapopt-takes-aim-at-previously-untargetable-p53 2024-07-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/21829e2176281a45/eu-commission-president-unveils-ambitious-2025-biotech-act-to-boost-european-life-sciences 2024-07-18T22:18:43+00:00 weekly 0.7 https://trial.medpath.com/news/44000c6547efdf8c/phathom-pharmaceuticals-announces-fda-approval-of-voquezna-vonoprazan-tablets-for-the-relief-of-heartburn-associated-with-non-erosive-gerd-in-adults 2024-07-18T21:07:46+00:00 weekly 0.7 https://trial.medpath.com/news/b5c8f05b6213974a/fda-advises-against-accelerated-approval-for-botensilimab-balstilimab-in-mss-colorectal-cancer-despite-phase-3-advancement 2024-07-18T15:16:21+00:00 weekly 0.7 https://trial.medpath.com/news/3085c19ac8f526ab/phase-1-helios-trial-shows-promise-for-otx-tki-in-non-proliferative-diabetic-retinopathy 2024-07-18T13:00:36+00:00 weekly 0.7 https://trial.medpath.com/news/0f05eb258d3cc4c6/car-t-cell-therapy-advances-overcoming-challenges-in-solid-tumors-and-enhancing-safety-through-innovative-engineering 2024-07-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/054f100295386694/asrs-2024-examining-real-world-use-of-faricimab-through-the-faretina 2024-07-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/b7af102d632a3249/boehringer-ingelheim-achieves-significant-pipeline-progress-in-first-half-of-2024 2024-07-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a02b736be329e81a/scientists-develop-breakthrough-anti-ageing-drug-that-extends-lifespan-by-25 2024-07-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/6ef16830f9de0cd9/biopharma-clinical-success-rates-drop-to-6-7-amid-evolving-r-d-landscape 2024-07-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/1ce8430a06a90bde/trofinetide-shows-promise-as-a-treatment-for-rett-syndrome 2024-07-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a1cbd7f9231a4b16/atara-biotherapeutics-announces-u-s-fda-acceptance-and-priority-review-of-the-biologics-license-application-for-tabelecleucel-tab-cel-r-for-the-treatment-of-epstein-barr-virus-positive-post-transplant-lymphoproliferative-disease 2024-07-17T23:07:48+00:00 weekly 0.7 https://trial.medpath.com/news/7f177fc1aca7302d/brentuximab-vedotin-triplet-shows-significant-survival-benefits-in-relapsed-refractory-dlbcl 2024-07-17T19:25:02+00:00 weekly 0.7 https://trial.medpath.com/news/a8ef6739d8cab0bf/first-in-arizona-commercial-use-of-new-cancer-therapy-shows-promising-results 2024-07-17T15:21:56+00:00 weekly 0.7 https://trial.medpath.com/news/400cec0c46168d5b/targeting-post-transcriptional-rna-modification-with-a-first-to-clinic-mettl3-inhibitor-stc15 2024-07-17T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/6a33687c553e5a6c/orexo-receives-a-complete-response-letter-regarding-the-nda-for-ox124-a-high-dose-naloxone-rescue-medication-in-development-for-opioid-overdose 2024-07-17T00:07:47+00:00 weekly 0.7 https://trial.medpath.com/news/089d45bb64229c62/fda-clears-investigational-new-drug-application-for-muscular-dystrophy-treatment-from-university-of-minnesota-startup-myogenica 2024-07-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/24dd3958f1b9a3e8/fda-grants-orphan-drug-designation-to-novel-b7-h3-targeting-adc-in-sclc 2024-07-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/891b244c2c9ff4ea/lexicon-pharmaceuticals-receives-december-20-2024-pdufa-goal-date-for-sotagliflozin-type-1-diabetes-nda-resubmission 2024-07-16T21:07:51+00:00 weekly 0.7 https://trial.medpath.com/news/3ab314955965fdb1/tenosynovial-giant-cell-tumors-treatment-market-to-see-significant-growth-by-2034 2024-07-16T05:48:25+00:00 weekly 0.7 https://trial.medpath.com/news/06ada89d7c74912a/global-clinical-trials-landscape-reveals-promising-advances-in-non-small-cell-lung-cancer-treatment 2024-07-16T01:35:09+00:00 weekly 0.7 https://trial.medpath.com/news/53e4abe48098cf17/more-men-with-advanced-prostate-cancer-could-benefit-from-precision-drug-olaparib 2024-07-15T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/0406603c8e5d7354/fda-completes-end-of-phase-2-meeting-for-annamycin-plus-cytarabine-in-aml 2024-07-15T15:27:18+00:00 weekly 0.7 https://trial.medpath.com/news/d1080ae1a8b912b8/eton-pharmaceuticals-announces-fda-acceptance-of-new-drug-application-for-et-400-hydrocortisone-oral-solution 2024-07-15T04:07:42+00:00 weekly 0.7 https://trial.medpath.com/news/8867cb17edce95be/maralixibat-shows-promise-in-treating-progressive-familial-intrahepatic-cholestasis 2024-07-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/b5595e6ef56db9de/dare-bioscience-publishes-positive-phase-2b-results-for-topical-sildenafil-cream-in-female-sexual-arousal-disorder 2024-07-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/6c3b7a7c97da09ab/new-drug-for-stiff-person-syndrome-granted-fast-track-designation-from-fda-fox-news 2024-07-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/096dba2f1e2624db/fda-grants-accelerated-approval-to-adagrasib-with-cetuximab-for-kras-g12c-mutated-advanced-colorectal-cancer 2024-07-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/b59b79856e29f8e1/eli-lilly-s-alzheimer-s-drug-obtains-fda-approval-here-s-why-the-stock-isn-t-taking-off 2024-07-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4fa0e7ae03cba88a/msd-completes-3-billion-acquisition-of-eyebio-gaining-novel-retinal-disease-candidate-restoret 2024-07-12T06:45:00+00:00 weekly 0.7 https://trial.medpath.com/news/397e443cfe447c50/novel-approaches-reshape-rare-disease-drug-development-experts-outline-path-to-success 2024-07-12T02:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/51592eb75b872d1b/novel-combination-of-pozelimab-and-cemdisiran-poze-cemdi-achieved 2024-07-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/3c35ffb93baf6bb0/phase-ii-study-of-acalabrutinib-venetoclax-and-obinutuzumab-in-a 2024-07-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/1b407b4a33a5e8d7/w-t7-shows-encouraging-response-rate-manageable 2024-07-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/89e12c75c70aad7d/breakthrough-immunotherapy-combination-shows-promise-against-common-colorectal-cancer-in-phase-1-trial 2024-07-11T13:14:48+00:00 weekly 0.7 https://trial.medpath.com/news/237aa30389e67d2c/is-eli-lilly-lly-a-buy-on-tirzepatide-success-in-sleep-apnea 2024-07-11T12:43:32+00:00 weekly 0.7 https://trial.medpath.com/news/c8227f41404e8a94/emerging-btk-degraders-show-promise-in-treating-resistant-b-cell-malignancies 2024-07-11T09:00:18+00:00 weekly 0.7 https://trial.medpath.com/news/337d944fccee1c8c/fresh-take-on-how-to-conduct-rare-disease-clinical-trials 2024-07-11T09:00:05+00:00 weekly 0.7 https://trial.medpath.com/news/17c7b886ac821529/biophytis-receives-fda-approval-for-phase-2-obesity-trial-of-bio101-to-address-muscle-loss-in-glp-1-therapy 2024-07-11T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/beef817313a0f554/genai-poised-to-transform-pharmaceutical-medical-writing-despite-implementation-challenges 2024-07-11T02:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/3927573121a0c5a0/amivantamab-plus-lazertinib-improves-pfs-over 2024-07-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/6fd857fc4c5cd786/mrna-cancer-vaccines-clinical-trials-market-opportunity 2024-07-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f368a9e87ef63eb6/spectral-medical-inc-announces-change-to-auditor-financial-post 2024-07-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/c5f1a31c0ec67039/delhi-high-court-bans-zydus-pertuzumab-biosimilar-sigrima-in-patent-infringement-case 2024-07-10T23:51:00+00:00 weekly 0.7 https://trial.medpath.com/news/794650d87ce59e50/advances-and-challenges-in-renal-cell-carcinoma-treatment 2024-07-10T16:10:00+00:00 weekly 0.7 https://trial.medpath.com/news/c197ec18fcbb3f8f/hybryte-shows-promising-results-in-early-stage-cutaneous-t-cell-lymphoma-treatment 2024-07-10T16:00:07+00:00 weekly 0.7 https://trial.medpath.com/news/09ce2d89a0173c65/amylyx-acquires-phase-3-ready-glp-1-receptor-antagonist-avexitide-for-hyperinsulinemic-hypoglycemia 2024-07-10T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/936bb984ba78f8b8/ema-grants-orphan-designations-for-rare-disease-treatments-in-pulmonary-fibrosis-and-b-cell-lymphoma 2024-07-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d92c8442b554d7c6/early-safety-findings-among-persons-aged-60-years 2024-07-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/5c75a0e95a8f03e5/fda-approves-arcutis-zoryve-roflumilast-cream-0-15-for-the-treatment-of-atopic-dermatitis-in-adults-and-children-down-to-6-years-of-age 2024-07-09T22:07:16+00:00 weekly 0.7 https://trial.medpath.com/news/fd0c3781b563da55/fda-approves-first-generic-methimazole-solution-for-feline-hyperthyroidism-treatment 2024-07-09T16:21:18+00:00 weekly 0.7 https://trial.medpath.com/news/ddcc1bf2e35f7281/bio-path-holdings-advances-in-clinical-trials-and-expands-into-obesity-treatment 2024-07-09T09:21:34+00:00 weekly 0.7 https://trial.medpath.com/news/fa21e2b642bfdfc1/intensity-therapeutics-initiates-phase-3-trial-of-int230-6-for-metastatic-sarcoma 2024-07-09T08:01:00+00:00 weekly 0.7 https://trial.medpath.com/news/8a6ba144f91e240c/neurosense-s-paradigm-als-clinical-trial-demonstrates-up-to-73-improved-complication-free-survival-following-statistically-significant-slowing-of-disease-progression 2024-07-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/61db99e56460634f/interius-biotherapeutics-receives-hrec-approval-and-ctn-clearance-from-the-tga-to-commence-a-phase-1-clinical-trial-for-its-first-in-class-in-vivo-car-therapeutic-for-b-cell-malignancies 2024-07-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/09ac466495d482e2/nda-resubmission-planned-for-rivoceranib-camrelizumab-in-onclive 2024-07-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/b3a28bc308d3f18d/flot-perioperative-chemotherapy-extends-survival-over-cross-protocol-in-esophageal-cancer 2024-07-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/50ee320ab02582a7/comparing-long-term-data-for-io-io-and-io-tki-in-favorable-risk-metastatic-renal-cell-carcinoma 2024-07-08T21:30:15+00:00 weekly 0.7 https://trial.medpath.com/news/793e2680d7be7ab1/global-breast-cancer-therapeutics-market-expected-to-reach-78-61-billion-by-2033 2024-07-08T21:21:39+00:00 weekly 0.7 https://trial.medpath.com/news/462d4911d1452436/fda-grants-fast-track-designation-to-225ac-fl-020-for-metastatic-castration-resistant-prostate-cancer 2024-07-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/9c4453e40802062c/china-dominates-ai-driven-drug-discovery-patent-landscape-reshaping-pharmaceutical-r-d 2024-07-06T20:12:10+00:00 weekly 0.7 https://trial.medpath.com/news/6eb7fd0f0e095fb8/cnipa-upholds-vortioxetine-crystal-form-patent-in-landmark-decision-for-pharmaceutical-ip-in-china 2024-07-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/5e71f73b679e4b79/fda-approves-genentechs-vabysmo-prefilled-syringe-pfs-for-three-leading-causes-of-vision-loss 2024-07-04T20:07:39+00:00 weekly 0.7 https://trial.medpath.com/news/8fd80a261bc30005/gsk-s-dostarlimab-expands-development-portfolio-to-target-multiple-advanced-cancers 2024-07-04T09:16:54+00:00 weekly 0.7 https://trial.medpath.com/news/c5d042c8416e7d99/uk-survey-reveals-8-year-treatment-delay-and-severe-impact-of-chronic-hand-eczema-on-daily-life 2024-07-04T08:10:47+00:00 weekly 0.7 https://trial.medpath.com/news/54a8a62e18df72c3/semaglutide-drugs-ozempic-and-wegovy-linked-to-increased-risk-of-blinding-eye-condition-in-new-study 2024-07-03T15:00:21+00:00 weekly 0.7 https://trial.medpath.com/news/86c17be171ca77f2/hiv-breakthrough-twice-yearly-injection-shows-100-efficacy-in-preventing-infection 2024-07-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/26ca8ad78f415daf/annovis-stock-swells-after-phase-iii-parkinson-s-subgroup 2024-07-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/7a4a55364d653436/fda-approves-kisunla-donanemab-azbt-for-the-treatment-of-early-symptomatic-alzheimer-s-disease 2024-07-02T19:07:52+00:00 weekly 0.7 https://trial.medpath.com/news/6079a0ee3a21db8a/fda-approves-new-endometrial-cancer-therapies-expanding-treatment-options 2024-07-02T19:00:51+00:00 weekly 0.7 https://trial.medpath.com/news/29ac1fb2480f4af0/fda-releases-new-draft-guidance-on-diversity-action-plans-for-clinical-studies 2024-07-02T11:45:50+00:00 weekly 0.7 https://trial.medpath.com/news/fe1242fb315e49a1/vertex-announces-fda-acceptance-of-new-drug-application-for-vanzacaftor-tezacaftor-deutivacaftor-a-next-in-class-triple-combination-treatment-for-cystic-fibrosis 2024-07-02T05:07:13+00:00 weekly 0.7 https://trial.medpath.com/news/09121efc87f08a0e/fda-approves-second-alzheimers-drug-that-can-slow-onset-of-disease-alzheimer-s-the-guardian 2024-07-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/07edc023af0ff37a/fda-approvals-in-oncology-april-june-2024-blog-aacr 2024-07-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d96bee143bfb0c48/cilta-cel-generates-os-benefit-in-r-r-myeloma-after-1-prior-therapy 2024-07-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/c8ae1a778ef78066/dementia-global-clinical-trials-review-2024-comparative-scenario-of-completed-and-uncompleted-terminated-suspended-withdrawn-trials 2024-07-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bbc591f1a9cb5bda/what-to-know-about-the-next-generation-of-covid-19-vaccines-abc-news 2024-07-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/1b8346f957c4db32/fda-approves-ahzantive-aflibercept-mrbb-a-biosimilar-to-eylea 2024-07-01T23:07:10+00:00 weekly 0.7